U.S. patent application number 11/019830 was filed with the patent office on 2005-10-06 for imidazo[4,5-c]pyridine compounds and methods of antiviral treatment.
This patent application is currently assigned to K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC., K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC.. Invention is credited to Bondy, Steven S., Dowdy, Eric Davis, Kim, Choung U., Neyts, Johan, Oare, David A., Puerstinger, Gerhard, Zia, Vahid.
Application Number | 20050222198 11/019830 |
Document ID | / |
Family ID | 34744004 |
Filed Date | 2005-10-06 |
United States Patent
Application |
20050222198 |
Kind Code |
A1 |
Bondy, Steven S. ; et
al. |
October 6, 2005 |
Imidazo[4,5-c]pyridine compounds and methods of antiviral
treatment
Abstract
The present invention relates to pharmaceutical compositions for
the treatment or prevention of viral infections comprising as an
active principle at least one imidazo[4,5-c]pyridine prodrug having
the general formula (A): 1 wherein the substituents are described
in the specification. The invention also relates to processes for
the preparation and screening of compounds according to the
invention having above mentioned general formula and their use in
the treatment or prophylaxis of viral infections.
Inventors: |
Bondy, Steven S.; (Danville,
CA) ; Dowdy, Eric Davis; (Foster City, CA) ;
Kim, Choung U.; (San Carlos, CA) ; Neyts, Johan;
(Kessel-Lo, BE) ; Oare, David A.; (Belmont,
CA) ; Puerstinger, Gerhard; (Igls, AT) ; Zia,
Vahid; (San Carlos, CA) |
Correspondence
Address: |
James J. Wong
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
CA
94404
US
|
Assignee: |
K.U. LEUVEN RESEARCH &
DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC.
|
Family ID: |
34744004 |
Appl. No.: |
11/019830 |
Filed: |
December 21, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60532292 |
Dec 22, 2003 |
|
|
|
60533963 |
Jan 2, 2004 |
|
|
|
60591069 |
Jul 26, 2004 |
|
|
|
60591024 |
Jul 26, 2004 |
|
|
|
60590989 |
Jul 26, 2004 |
|
|
|
60590990 |
Jul 26, 2004 |
|
|
|
Current U.S.
Class: |
514/303 ;
546/117 |
Current CPC
Class: |
A61P 31/12 20180101;
A61P 43/00 20180101; A61P 31/14 20180101; A61P 3/12 20180101; C07D
471/04 20130101 |
Class at
Publication: |
514/303 ;
546/117 |
International
Class: |
A61K 031/4745; C07D
471/02 |
Claims
We claim:
1. A compound having the general formula (A), 698wherein: the
dotted lines represent an optional double bond, provided that no
two double bonds are adjacent to one another, and that the dotted
lines represent at least 3, optionally 4 double bonds; R.sup.1 is
selected from hydrogen, aryl, heterocyclic, C.sub.1-C.sub.10
alkoxy, C.sub.1-C.sub.10 thioalkyl, C.sub.1-C.sub.10 alkyl-amino,
C.sub.1-C.sub.10 dialkyl-amino, C.sub.3-10cycloalkyl, C.sub.4-10
cycloalkenyl, and C.sub.4-10 cycloalkynyl, wherein each are
optionally substituted with 1 or more R.sup.6; Y is selected from
single bond, O, S(O).sub.m, NR.sup.11, or C.sub.1-10 alkylene,
C.sub.2-10 alkenylene, C.sub.2-10 alkynylene, wherein each may
optionally include 1 to 3 heteroatoms selected from O, S or N;
R.sup.2 and R.sup.4 are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, halogen, --OH, --CN,
--NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy, haloalkyl,
--C(.dbd.O)R.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10
cycloalkyl, C.sub.3-10 cycloalkyloxy, C.sub.3-10cycloalkylthio,
C.sub.3-10 cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic,
provided that when one of R.sup.25 or R.sup.26 is present, then
either R.sup.2 or R.sup.4 is selected from (.dbd.O), (.dbd.S), and
.dbd.NR.sup.27; X is selected from C.sub.1-C.sub.10 alkylene,
C.sub.2-10 alkenylene or C.sub.2-10 alkynylene, where each may
include one or more heteroatoms selected from O, S, or N, provided
any such heteroatom is not adjacent to the N in the ring; m is any
integer from 0 to 2; R.sup.3 is selected from aryl, aryloxy,
arylthio, cycloalkyl, cycloalkenyl, cycloalkynyl,
aryl-N(R.sup.10)--, or heterocyclic, where each said substituent
may be optionally substituted with at least one R.sup.17, provided
that for cycloalkenyl the double bond is not adjacent to a
nitrogen, and provided R.sup.3 M-Q- is not biphenyl; R.sup.5 is
selected from hydrogen; C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, C.sub.1-18 alkoxy, C.sub.1-18 alkylthio,
halogen, --OH, --CN, --NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy,
haloalkyl, --C(.dbd.O)R.sup.9, --C(.dbd.O)OR.sup.9,
--C(.dbd.S)R.sup.9, SH, aryl, aryloxy, arylthio, arylalkyl,
C.sub.1-18 hydroxyalkyl, C.sub.3-10 cycloalkyl, C.sub.3-10
cycloalkyloxy, C.sub.3-10 cycloalkylthio, C.sub.3-10 cycloalkenyl,
C.sub.7-10 cycloalkynyl, or heterocyclic; R.sup.6 is selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, C.sub.1-18 alkylsulfoxide,
C.sub.1-18 alkylsulfone, C.sub.1-18 halo-alkyl, C.sub.2-18
halo-alkenyl, C.sub.2-18 halo-alkynyl, C.sub.1-18 halo-alkoxy,
C.sub.1-18 halo-alkylthio, C.sub.3-10 cycloalkyl, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, halogen, OH, CN, cyanoalkyl,
--CO.sub.2R.sup.18, NO.sub.2, --NR.sup.7R.sup.8, C.sub.1-18
haloalkyl, C(.dbd.O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy,
arylthio, arylsulfoxide, arylsulfone, arylsulfonamide,
aryl(C.sub.1-18)alkyl, aryl(C.sub.1-18)alkyloxy,
aryl(C.sub.-18)alkylthio, heterocyclic, C.sub.1-18 hydroxyalkyl,
where each may be optionally substituted with at least 1 R.sup.19;
R.sup.7 and R.sup.8 are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.1-18 alkenyl, aryl, C.sub.3-10 cycloalkyl,
C.sub.4-10 cycloalkenyl, heterocyclic, --C(.dbd.O)R.sup.12;
--C(.dbd.S)R.sup.12, an amino acid residue linked through a
carboxyl group thereof, or where R.sup.7 and R.sup.8 together with
the nitrogen form a heterocyclic; R.sup.9 and R.sup.18 are
independently selected from hydrogen, OH, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
C.sub.1-18 alkoxy, --NR.sup.15R.sup.16, aryl, an amino acid residue
linked through an amino group of the amino acid,
CH.sub.2OCH(.dbd.O)R.sup.9a, or CH.sub.2C(.dbd.O)OR.sup.9a where
R.sup.9a is C.sub.1-C.sub.12 alkyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 alkylaryl or C.sub.6-C.sub.20 aralkyl; R.sup.10
and R.sup.11 are independently selected from the group consisting
of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, aryl, --C(.dbd.O)R.sup.12,
heterocyclic, or an amino acid residue; R.sup.12 is selected from
the group consisting of hydrogen, C.sub.1-18 alkyl, C.sub.2-18
alkenyl, aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, or
an amino acid residue; R.sup.15 and R.sup.16 are independently
selected from hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, aryl, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, or an amino acid residue; R.sup.17 is independently
M-Q- wherein M is a ring optionally substituted with 1 or more
R.sup.19, and Q is a bond or a linking group connecting M to
R.sup.3 having 1 to 10 atoms and optionally substituted with 1 or
more R.sup.19; R.sup.19 is selected from hydrogen, C.sub.1-18
alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.2-18 alkenyloxy, C.sub.2-18 alkynyloxy, C.sub.1-18alkylthio,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, C.sub.4-10
cycloalkynyl, halogen, --OH, --CN, cyanoalkyl, --NO.sub.2,
--NR.sup.20R.sup.21, C.sub.1-18 haloalkyl, C.sub.1-18 haloalkyloxy,
--C(.dbd.O)R.sup.18, --C(.dbd.O)OR.sup.18,
--OalkenylC(.dbd.O)OR.sup.18, --OalkylC(.dbd.O)NR.sup.20R.sup.21,
--OalkylOC(.dbd.O)R.sup.18, --C(.dbd.S)R.sup.18, SH,
--C(.dbd.O)N(C.sub.1-6 alkyl), --N(H)S(O)(O)(C.sub.1-6 alkyl),
aryl, heterocyclic, C.sub.1-8alkylsulfone, arylsulfoxide,
arylsulfonamide, aryl(C.sub.1-18)alkyloxy, aryloxy, aryl(C.sub.1-18
alkyl)oxy, arylthio, aryl(C.sub.1-18)alkylthio or
aryl(C.sub.1-18)alkyl, where each may be optionally substituted
with 1 or more .dbd.O, NR.sup.20R.sup.21, CN, C.sub.1-18alkoxy,
heterocyclic, C.sub.1-18 haloalkyl, heterocyclic alkyl,
heterocyclic connected to R.sup.17 by alkyl, alkoxyalkoxy or
halogen; R.sup.20 and R.sup.21 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
--C(.dbd.O)R.sup.12, or --C(.dbd.S)R.sup.12; R.sup.27 is selected
from hydrogen, C.sub.1-18 alkyl, C.sub.3-10 cycloalkyl, (C.sub.3-10
cycloalkyl)-C.sub.1-6 alkyl, aryl, and aryl C.sub.1-18 alkyl, and
salts, tautomers, isomers and solvates thereof.
2. A compound having the general formula (A), 699wherein: the
dotted lines represent an optional double bond, provided that no
two double bonds are adjacent to one another, and that the dotted
lines represent at least 3, optionally 4 double bonds; R.sup.1 is
selected from hydrogen, aryl, heterocyclic, C.sub.1-C.sub.10
alkoxy, C.sub.1C.sub.10 thioalkyl, C.sub.1-C.sub.10 alkyl-amino,
C.sub.1-C.sub.10 dialkyl-amino, C.sub.3-10cycloalkyl, C.sub.4-10
cycloalkenyl, and C.sub.4-10 cycloalkynyl, wherein each are
optionally substituted with 1 or more R.sup.6; Y is selected from
single bond, O, S(O).sub.m, NR.sup.11, or C.sub.1-10 alkylene,
C.sub.2-10 alkenylene, C.sub.2-10 alkynylene, wherein each may
optionally include 1 to 3 heteroatoms selected from O, S or N;
R.sup.2 and R.sup.4 are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, halogen, --OH, --CN,
--NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy, haloalkyl,
--C(.dbd.O)R.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10cycloalkyl,
C.sub.3-10cycloalkyloxy, C.sub.3-10 cycloalkylthio, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic, provided
that when one of R.sup.25 or R.sup.26 is present, then either
R.sup.2 or R.sup.4 is selected from (.dbd.O), (.dbd.S), and
.dbd.NR.sup.27; X is selected from C.sub.1-C.sub.10 alkylene,
C.sub.2-10 alkenylene or C.sub.2-10 alkynylene, where each may
include one or more heteroatoms selected from O, S, or N, provided
any such heteroatom is not adjacent to the N in the ring; m is any
integer from 0 to 2; R.sup.3 is a heterocycle optionally
substituted with at least one R.sup.17 provided, however, that
R.sup.3 optionally substituted with at least one R.sup.17 is not
pyridinyl or 5-chlorothienyl, provided that R.sup.3-MQ is not
biphenyl; R.sup.5 is selected from hydrogen; C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, halogen, --OH, --CN, --NO.sub.2,
--NR.sup.7R.sup.8, haloalkyloxy, haloalkyl, --C(.dbd.O)R.sup.9,
--C(.dbd.O)OR.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10
cycloalkyl, C.sub.3-10 cycloalkyloxy, C.sub.3-10 cycloalkylthio,
C.sub.3-10 cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic;
R.sup.6 is selected from hydrogen, C.sub.1-18 alkyl, C.sub.2-18
alkenyl, C.sub.2-18 alkynyl, heterocyclic, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, C.sub.1-18 alkylsulfoxide, C.sub.1-18
alkylsulfone, C.sub.1-18 halo-alkyl, C.sub.2-18 halo-alkenyl,
C.sub.2-18 halo-alkynyl, C.sub.1-18 halo-alkoxy, C.sub.1-18
halo-alkylthio, C.sub.3-10 cycloalkyl, C.sub.3-10 cycloalkenyl,
C.sub.7-10 cycloalkynyl, halogen, OH, CN, cyanoalkyl,
--CO.sub.2R.sup.18, NO.sub.2, --NR.sup.7R.sup.8, C.sub.1-18
haloalkyl, C(.dbd.O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy,
arylthio, arylsulfoxide, arylsulfone, arylsulfonamide,
aryl(C.sub.1-18)alkyl, aryl(C.sub.1-18)alkyloxy,
aryl(C.sub.1-18)alkylthi- o, C.sub.1-18 hydroxyalkyl, where each
may be optionally substituted with at least 1 R.sup.19; R.sup.7 and
R.sup.8 are independently selected from hydrogen, C.sub.1-18 alkyl,
C.sub.1-18 alkenyl, aryl, C.sub.3-10cycloalkyl, C.sub.4-10
cycloalkenyl, heterocyclic, --C(.dbd.O)R.sup.12;
--C(.dbd.S)R.sup.12, an amino acid residue linked through a
carboxyl group thereof, or where R.sup.7 and R.sup.8 together with
the nitrogen form a heterocyclic; R.sup.9 and R.sup.18 are
independently selected from hydrogen, OH, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
C.sub.1-18 alkoxy, --NR.sup.15R.sup.16, aryl, an amino acid residue
linked through an amino group of the amino acid,
CH.sub.2OCH(.dbd.O)R.sup.9a, or CH.sub.2C(.dbd.O)OR.sup.9a where
R.sup.9a is C.sub.1-C.sub.12 alkyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 alkylaryl or C.sub.6-C.sub.20 aralkyl; R.sup.10
and R.sup.11 are independently selected from the group consisting
of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, aryl, --C(.dbd.O)R.sup.12,
heterocyclic, or an amino acid residue; R.sup.12 is selected from
the group consisting of hydrogen, C.sub.1-18 alkyl, C.sub.2-18
alkenyl, aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, or
an amino acid residue; R.sup.15 and R.sup.16 are independently
selected from hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, aryl, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, or an amino acid residue; R.sup.17 is independently
selected from the group consisting of hydrogen, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, C.sub.1-18 alkylsulfoxide, C.sub.1-18
alkylsulfone, C.sub.1-18 halogenated alkyl, C.sub.2-18 halogenated
alkenyl, C.sub.2-18 halogenated alkynyl, C.sub.1-18 halogenated
alkoxy, C.sub.1-18 halogenated alkylthio, C.sub.3-10cycloalkyl,
C.sub.3-10 cycloalkenyl, C.sub.7-10 cycloalkynyl, halogen, OH, CN,
CO.sub.2H, CO.sub.2R.sup.18, NO.sub.2, NR.sup.7R.sup.8, haloalkyl,
C(.dbd.O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy, arylthio,
arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl,
arylalkyloxy, arylalkylthio, heterocyclic, C.sub.1-18 hydroxyalkyl,
where each of said aryl, aryloxy, arylthio, arylsulfoxide,
arylsulfone, arylsulfonamide, arylalkyl, arylalkyloxy,
arylalkylthio, heterocycle, or C.sub.1-18 hydroxyalkyl is
optionally substituted with 1 or more R.sup.19; R.sup.19 is
selected from hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, C.sub.1-18 alkoxy, C.sub.2-18 alkenyloxy,
C.sub.2-18 alkynyloxy, C.sub.1-18alkylthio, C.sub.3-10 cycloalkyl,
C.sub.4-10 cycloalkenyl, C.sub.4-10 cycloalkynyl, halogen, --OH,
--CN, cyanoalkyl, --NO.sub.2, --NR.sup.20R.sup.21, C.sub.1-18
haloalkyl, C.sub.1-18 haloalkyloxy, --C(.dbd.O)R.sup.18,
--C(.dbd.O)OR.sup.18, --OalkenylC(.dbd.O)OR.sup.18,
--OalkylC(.dbd.O)NR.sup.20R.sup.21, --OalkylOC(.dbd.O)R.sup.18,
--C(.dbd.S)R.sup.15, SH, --C(.dbd.O)N(C.sub.1-6 alkyl),
--N(H)S(O)(O)(C.sub.1-6 alkyl), aryl, heterocyclic,
C.sub.1-18alkylsulfone, arylsulfoxide, arylsulfonamide,
aryl(C.sub.1-18)alkyloxy, aryloxy, aryl(C.sub.1-18 alkyl)oxy,
arylthio, aryl(C.sub.1-18)alkylthio or aryl(C.sub.1-18)alkyl, where
each may be optionally substituted with 1 or more .dbd.O,
NR.sup.20R.sup.21, CN, C.sub.1-18 alkoxy, heterocyclic, C.sub.1-18
haloalkyl, heterocyclic alkyl, heterocyclic connected to R.sup.17
by alkyl, alkoxyalkoxy or halogen; R.sup.20 and R.sup.21 are
independently selected from hydrogen, C.sub.1-18alkyl, C.sub.2-18
alkenyl, C.sub.2-18 alkynyl, aryl, C.sub.3-10 cycloalkyl,
C.sub.4-10 cycloalkenyl, --C(.dbd.O)R.sup.12,
carboxylester-substituted heterocyclic or --C(.dbd.S)R.sup.12;
R.sup.25 and R.sup.26 are not present, or are independently
selected from hydrogen, C.sub.1-18 alkyl, C.sub.3-10 cycloalkyl,
aryl, heterocyclic, where each is optionally independently
substituted with 1 to 4 of C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo,
CH.sub.2OH, benzyloxy, and OH; and R.sup.27 is selected from
hydrogen, C.sub.1-18 alkyl, C.sub.3-10 cycloalkyl,
(C.sub.3-10cycloalkyl)-C.sub.1-6alkyl, aryl, and aryl C.sub.1-18
alkyl, and the salts, tautomers, isomers and solvates thereof.
3. A compound having the general formula (A), 700wherein: the
dotted lines represent an optional double bond, provided that no
two double bonds are adjacent to one another, and that the dotted
lines represent at least 3, optionally 4 double bonds; R.sup.1 is
selected from hydrogen, aryl, heterocyclic, C.sub.1-C.sub.10
alkoxy, C.sub.1-C.sub.10 thioalkyl, C.sub.1-C.sub.10 alkyl-amino,
C.sub.1-C.sub.10 dialkyl-amino, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, and C.sub.4-10 cycloalkynyl, wherein each are
optionally substituted with 1 or more R.sup.6; Y is selected from
single bond, O, S(O).sub.m, NR.sup.11, or C.sub.1-10 alkylene,
C.sub.2-10 alkenylene, C.sub.2-10 alkynylene, wherein each may
optionally include 1 to 3 heteroatoms selected from O, S or N;
R.sup.2 and R.sup.4 are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, halogen, --OH, --CN,
--NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy, haloalkyl,
--C(.dbd.O)R.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10cycloalkyl,
C.sub.3-10 cycloalkyloxy, C.sub.3-10cycloalkylthio, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic, provided
that when one of R.sup.25 or R.sup.26 is present, then either
R.sup.2 or R.sup.4 is selected from (.dbd.O), (.dbd.S), and
.dbd.NR.sup.27; X is selected from C.sub.1-C.sub.10 alkylene,
C.sub.2-10 alkenylene or C.sub.2-10 alkynylene, where each may
include one or more heteroatoms selected from O, S, or N, provided
any such heteroatom is not adjacent to the N in the ring; m is any
integer from 0 to 2; R.sup.3 is a heterocycle optionally
substituted with at least one R.sup.17, provided R.sup.3-M-Q is not
biphenyl; R.sup.5 is selected from hydrogen; C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, halogen, --OH, --CN, --NO.sub.2,
--NR.sup.7R.sup.8, haloalkyloxy, haloalkyl, --C(.dbd.O)R.sup.9,
--C(.dbd.O)OR.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10cycloalkyl,
C.sub.3-10 cycloalkyloxy, C.sub.3-10cycloalkylthio, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic; R.sup.6 is
selected from hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, C.sub.1-18 alkoxy, C.sub.1-18 alkylthio,
C.sub.1-18 alkylsulfoxide, C.sub.1-18 alkylsulfone, C.sub.1-18
halo-alkyl, C.sub.2-18 halo-alkenyl, C.sub.2-18 halo-alkynyl,
C.sub.1-18 halo-alkoxy, C.sub.1-18 halo-alkylthio, C.sub.3-10
cycloalkyl, C.sub.3-10 cycloalkenyl, C.sub.7-10 cycloalkynyl,
halogen, OH, CN, cyanoalkyl, --CO.sub.2R.sup.18, NO.sub.2,
--NR.sup.7R.sup.8, C.sub.1-18 haloalkyl, C(.dbd.O)R.sup.18,
C(.dbd.S)R.sup.18, SH, aryl, aryloxy, arylthio, arylsulfoxide,
arylsulfone, arylsulfonamide, aryl(C.sub.1-18)alkyl,
aryl(C.sub.1-18)alkyloxy, aryl(C.sub.1-18)alkylthio, heterocyclic,
C.sub.1-18 hydroxyalkyl, where each may be optionally substituted
with at least 1 R.sup.19; R.sup.7 and R.sup.8 are independently
selected from hydrogen, C.sub.1-18 alkyl, C.sub.1-18 alkenyl, aryl,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, heterocyclic,
--C(.dbd.O)R.sup.12; --C(.dbd.S)R.sup.12, an amino acid residue
linked through a carboxyl group thereof, or where R.sup.7 and
R.sup.8 together with the nitrogen form a heterocyclic; R.sup.9 and
R.sup.18 are independently selected from hydrogen, OH, C.sub.1-18
alkyl, C.sub.2-18 alkenyl, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, C.sub.1-18 alkoxy, --NR.sup.15R.sup.16, aryl, an
amino acid residue linked through an amino group of the amino acid,
CH.sub.2OCH(.dbd.O)R.sup.9a, or CH.sub.2C(.dbd.O)OR.sup.9a where
R.sup.9a is C.sub.1-C.sub.12 alkyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 alkylaryl or C.sub.6-C.sub.20 aralkyl; R.sup.10
and R.sup.11 are independently selected from the group consisting
of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, aryl, --C(.dbd.O)R.sup.12,
heterocyclic, or an amino acid residue; R.sup.12 is selected from
the group consisting of hydrogen, C.sub.1-18 alkyl, C.sub.2-18
alkenyl, aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, or
an amino acid residue; R.sup.15 and R.sup.16 are independently
selected from hydrogen, C.sub.1-1 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, aryl, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, or an amino acid residue; R.sup.17 is M-Q-, wherein M
is a C.sub.3-10 cycloalkyl optionally substituted with 1 or more
R.sup.19, and Q is a bond, or C.sub.1-10 alkyl optionally
substituted with 1 or more R.sup.19; R.sup.19 is selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.2-18 alkenyloxy, C.sub.2-18 alkynyloxy,
C.sub.1-18alkylthio, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, C.sub.4-10 cycloalkynyl, halogen, --OH, --CN,
cyanoalkyl, --NO.sub.2, --NR.sup.20R.sup.21 C.sub.1-18 haloalkyl,
C.sub.1-18 haloalkyloxy, --C(.dbd.O)R.sup.18, --C(.dbd.O)OR.sup.18,
--OalkenylC(.dbd.O)OR.sup.18, --OalkylC(.dbd.O)NR.sup.20R.sup.20,
--OalkylOC(.dbd.O)R.sup.18, --C(.dbd.S)R.sup.18, SH,
--C(.dbd.O)N(C.sub.1-6 alkyl), --N(H)S(O)(O)(C.sub.1-6 alkyl),
aryl, heterocyclic, C.sub.1-18alkylsulfone, arylsulfoxide,
arylsulfonamide, aryl(C.sub.1-18)alkyloxy, aryloxy, aryl(C.sub.1-18
alkyl)oxy, arylthio, aryl(C.sub.1-18)alkylthio or
aryl(C.sub.1-18)alkyl, where each may be optionally substituted
with 1 or more .dbd.O, NR.sup.20R.sup.21, CN, C.sub.1-18 alkoxy,
heterocyclic, C.sub.1-18 haloalkyl, heterocyclic alkyl,
heterocyclic connected to R.sup.17 by alkyl, alkoxyalkoxy or
halogen; R.sup.20 and R.sup.21 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10cycloalkyl, C.sub.4-10 cycloalkenyl,
--C(.dbd.O)R.sup.12, or --C(.dbd.S)R.sup.12; R.sup.25 and R.sup.26
are not present, or are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.3-10 cycloalkyl, aryl, heterocyclic, where
each is optionally independently substituted with 1 to 4 of
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo, CH.sub.2OH, benzyloxy, and
OH; and R.sup.27 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.3-10 cycloalkyl, (C.sub.3-10 cycloalkyl)-C.sub.1-6 alkyl,
aryl, and aryl C.sub.1-18 alkyl, and the salts, tautomers, isomers
and solvates thereof.
4. The compound of claim 1, 2 or 3 wherein R.sup.3 is
heterocycle.
5. The compound of claims 1, 2 or 3 wherein YR.sup.1 is
halophenyl.
6. The compound of claim 5 wherein halophenyl is
ortho-fluorophenyl.
7. The compound of claims 1, 2 or 3 wherein R.sup.3 is isoxazolyl
substituted with 1 R.sup.17.
8. The compound of claims 1, 2 or 3 wherein R.sup.17 is aryl or an
aromatic heterocycle which is substituted with 1, 2 or 3
R.sup.19.
9. The compound of claims 1, 2 or 3 wherein YR.sup.1 is none of
hydrogen, an unsubstituted C.sub.3-10 cycloalkyl, or C.sub.1-6
alkyl.
10. The compound of claim 9 wherein YR.sup.1 is not hydrogen.
11. The compound of claims 1, 2 or 3 wherein R.sup.19 is
trihalomethyl, trihalomethoxy, alkoxy or halogen.
12. The compound of claims 1, 2 or 3 wherein R.sup.1 is aryl or
aromatic heterocyle substituted with 1, 2 or 3 R.sup.6 wherein
R.sup.6 is halogen, C.sub.1-18 alkoxy; or C.sub.1-18 haloalkyl.
13. The compound of claims 12 wherein R.sup.1 is phenyl substituted
with 1, 2 or 3 halogens.
14. The compound of claims 1, 2 or 3 wherein halogen is fluoro.
15. The compound of claims 1, 2 or 3 wherein Y is a single bond, O,
C.sub.1-6 alkylene, C.sub.2-6 alkenylene, C.sub.2-6 alkynylene or
one of said groups containing 1 to 3 heteroatoms selected from O, S
or NR.sup.11.
16. The compound of claim 15 wherein Y is --O(CH.sub.2).sub.1-5--,
--(CH.sub.2).sub.1-4--O--(CH.sub.2).sub.1-4--,
--S--(CH.sub.2).sub.1-5--,
--(CH.sub.2).sub.1-4--S--(CH.sub.2).sub.1-4--,
--NR.sup.11--(CH.sub.2).su- b.1-5--,
--(CH.sub.2).sub.1-4--NR.sup.11--(CH.sub.2).sub.1-4 or C.sub.3-10
cycloalkylidene.
17. The compound of claim 15 wherein Y is --OCH.sub.2--,
--CH.sub.2O--, C.sub.1-2 alkylene, C.sub.2-3 alkenylene, C.sub.2-3
alkynylene, O or a bond.
18. The compound of claim 15 wherein Y is a bond.
19. The compound of claims 1, 2 or 3 wherein YR.sup.1 is not any
one of H, an unsubstituted C.sub.3-10 cycloalkyl or C.sub.1-C.sub.6
alkyl.
20. The compound of claims 1, 2 or 3 wherein YR.sup.1 is not H.
21. The compound of claims 1, 2 or 3 wherein YR.sup.1 is halo or
halomethyl-substituted phenyl.
22. The compound of claims 1, 2 or 3 wherein halo or halomethyl are
ortho or meta.
23. The compound of claims 1, 2 or 3 wherein X is selected from the
group consisting of alkylene, alkynylene or alkenylene and said
hydrocarbons having an intrachain N, O or S heteroatom.
24. The compound of claims 1, 2 or 3 wherein X is alkyl.
25. The compound of claim 23 wherein X is selected from the group
consisting of --CH.sub.2--, --CH(CH.sub.3)--,
--CH.sub.2--CH.sub.2--, --CH.sub.2--CH.sub.2-CH.sub.2--,
--CH.sub.2--CH.sub.2-CH.sub.2--CH.sub.2,
--(CH.sub.2).sub.2-4--O--(CH.sub.2).sub.2-4--,
--(CH.sub.2).sub.2-4--S--(- CH.sub.2).sub.2-4--,
--(CH.sub.2).sub.2-4--NR.sup.10--(CH.sub.2).sub.2-4--- , C.sub.3-10
cycloalkylidene, C.sub.2-6 alkenylene and C.sub.2-6 alkynylene.
26. The compound of claims 1, 2 or 3 wherein X is methylene.
27. The compound of claims 1, 2 or 3 wherein R.sup.3 is aryl or a
heterocycle substituted with 0 to 3 R.sup.17.
28. The compound of claim 27 wherein the heterocycle is an aromatic
heterocycle.
29. The compound of claim 28 wherein the heterocycle contains 1, 2
or 3 N, S or O atoms in the ring, is linked to X through a ring
carbon atom and contains 4 to 6 total ring atoms.
30. The compound of claims 1, 2 or 3 wherein R.sup.3 is isoxazolyl
substituted with 1 to 3 R.sup.17.
31. The compound of claims 1, 2 or 3 wherein R.sup.17 is aryl or a
heterocycle further substituted with 1 to 3 R.sup.19.
32. The compound of claims 1 or 3 wherein M is aryl or aromatic
heterocycle.
33. The compound of claims 1 or 3 wherein Q contains 0 to 20 atoms
selected from C, O, S, N and H.
34. The compound of claims 1 or 3 wherein M is a cyclic group
selected from R.sup.17.
35. The compound of claim 2 wherein R.sup.17 is selected from the
group consisting of C.sub.3-10cycloalkyl, C.sub.3-10 cycloalkenyl,
C.sub.7-10 cycloalkynyl, halogen, aryl, aryloxy, arylthio,
arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl;
arylalkyloxy; arylalkylthio; heterocycle; C.sub.1-18 hydroxyalkyl,
each of said C.sub.3-10 cycloalkyl, C.sub.3-10 cycloalkenyl,
C.sub.7-10 cycloalkynyl, halogen, aryl, aryloxy, arylthio,
arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl;
arylalkyloxy; arylalkylthio; heterocycle; and C.sub.1-18
hydroxyalkyl is unsubstituted or is substituted 1 or more
R.sup.19.
36. The compound of claim 2 wherein R.sup.17 is selected from the
group consisting of aryl and heterocycle, and where said aryl or
heterocycle is optionally substituted with 1 or more R.sup.19.
37. The compound of claims 1, 2 or 3 wherein R.sup.9 and R.sup.18
are H, OH or alkyl.
38. The compound of claims 1, 2 or 3 wherein R.sup.5 is H.
39. The compound of claims 1, 2 or 3 wherein R.sup.6 is
halogen.
40. The compound of claims 1, 2 or 3 wherein R.sup.7, R.sup.8,
R.sup.10, R.sup.11, R.sup.15, R.sup.16, R.sup.20 and R.sup.21 are
independently H or C.sub.1-18 alkyl.
41. The compound of claims 1, 2 or 3 wherein R.sup.12 is OH or
alkyl.
42. The compound of claims 1, 2 or 3 wherein R.sup.19 is selected
from the group consisting of H; C.sub.1-18 alkyl; C.sub.2-18
alkenyl; C.sub.2-18 alkynyl; C.sub.1-18 alkoxy; alkenyloxy;
alkynyloxy; C.sub.1-18 alkylthio; C.sub.3-10 cycloalkyl; C.sub.4-10
cycloalkenyl; C.sub.4-10 cycloalkynyl; halogen; OH; CN; cyanoalkyl;
NO.sub.2; NR.sup.20R.sup.21; haloalkyl; haloalkyloxy;
C(.dbd.O)R.sup.18; C(.dbd.O)OR.sup.18; OalkenylC(.dbd.O)OR.sup.18;
--OalkylC(.dbd.O)NR.sup.20R.sup.21; aryl; heterocycle;
--OalkylOC(.dbd.O)R.sup.18; C(.dbd.O)N(C.sub.1-6 alkyl),
N(H)S(O)(O)(C.sub.1-6 alkyl); arylalkyloxy; aryloxy; arylalkyloxy;
and arylalkyl; each of which is unsubstituted or substituted with 1
or more .dbd.O; NR.sup.20R.sup.21; CN; alkoxy; heterocycle;
haloalkyl- or alkyl-substituted heterocycle; and heterocycle linked
to R.sup.17 by alkyl; alkoxyalkoxy or halogen.
43. The compound of claim 42 wherein R.sup.19 is independently
selected from the group consisting of halogen, N(R.sup.20
R.sup.21), alkoxy. halo-substituted alkyl and halo-substituted
alkoxy.
44. The compound of claims 1, 2 or 3 wherein R.sup.25 and R.sup.26
are not present.
45. The compound of claims 1, 2 or 3 which is not substituted at
R.sup.25 but is substituted at R.sup.26, and either R.sup.2 or
R.sup.4 is selected from (.dbd.O), (.dbd.S), and
(.dbd.NR.sup.27).
46. The compound of claims 1, 2 or 3 wherein haloalkyl or
haloalkyloxy is --CF3 or --OCF3.
47. A composition comprising a pharmaceutically acceptable
excipient and a 25 compound of claims 1, 2 or 3.
48. A compound having the general formula (B), 701wherein: the
dotted lines represent an optional double bond, provided that no
two double bonds are adjacent to one another, and that the dotted
lines represent at least 3, optionally 4 double bonds; R.sup.1 is
selected from hydrogen, aryl, heterocyclic, C.sub.1-C.sub.10
alkoxy, C.sub.1-C.sub.10 thioalkyl, C.sub.1-C.sub.10 alkyl-amino,
C.sub.1-C.sub.10 dialkyl-amino, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, and C.sub.4-10 cycloalkynyl, wherein each are
optionally substituted with 1 or more R.sup.6; Y is selected from
single bond, O, S(O).sub.m, NR.sup.11, or C.sub.1-10 alkylene,
C.sub.2-10 alkenylene, C.sub.2-10 alkynylene, wherein each may
optionally include 1 to 3 heteroatoms selected from O, S or N;
R.sup.2 and R.sup.4 are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, halogen, --OH, --CN,
--NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy, haloalkyl,
--C(.dbd.O)R.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10
cycloalkyl, C.sub.3-10 cycloalkyloxy, C.sub.3-10cycloalkylthio,
C.sub.3-10 cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic,
provided that when one of R.sup.25 or R.sup.26 is present, then
either R.sup.2 or R.sup.4 is selected from (.dbd.O), (.dbd.S), and
.dbd.NR.sup.27; X is selected from C.sub.1-C.sub.10 alkylene,
C.sub.2-10 alkenylene or C.sub.2-10 alkynylene, where each may
include one or more heteroatoms selected from O, S, or N, provided
any such heteroatom is not adjacent to the N in the ring; m is any
integer from 0 to 2; R.sup.3 is selected from aryl, aryloxy,
arylthio, cycloalkyl, cycloalkenyl, cycloalkynyl,
aryl-N(R.sup.10)--, or heterocyclic, where each said substituent
may be optionally substituted with at least one R.sup.17, provided
that for cycloalkenyl the double bond is not adjacent to a
nitrogen, and provided R.sup.3 M-Q- is not biphenyl; R.sup.5 is
selected from hydrogen; C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, C.sub.1-18 alkoxy, C.sub.1-18 alkylthio,
halogen, --OH, --CN, --NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy,
haloalkyl, --C(.dbd.O)R.sup.9, --C(.dbd.O)OR.sup.9,
--C(.dbd.S)R.sup.9, SH, aryl, aryloxy, arylthio, arylalkyl,
C.sub.1-18 hydroxyalkyl, C.sub.3-10 cycloalkyl, C.sub.3-10
cycloalkyloxy, C.sub.3-10 cycloalkylthio, C.sub.3-10 cycloalkenyl,
C.sub.7-10 cycloalkynyl, or heterocyclic; R.sup.6 is selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, C.sub.1-18 alkylsulfoxide,
C.sub.1-18 alkylsulfone, C.sub.1-18 halo-alkyl, C.sub.2-18
halo-alkenyl, C.sub.2-18 halo-alkynyl, C.sub.1-18 halo-alkoxy,
C.sub.1-18 halo-alkylthio, C.sub.3-10cycloalkyl, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, halogen, OH, CN, cyanoalkyl,
--CO.sub.2R.sup.18, NO.sub.2, --NR.sup.7R.sup.8, C.sub.1-18
haloalkyl, C(.dbd.O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy,
arylthio, arylsulfoxide, arylsulfone, arylsulfonamide,
aryl(C.sub.1-18)alkyl, aryl(C.sub.1-18)alkyloxy,
aryl(C.sub.1-18)alkylthio, heterocyclic, C.sub.1-18 hydroxyalkyl,
where each may be optionally substituted with at least 1 R.sup.19;
R.sup.7 and R.sup.8 are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.1-18 alkenyl, aryl, C.sub.3-10cycloalkyl,
C.sub.4-10 cycloalkenyl, heterocyclic, --C(.dbd.O)R";
--C(.dbd.S)R.sup.12, an amino acid residue linked through a
carboxyl group thereof, or where R.sup.7 and R.sup.8 together with
the nitrogen form a heterocyclic; R.sup.9 and R.sup.18 are
independently selected from hydrogen, OH, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
C.sub.1-18 alkoxy, --NR.sup.15R.sup.16, aryl, an amino acid residue
linked through an amino group of the amino acid,
CH.sub.2OCH(.dbd.O)R.sup.9a, or CH.sub.2C(.dbd.O)OR.sup.9a where
R.sup.9a is C.sub.1-C.sub.12 alkyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 alkylaryl or C.sub.6-C.sub.20 aralkyl; R.sup.10
and R.sup.11 are independently selected from the group consisting
of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, aryl, --C(.dbd.O)R.sup.12,
heterocyclic, or an amino acid residue; R.sup.12 is selected from
the group consisting of hydrogen, C.sub.1-18 alkyl, C.sub.2-18
alkenyl, aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, or
an amino acid residue; R.sup.15 and R.sup.16 are independently
selected from hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, aryl, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, or an amino acid residue; R.sup.17 is independently
M-Q- wherein M is a ring optionally substituted with 1 or more
R.sup.19, and Q is a bond or a linking group connecting M to
R.sup.3 having 1 to 10 atoms and optionally substituted with 1 or
more R.sup.19; R.sup.19 is selected from hydrogen, C.sub.1-18
alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.2-18 alkenyloxy, C.sub.2-18 alkynyloxy, C.sub.1-18alkylthio,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, C.sub.4-10
cycloalkynyl, halogen, --OH, --CN, cyanoalkyl, --NO.sub.2,
--NR.sup.20R.sup.21, C.sub.1-18 haloalkyl, C.sub.1-18 haloalkyloxy,
--C(.dbd.O)R.sup.18, --C(.dbd.O)OR.sup.18,
--OalkenylC(.dbd.O)OR.sup.18, --OalkylC(.dbd.O)NR.sup.20R.sup.21,
--OalkylOC(.dbd.O)R.sup.15, --C(.dbd.S)R.sup.18, SH,
--C(.dbd.O)N(C.sub.1-6 alkyl), --N(H)S(O)(O)(C.sub.1-6 alkyl),
aryl, heterocyclic, C.sub.1-18alkylsulfone, arylsulfoxide,
arylsulfonamide, aryl(C.sub.1-18)alkyloxy, aryloxy, aryl(C.sub.1-18
alkyl)oxy, arylthio, aryl(C.sub.1-18)alkylthio or
aryl(C.sub.1-18)alkyl, where each may be optionally substituted
with 1 or more .dbd.O, NR.sup.20R.sup.21, CN, C.sub.1-18alkoxy,
heterocyclic, C.sub.1-18 haloalkyl, heterocyclic alkyl,
heterocyclic connected to R.sup.17 by alkyl, alkoxyalkoxy or
halogen; R.sup.20 and R.sup.21 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
--C(.dbd.O)R.sup.12, or --C(.dbd.S)R.sup.12; R.sup.27 is selected
from hydrogen, C.sub.1-18 alkyl, C.sub.3-10 cycloalkyl, (C.sub.3-10
cycloalkyl)-C.sub.1-6alkyl, aryl, and aryl C.sub.1-18 alkyl, and
salts, tautomers, isomers and solvates thereof.
49. The compound of claim 48 wherein Y is a single bond, and
R.sup.1 is aryl.
50. The compound of claim 48 wherein X is C.sub.1-C.sub.10
alkylene, C.sub.2-10 alkenylene or C.sub.2-10 alkynylene.
51. The compound of claim 48 wherein R.sup.3 is heterocylic.
52. The compound of claim 48 wherein R.sup.3 is heterocyclic
substituted with R.sup.17 where Q is a bond and M is aryl.
53. The compound of claim 48 wherein Y is a single bond, and
R.sup.1 is phenyl.
54. The compound of claim 48 wherein R.sup.3 is isoxazole
substituted with R.sup.17 where Q is a bond and M is aryl.
55. The compound of claim 48 wherein R.sup.3 is isoxazole
substituted with R.sup.17 where Q is a bond and M is phenyl.
56. A compound having the general formula (C), 702wherein: the
dotted lines represent an optional double bond, provided that no
two double bonds are adjacent to one another, and that the dotted
lines represent at least 3, optionally 4 double bonds; R.sup.1 is
selected from hydrogen, aryl, heterocyclic, C.sub.1-C.sub.10
alkoxy, C.sub.1-C.sub.10 thioalkyl, C.sub.1-C.sub.10 alkyl-amino,
C.sub.1-C.sub.10 dialkyl-amino, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, and C.sub.4-10 cycloalkynyl, wherein each are
optionally substituted with 1 or more R.sup.6; Y is selected from
single bond, O, S(O).sub.m, NR.sup.11, or C.sub.1-10 alkylene,
C.sub.2-10 alkenylene, C.sub.2-10 alkynylene, wherein each may
optionally include 1 to 3 heteroatoms selected from O, S or N;
R.sup.2 and R.sup.4 are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, halogen, --OH, --CN,
--NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy, haloalkyl,
--C(.dbd.)R.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy, arylthio,
arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10 cycloalkyl,
C.sub.3-10 cycloalkyloxy, C.sub.3-10 cycloalkylthio, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic, provided
that when one of R.sup.25 or R.sup.26 is present, then either
R.sup.2 or R.sup.4 is selected from (.dbd.O), (.dbd.S), and
.dbd.NR.sup.27; X is selected from C.sub.1-C.sub.10 alkylene,
C.sub.2-10 alkenylene or C.sub.2-10 alkynylene, where each may
include one or more heteroatoms selected from O, S, or N, provided
any such heteroatom is not adjacent to the N in the ring; m is any
integer from 0 to 2; R.sup.3 is selected from aryl, aryloxy,
arylthio, cycloalkyl, cycloalkenyl, cycloalkynyl,
aryl-N(R.sup.10)--, or heterocyclic, where each said substituent
may be optionally substituted with at least one R.sup.17, provided
that for cycloalkenyl the double bond is not adjacent to a
nitrogen, and provided R.sup.3 M-Q- is not biphenyl; R.sup.5 is
selected from hydrogen; C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.2-18 alkynyl, C.sub.1-18 alkoxy, C.sub.1-18 alkylthio,
halogen, --OH, --CN, --NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy,
haloalkyl, --C(.dbd.O)R.sup.9, --C(.dbd.O)OR.sup.9,
--C(.dbd.S)R.sup.9, SH, aryl, aryloxy, arylthio, arylalkyl,
C.sub.1-18 hydroxyalkyl, C.sub.3-10 cycloalkyl, C.sub.3-10
cycloalkyloxy, C.sub.3-10cycloalkylthio, C.sub.3-10cycloalkenyl,
C.sub.7-10 cycloalkynyl, or heterocyclic; R.sup.6 is selected from
hydrogen, C-.sub.18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, C.sub.1-18 alkylsulfoxide,
C.sub.1-18 alkylsulfone, C.sub.1-18 halo-alkyl, C.sub.2-18
halo-alkenyl, C.sub.2-18 halo-alkynyl, C.sub.1-18 halo-alkoxy,
C.sub.1-18 halo-alkylthio, C.sub.3-10cycloalkyl, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, halogen, OH, CN, cyanoalkyl,
--CO.sub.2R.sup.18, NO.sub.2, --NR.sup.7R.sup.8, C.sub.1-18
haloalkyl, C(.dbd.O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy,
arylthio, arylsulfoxide, arylsulfone, arylsulfonamide,
aryl(C.sub.1-18)alkyl, aryl(C.sub.1-18)alkyloxy,
aryl(C.sub.1-18)alkylthio, heterocyclic, C.sub.1-18 hydroxyalkyl,
where each may be optionally substituted with at least 1 R.sup.19;
R.sup.7 and R.sup.8 are independently selected from hydrogen,
C.sub.1-18 alkyl, C.sub.1-18 alkenyl, aryl, C.sub.3-10 cycloalkyl,
C.sub.4-10 cycloalkenyl, heterocyclic, --C(.dbd.O)R.sup.12;
--C(.dbd.S)R.sup.12, an amino acid residue linked through a
carboxyl group thereof, or where R.sup.7 and R.sup.8 together with
the nitrogen form a heterocyclic; R.sup.9 and R.sup.18 are
independently selected from hydrogen, OH, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.3-10cycloalkyl, C.sub.4-10 cycloalkenyl,
C.sub.1-18 alkoxy, --NR.sup.15R.sup.16, aryl, an amino acid residue
linked through an amino group of the amino acid,
CH.sub.2OCH(.dbd.O)R.sup.9a, or CH.sub.2C(.dbd.O)OR.sup.9a where
R.sup.9a is C.sub.1-C.sub.12 alkyl, C.sub.6-C.sub.20 aryl,
C.sub.6-C.sub.20 alkylaryl or C.sub.6-C.sub.20 aralkyl; R.sup.10
and R.sup.11 are independently selected from the group consisting
of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.3-10cycloalkyl, C.sub.4-10 cycloalkenyl, aryl,
--C(.dbd.O)R.sup.12, heterocyclic, or an amino acid residue;
R.sup.12 is selected from the group consisting of hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, aryl, C.sub.3-10 cycloalkyl,
C.sub.4-10 cycloalkenyl, or an amino acid residue; R.sup.15 and
R.sup.16 are independently selected from hydrogen, C.sub.1-18
alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, aryl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, or an amino acid residue;
R.sup.17 is independently M-Q- wherein M is a ring optionally
substituted with 1 or more R.sup.19, and Q is a bond or a linking
group connecting M to R.sup.3 having 1 to 10 atoms and optionally
substituted with I or more R.sup.19; R.sup.19 is selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.2-18 alkenyloxy, C.sub.2-18 alkynyloxy,
C.sub.1-18alkylthio, C.sub.3-10 cycloalkyl, C.sub.4-10
cycloalkenyl, C.sub.4-10 cycloalkynyl, halogen, --OH, --CN,
cyanoalkyl, --NO.sub.2, --NR.sup.20R.sup.21, C.sub.1-18 haloalkyl,
C.sub.1-18 haloalkyloxy, --C(.dbd.O)R.sup.18, --C(.dbd.O)OR.sup.18,
--OalkenylC(.dbd.O)OR.sup.18, --OalkylC(.dbd.O)NR.sup.20R.sup.21,
--OalkylOC(.dbd.O)R.sup.18, --C(.dbd.S)R.sup.18, SH,
--C(.dbd.O)N(C.sub.1-6 alkyl), --N(H)S(O)(O)(C.sub.1-6 alkyl),
aryl, heterocyclic, C.sub.-18alkylsulfone, arylsulfoxide,
arylsulfonamide, aryl(C.sub.1-18)alkyloxy, aryloxy, aryl(C.sub.1-18
alkyl)oxy, arylthio, aryl(C.sub.1-18)alkylthio or
aryl(C.sub.1-18)alkyl, where each may be optionally substituted
with 1 or more .dbd.O, NR.sup.20R.sup.21, CN, C.sub.1-18 alkoxy,
heterocyclic, C.sub.1-18 haloalkyl, heterocyclic alkyl,
heterocyclic connected to R.sup.17 by alkyl, alkoxyalkoxy or
halogen; R.sup.20 and R.sup.21 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
--C(.dbd.O)R.sup.12, or --C(.dbd.S)R.sup.12; R.sup.27 is selected
from hydrogen, C.sub.1-18 alkyl, C.sub.3-10 cycloalkyl, (C.sub.3-10
cycloalkyl)-C.sub.1-6 alkyl, aryl, and aryl C.sub.1-18 alkyl, and
salts, tautomers, isomers and solvates thereof.
57. The compound of claim 56 wherein Y is a single bond, and
R.sup.1 is aryl.
58. The compound of claim 56 wherein X is C.sub.1-C.sub.10
alkylene, C.sub.2-10 alkenylene or C.sub.2-10 alkynylene.
59. The compound of claim 56 wherein R.sup.3 is heterocylic.
60. The compound of claim 56 wherein R.sup.3 is heterocyclic
substituted with R.sup.17 where Q is a bond and M is aryl.
61. The compound of claim 56 wherein Y is a single bond, and
R.sup.1 is phenyl.
62. The compound of claim 56 wherein R.sup.3 is isoxazole
substituted with R.sup.17 where Q is a bond and M is aryl.
63. The compound of claim 56 wherein R.sup.3 is isoxazole
substituted with R.sup.17 where Q is a bond and M is phenyl.
64. A method comprising administering to a subject in need of
treatment or prophylaxis of a viral infection an antivirally
effective amount of a compound of claims 1, 2, 3, 48 or 56.
65. The method of claim 64, wherein the viral infection is an
infection of a hepatitis-C virus.
66. The method of claim 65 further comprising administering at
least one additional antiviral therapy to the subject.
67. The method of claim 66 wherein the additional therapy is is
selected from the group consisting of an interferon alpha and
ribavirin.
68. A method of screening antiviral compounds which comprises
providing a compound of claims 1, 2, 3, 48 or 56 and determining
the anti-viral activity of said compound.
69. The method of claim 68 wherein said anti-viral activity is
determined by the activity of said compound against one or more
viruses belonging to the family of the Flaviviridae and/or of the
Picornaviridae.
70. A method for assaying the structure-activity of analogues of
formula (A) compounds 703wherein the substituents are defined in WO
2004/005286, comprising (c) preparing a compound of formula (A) in
which at least one substituent is not disclosed by WO 2004/005286;
and (d) determining the anti-HCV activity of the compound of step
(a).
71. The method of claim 70 wherein the substituent is located at
R.sup.3, R.sup.2, R.sup.4, R.sup.26 and/or R.sup.5.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to a series of novel
imidazo[4,5-c]pyridine compounds, processes for their preparation,
their use to treat or prevent viral infections and their use to
manufacture a medicine to treat or prevent viral infections,
particularly infections with viruses belonging to the family of the
Flaviviridae and Picornaviridae and more preferably infections with
hepatitis-C-virus (HCV).
BACKGROUND OF THE INVENTION
[0002] The family of the Flaviviridae consists of 3 genera, the
pestiviruses, the flaviviruses and the hepaciviruses and also
contains the hepatitis G virus (HGV/GBV-C) that has not yet been
assigned to a genus. Pestiviruses such as the Classical Swine Fever
Virus (CSFV), the Bovine Viral Diarrhea Virus (BVDV) and the Border
Disease Virus (BDV) cause infections of domestic livestock
(respectively pigs, cattle and sheep) and are responsible for
significant economic losses world-wide. BVDV, the prototypic
representative of the pestivirus genus is ubiquitous and causes a
range of clinical manifestations, including abortion,
teratogenesis, respiratory problems, chronic wasting disease,
immune system dysfunction, and predisposition to secondary viral
and bacterial infections and may also cause acute fatal disease.
Fetuses of cattle can be infected persistently with BVDV, these
animals remain viremic throughout life and serve as a continuous
source for virus spread in herds.
[0003] Vaccines are used in some countries with varying degrees of
success to control pestivirus disease. In other countries, animal
culling and slaughter are used to contain pestivirus disease
outbreaks.
[0004] The World Health Organization estimates that world-wide 170
million people (3% of the world's population) are chronically
infected with HCV. These chronic carriers are at risk of developing
cirrhosis and/or liver cancer. In studies with a 10 to 20 year
follow-up, cirrhosis developed in 20-30% of the patients, 1 to 5%
of who may develop liver cancer during the next then years. The
only treatment option available today is the use of interferon
.alpha.-2 (or its pegylated from) either alone or combined with
ribavirin. However, sustained response is only observed in about
40% of the patients and treatment is associated with serious
adverse effects. There is thus an urgent need for potent and
selective inhibitors of the replication of the HCV in order to
treat infections with HCV. Furthermore, the study of specific
inhibitors of HCV replication has been hampered by the fact that it
is not possible to propagate HCV (efficiently) in cell culture.
Since HCV and pestiviruses belong to the same virus family and
share many similarities (organization of the genome, analogous gene
products and replication cycle), pestiviruses have been adopted as
a model and surrogate for HCV. For example, BVDV is closely related
to hepatitis C virus (HCV) and used as a surrogate virus in drug
development for HCV infection.
[0005] The compound
3-[((2-dipropylamino)ethyl)thio]-5H-1,2,4-triazino[5,6- -b]indole
has been reported to selectively inhibit the replication of BVDV
and other pestiviruses (Baginski SG et al., Proc. Natl. Acad. Sci.
U.S.A. 2000 July 5;97(14):7981-6). Currently, there is no treatment
strategy available for controlling infections caused by
pestiviruses.
[0006] Coxsackie viruses belong to the group of the enteroviruses,
family of the Picornaviridae. They cause a heterogeneous group of
infections including herpangina, aseptic meningitis, a
common-cold-like syndrome, a non-paralytic poliomyelitis-like
syndrome, epidemic pleurodynia (an acute, febrile, infectious
disease generally occurring in epidemics), hand-foot-mouth
syndrome, pediatric and adult pancreatitis and serious
myocarditis.
[0007] Currently only pleconaril
(3-13,5-dimethyl-4-[[3-methyl-5-isoxazoly-
l)propyl]phenyl]-5-(trifluoromethyl-1,2,4-oxadiazole)) and
enviroxime (2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenyl
ketone oxime) have been studied clinically for the treatment of
infections with enteroviruses. Pleconaril is a so called "capsid
function-inhibitor"; enviroxime prevents the formation of the RNA
replicative intermediate. Enviroxime resulted in only modest
clinical and virological benefit in some studies and no benefits in
others. Clinical response with pleconaril has been observed in some
studies, but the compound has not been approved by the Food and
Drug Administration (hearing of Mar. 18, 2002).
[0008] Relevant disclosures include U.S. Pat. Nos. 4,914,108;
4,988,707; 4,990,518; 5,137,896; 5,208,242; 5,227,384; 5,302,601;
5,374,638; 5,405,964; 5,438,063; 5,486,525; 6,479,508; and U.S.
Patent Publication No. U.S. 2003/0108862 A1, Canadian Patent No.
2423800 A1, German Patent Nos. 4211474 A1, 4236026, 4309969,
4318813, European Patent Nos. EP 0 138 552 A2, EP 0 706 795 A2, EP
1 132 381 A1, Great Britain Patent No. 2158440 A, PCT Patent
Publication Nos. WO 00/20416, WO 00/39127, WO 00/40583, WO
03/007945 A1, WO 03/010140 A2, WO 03/010141 A2, WO 93/02080, WO
93/14072, WO 96/11192, WO 96/12703, WO 99/27929, Akamatsu, et al.,
New Efficient Route for Solid-Phase Synthesis of Benzimidazole
Derivatives", 4:475-483, J. COMB. CHEM, 2002, Cleve et al.,
"Derivate des Imidazo[4.5-b]- und Imidazo[4.5-c]pyridins",
747:158-171, JUSTUS LIEBIGS ANNALEN DER CHEMACA, 1971, Kiyama, et
al., "Synthesis and Evaluation of Novel Nonpeptide Angiotensin II
Receptor Antagonists: Imidazo[4,5-c]pyridine Derivatives with an
Aromatic Substituent", 43(3):450-60, CHEM PHARM BULL, 1995,
Mederski et al., "Synthesis and Structural Assignment of Some
N-substituted Imidazopyridine Derivatives", 48(48):10549-58,
TETRAHEDRON, 1992, Yutilov et al., 23(1):56-9,
KHIMAKO-FARMATSEVTICHESKII ZHURNAL, 1989. The disclosures of all
citations set forth herein are expressly incorporated by reference
to the extent such disclosures are relevant to the contents
herein.
[0009] A need exists for compounds having antiviral and other
desirable properties, such as bioavailability, efficacy,
nontoxicity, optimal clearance, potency and the like. In
particular, a need exists for compounds having selective activity
against viruses belonging to the family of Flaviviridae including
hepatitis C virus, and against viruses belonging to the family of
Picornaviridae. These and other objects of this invention will be
apparent to one skilled in the art from consideration of this
specification as a whole.
SUMMARY OF THE INVENTION
[0010] An embodiment of the present invention provides compounds
having the general formula (A), 2
[0011] wherein:
[0012] the dotted lines represent an optional double bond, provided
that no two double bonds are adjacent to one another, and that the
dotted lines represent at least 3, optionally 4 double bonds;
[0013] R.sup.1 is selected from hydrogen, aryl, heterocyclic,
C.sub.1-C.sub.10 alkoxy, C.sub.1-C.sub.10 thioalkyl,
C.sub.1-C.sub.10 alkyl-amino, C.sub.1-C.sub.10 dialkyl-amino,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, and C.sub.4-10
cycloalkynyl, wherein each are optionally substituted with 1 or
more R.sup.6;
[0014] Y is selected from single bond, O, S(O).sub.m, NR.sup.11, or
C.sub.1-10 alkylene, C.sub.2-10 alkenylene, C.sub.2-10 alkynylene,
wherein each may optionally include 1 to 3 heteroatoms selected
from O, S or N;
[0015] R.sup.2 and R.sup.4 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, halogen, --OH, --CN,
--NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy, haloalkyl,
--C(.dbd.O)R.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10
cycloalkyl, C.sub.3-10 cycloalkyloxy, C.sub.3-10 cycloalkylthio,
C.sub.3-10 cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic,
provided that when one of R.sup.25 or R.sup.26 is present, then
either R.sup.2 or R.sup.4 is selected from (.dbd.O), (.dbd.S), and
.dbd.NR.sup.27;
[0016] X is selected from C.sub.1-C.sub.10 alkylene, C.sub.2-10
alkenylene or C.sub.2-10 alkynylene, where each may include one or
more heteroatoms selected from O, S, or N, provided any such
heteroatom is not adjacent to the N in the ring;
[0017] m is any integer from 0 to 2;
[0018] R.sup.3 is selected from aryl, aryloxy, arylthio,
cycloalkyl, cycloalkenyl, cycloalkynyl, aryl-N(R.sup.10)--, or
heterocyclic, where each said substituent may be optionally
substituted with at least one R.sup.17, provided that for
cycloalkenyl the double bond is not adjacent to a nitrogen, and
provided R.sup.3-M-Q is not biphenyl;
[0019] R.sup.5 is selected from hydrogen; C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, halogen, --OH, --CN, --NO.sub.2,
--NR.sup.7R.sup.8, haloalkyloxy, haloalkyl, --C(.dbd.O)R.sup.9,
--C(.dbd.O)OR.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10
cycloalkyl, C.sub.3-10cycloalkyloxy, C.sub.3-10cycloalkylthio,
C.sub.3-10cycloalkenyl, C.sub.7-10 cycloalkynyl, or
heterocyclic;
[0020] R.sup.6 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, C.sub.1-18 alkylsulfoxide, C.sub.1-18
alkylsulfone, C.sub.1-18 halo-alkyl, C.sub.2-18 halo-alkenyl,
C.sub.2-18 halo-alkynyl, C.sub.1-18 halo-alkoxy, C.sub.1-18
halo-alkylthio, C.sub.3-10 cycloalkyl, C.sub.3-10 cycloalkenyl,
C.sub.7-10 cycloalkynyl, halogen, OH, CN, cyanoalkyl,
--CO.sub.2R.sup.18, NO.sub.2, --NR.sup.7R.sup.8, C.sub.1-18
haloalkyl, C(.dbd.O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy,
arylthio, arylsulfoxide, arylsulfone, arylsulfonamide,
aryl(C.sub.1-18)alkyl, aryl(C.sub.1-18)alkyloxy,
aryl(C.sub.1-18)alkylthio, heterocyclic, C.sub.1-18 hydroxyalkyl,
where each may be optionally substituted with at least 1
R.sup.19;
[0021] R.sup.7 and R.sup.8 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.1-18 alkenyl, aryl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, heterocyclic,
--C(.dbd.O)R.sup.12; --C(.dbd.S)R.sup.12, an amino acid residue
linked through a carboxyl group thereof, or where R.sup.7 and
R.sup.8 together with the nitrogen form a heterocyclic;
[0022] R.sup.9 and R.sup.18 are independently selected from
hydrogen, OH, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, C.sub.1-18 alkoxy,
--NR.sup.15R.sup.16, aryl, an amino acid residue linked through an
amino group of the amino acid, CH.sub.2OCH(O)R.sup.9a, or
CH.sub.2C(.dbd.O)OR.sup.9a where R.sup.9a is C.sub.1-C.sub.12
alkyl, C.sub.6-C.sub.20 aryl, C.sub.6-C.sub.20 alkylaryl or
C.sub.6-C.sub.20 aralkyl;
[0023] R.sup.10 and R.sup.11 are independently selected from the
group consisting of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, aryl,
--C(.dbd.O)R.sup.12, heterocyclic, or an amino acid residue;
[0024] R.sup.12 is selected from the group consisting of hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, aryl, C.sub.3-10 cycloalkyl,
C.sub.4-10 cycloalkenyl, or an amino acid residue;
[0025] R.sup.13 and R.sup.14 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, aryl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, --C(.dbd.O)R.sup.12,
--C(.dbd.S)R.sup.12, or an amino acid residue;
[0026] R.sup.15 and R.sup.16 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10cycloalkyl, C.sub.4-10 cycloalkenyl, or an amino
acid residue;
[0027] R.sup.17 is independently M-Q- wherein M is a ring
optionally substituted with 1 or more R.sup.19, and Q is a bond or
a linking group connecting M to R.sup.3 having 1 to 10 atoms and
optionally substituted with 1 or more R.sup.19;
[0028] R.sup.19 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.2-18 alkenyloxy, C.sub.2-18 alkynyloxy, C.sub.1-18alkylthio,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, C.sub.4-10
cycloalkynyl, halogen, --OH, --CN, cyanoalkyl, --NO.sub.2,
--NR.sup.20R.sup.21, C.sub.1-18 haloalkyl, C.sub.1-18 haloalkyloxy,
--C(.dbd.O)R.sup.18, --C(.dbd.O)OR.sup.18,
--OalkenylC(.dbd.O)OR.sup.18, --OalkylC(.dbd.O)NR.sup.20R.sup.21,
--OalkylOC(.dbd.O)R.sup.18, --C(.dbd.S)R.sup.18, SH,
--C(.dbd.O)N(C.sub.1-6 alkyl), --N(H)S(O)(O)(C.sub.1-6 alkyl),
aryl, heterocyclic, C.sub.1-18alkylsulfone, arylsulfoxide,
arylsulfonamide, aryl(C.sub.1-18)alkyloxy, aryloxy, aryl(C.sub.1-18
alkyl)oxy, arylthio, aryl(C.sub.1-18)alkylthio or
aryl(C.sub.1-18)alkyl, where each may be optionally substituted
with 1 or more .dbd.O, NR.sup.20R.sup.21, CN, C.sub.1-18 alkoxy,
heterocyclic, C.sub.1-18 haloalkyl, heterocyclic alkyl,
heterocyclic connected to R.sup.17 by alkyl, alkoxyalkoxy or
halogen;
[0029] R.sup.20 and R.sup.21 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
--C(.dbd.O)R.sup.12, or --C(.dbd.S)R.sup.12;
[0030] R.sup.22 is selected from hydrogen, --OH, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.1-18 alkoxy, --NR.sup.23R.sup.24, aryl,
C.sub.3-10 cycloalkyl, and C.sub.4-10 cycloalkenyl;
[0031] R.sup.23 and R.sup.24 are independently selected from
hydrogen, C.sub.1-18 alkyl, or a heterocyclic formed by taking
C.sub.2-3 alkyl together with N of R.sup.22, which heterocyclic is
optionally substituted with OH or aryl, or an amino acid residue
linked through a carboxyl group of the amino acid;
[0032] R.sup.25 and R.sup.26 are not present, or are independently
selected from hydrogen, C.sub.1-18 alkyl, C.sub.3-10cycloalkyl,
aryl, heterocyclic, where each is optionally independently
substituted with 1 to 4 of C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo,
CH.sub.2OH, benzyloxy, and OH; and
[0033] R.sup.27 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.3-10cycloalkyl, (C.sub.3-10 cycloalkyl)-C.sub.1-6 alkyl,
aryl, and aryl C.sub.1-18 alkyl, and
[0034] salts, tautomers, isomers and solvates thereof.
[0035] Another embodiment of the present invention provides
compounds having the general formula (A), 3
[0036] wherein:
[0037] the dotted lines represent an optional double bond, provided
that no two double bonds are adjacent to one another, and that the
dotted lines represent at least 3, optionally 4 double bonds;
[0038] R.sup.1 is selected from hydrogen, aryl, heterocyclic,
C.sub.1-C.sub.10 alkoxy, C.sub.1-C.sub.10 thioalkyl,
C.sub.1-C.sub.10 alkyl-amino, C.sub.1C.sub.10 dialkyl-amino,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, and C.sub.4-10
cycloalkynyl, wherein each are optionally substituted with 1 or
more R.sup.6;
[0039] Y is selected from single bond, O, S(O).sub.m, NR.sup.11, or
C.sub.1-10 alkylene, C.sub.2-10 alkenylene, C.sub.2-10 alkynylene,
wherein each may optionally include 1 to 3 heteroatoms selected
from O, S or N;
[0040] R.sup.2 and R.sup.4 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-.sub.18 alkylthio, halogen, --OH, --CN,
--NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy, haloalkyl,
--C(--O)R.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy, arylthio,
arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10 cycloalkyl,
C.sub.3-10 cycloalkyloxy, C.sub.3-10 cycloalkylthio, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic, provided
that when one of R.sup.25 or R.sup.26 is present, then either
R.sup.2 or R.sup.4 is selected from (--O), (.dbd.S), and
.dbd.NR.sup.27;
[0041] X is selected from C.sub.1-C.sub.10 alkylene, C.sub.2-10
alkenylene or C.sub.2-10 alkynylene, where each may include one or
more heteroatoms selected from O, S, or N, provided any such
heteroatom is not adjacent to the N in the ring;
[0042] m is any integer from 0 to 2;
[0043] R.sup.3 is a heterocycle optionally substituted with at
least one R.sup.17 provided, however, that R.sup.3 optionally
substituted with at least one R.sup.17 is not pyridinyl or
5-chlorothienyl, provided that R.sup.3-MQ is not biphenyl;
[0044] R.sup.5 is selected from hydrogen; C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, halogen, --OH, --CN, --NO.sub.2,
--NR.sup.7R.sup.8, haloalkyloxy, haloalkyl, --C(.dbd.O)R.sup.9,
--C(.dbd.O)OR.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10cycloalkyl,
C.sub.3-10 cycloalkyloxy, C.sub.3-10cycloalkylthio, C.sub.3-10
cycloalkenyl, C.sub.7-.sub.10 cycloalkynyl, or heterocyclic;
[0045] R.sup.6 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, heterocyclic, C.sub.1-18
alkoxy, C.sub.1-18 alkylthio, C.sub.1-18 alkylsulfoxide, C.sub.1-18
alkylsulfone, C.sub.1-18 halo-alkyl, C.sub.2-18 halo-alkenyl,
C.sub.2-18 halo-alkynyl, C.sub.1-18 halo-alkoxy, C.sub.1-18
halo-alkylthio, C.sub.3-10 cycloalkyl, C.sub.3-10cycloalkenyl,
C.sub.7-10 cycloalkynyl, halogen, OH, CN, cyanoalkyl,
--CO.sub.2R.sup.18, NO.sub.2, --NR.sup.7R.sup.8, C.sub.1-18
haloalkyl, C(--O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy,
arylthio, arylsulfoxide, arylsulfone, arylsulfonamide,
aryl(C.sub.1-18)alkyl, aryl(C.sub.1-18)alkyloxy,
aryl(C.sub.1-18)alkylthi- o, C.sub.1-18 hydroxyalkyl, where each
may be optionally substituted with at least 1 R.sup.19;
[0046] R.sup.7 and R.sup.8 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.1-18 alkenyl, aryl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, heterocyclic,
--C(.dbd.O)R.sup.12; --C(.dbd.S)R.sup.12, an amino acid residue
linked through a carboxyl group thereof, or where R.sup.7 and
R.sup.8 together with the nitrogen form a heterocyclic;
[0047] R.sup.9 and R.sup.18 are independently selected from
hydrogen, OH, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, C.sub.1-18 alkoxy,
--NR.sup.15R.sup.16, aryl, an amino acid residue linked through an
amino group of the amino acid, CH.sub.2OCH(.dbd.O)R.sup.9a, or
CH.sub.2OC(--O)OR.sup.9a where R.sup.9a is C.sub.1-C.sub.12 alkyl,
C.sub.6-C.sub.20 aryl, C.sub.6-C.sub.20 alkylaryl or
C.sub.6-C.sub.20 aralkyl;
[0048] R.sup.10 and R.sup.11 are independently selected from the
group consisting of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, aryl,
--C(.dbd.O)R.sup.12, heterocyclic, or an amino acid residue;
[0049] R.sup.12 is selected from the group consisting of hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, aryl, C.sub.3-10 cycloalkyl,
C.sub.4-10 cycloalkenyl, or an amino acid residue;
[0050] R.sup.13 and R.sup.14 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, aryl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, --C(.dbd.O)R.sup.12,
--C(.dbd.S)R.sup.12, or an amino acid residue;
[0051] R.sup.15 and R.sup.16 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, or an amino
acid residue;
[0052] R.sup.17 is independently selected from the group consisting
of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18
alkynyl, C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, C.sub.1-18
alkylsulfoxide, C.sub.1-18 alkylsulfone, C.sub.1-18 halogenated
alkyl, C.sub.2-18 halogenated alkenyl, C.sub.2-18 halogenated
alkynyl, C.sub.1-18 halogenated alkoxy, C.sub.1-18 halogenated
alkylthio, C.sub.3-10 cycloalkyl, C.sub.3-10 cycloalkenyl,
C.sub.7-10 cycloalkynyl, halogen, OH, CN, CO.sub.2H,
CO.sub.2R.sup.18, NO.sub.2, NR.sup.7R.sup.8, haloalkyl,
C(--O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy, arylthio,
arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl,
arylalkyloxy, arylalkylthio, heterocyclic, C.sub.1-18 hydroxyalkyl,
where each of said aryl, aryloxy, arylthio, arylsulfoxide,
arylsulfone, arylsulfonamide, arylalkyl, arylalkyloxy,
arylalkylthio, heterocycle, or C.sub.1-18 hydroxyalkyl is
optionally substituted with 1 or more R.sup.19;
[0053] R.sup.19 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.2-18 alkenyloxy, C.sub.2-18 alkynyloxy, C.sub.1-18 alkylthio,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, C.sub.4-10
cycloalkynyl, halogen, --OH, --CN, cyanoalkyl, --NO.sub.2,
--NR.sup.20R.sup.21, C.sub.1-18 haloalkyl, C.sub.1-18 haloalkyloxy,
--C(.dbd.O)R.sup.18, --C(.dbd.O)OR.sup.18,
--OalkenylC(.dbd.O)OR.sup.18, OalkylC(.dbd.O)NR.sup.20R.sup.21,
--OalkylOC(.dbd.O)R.sup.18, --C(.dbd.S)R.sup.18, SH,
--C(.dbd.O)N(C.sub.1-6 alkyl), --N(H)S(O)(O)(C.sub.1-6 alkyl),
aryl, heterocyclic, C.sub.1-18alkylsulfone, arylsulfoxide,
arylsulfonamide, aryl(C.sub.1-18)alkyloxy, aryloxy, aryl(C.sub.1-18
alkyl)oxy, arylthio, aryl(C.sub.1-18)alkylthio or
aryl(C.sub.1-18)alkyl, where each may be optionally substituted
with 1 or more .dbd.O, NR.sup.20R.sup.21, CN, C.sub.1-18 alkoxy,
heterocyclic, C.sub.1-18 haloalkyl, heterocyclic alkyl,
heterocyclic connected to R.sup.17 by alkyl, alkoxyalkoxy or
halogen;
[0054] R.sup.20 and R.sup.21 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
--C(.dbd.O)R.sup.12, carboxylester-substituted heterocyclic or
--C(.dbd.S)R.sup.12;
[0055] R.sup.22 is selected from hydrogen, --OH, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.1-18 alkoxy, --NR.sup.23R.sup.24, aryl,
C.sub.3-10 cycloalkyl, and C.sub.4-10 cycloalkenyl;
[0056] R.sup.23 and R.sup.24 are independently selected from
hydrogen, C.sub.1-18 alkyl, or a heterocyclic formed by taking
C.sub.2-3 alkyl together with N of R.sup.22, which heterocyclic is
optionally substituted with OH or aryl, or an amino acid residue
linked through a carboxyl group of the amino acid;
[0057] R.sup.25 and R.sup.26 are not present, or are independently
selected from hydrogen, C.sub.1-18 alkyl, C.sub.3-10 cycloalkyl,
aryl, heterocyclic, where each is optionally independently
substituted with 1 to 4 of C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo,
CH.sub.2OH, benzyloxy, and OH; and
[0058] R.sup.27 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.3-10 cycloalkyl, (C.sub.3-10 cycloalkyl)-C.sub.1-6 alkyl,
aryl, and aryl C.sub.1-18 alkyl, and
[0059] the salts, tautomers, isomers and solvates thereof.
[0060] An embodiment of the present invention provides compounds
having the general formula (A), 4
[0061] wherein:
[0062] the dotted lines represent an optional double bond, provided
that no two double bonds are adjacent to one another, and that the
dotted lines represent at least 3, optionally 4 double bonds;
[0063] R.sup.1 is selected from hydrogen, aryl, heterocyclic,
C.sub.1-C.sub.10 alkoxy, C.sub.1-C.sub.10 thioalkyl,
C.sub.1-C.sub.10 alkyl-amino, C.sub.1-C.sub.10 dialkyl-amino,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, and C.sub.4-10
cycloalkynyl, wherein each are optionally substituted with 1 or
more R.sup.6;
[0064] Y is selected from single bond, O, S(O).sub.m, NR.sup.11, or
C.sub.1-10 alkylene, C.sub.2-10 alkenylene, C.sub.2-10 alkynylene,
wherein each may optionally include 1 to 3 heteroatoms selected
from O, S or N;
[0065] R.sup.2 and R.sup.4 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
C.sub.1-18 alkoxy, C.sub.1-18 alkylthio, halogen, --OH, --CN,
--NO.sub.2, --NR.sup.7R.sup.8, haloalkyloxy, haloalkyl,
--C(.dbd.O)R.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10cycloalkyl,
C.sub.3-10cycloalkyloxy, C.sub.3-10 cycloalkylthio,
C.sub.3-10cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic,
provided that when one of R.sup.25 or R.sup.26 is present, then
either R.sup.2 or R.sup.4 is selected from (.dbd.O), (--S), and
.dbd.NR.sup.27;
[0066] X is selected from C.sub.1-C.sub.10 alkylene, C.sub.2-10
alkenylene or C.sub.2-10 alkynylene, where each may include one or
more heteroatoms selected from O, S, or N, provided any such
heteroatom is not adjacent to the N in the ring;
[0067] m is any integer from 0 to 2;
[0068] R.sup.3 is a heterocycle optionally substituted with at
least one R.sup.17, provided R.sup.3-M-Q is not biphenyl;
[0069] R.sup.5 is selected from hydrogen; C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, halogen, --OH, --CN, --NO.sub.2,
--NR.sup.7R.sup.8, haloalkyloxy, haloalkyl, --C(.dbd.O)R.sup.9,
--C(.dbd.O)OR.sup.9, --C(.dbd.S)R.sup.9, SH, aryl, aryloxy,
arylthio, arylalkyl, C.sub.1-18 hydroxyalkyl, C.sub.3-10cycloalkyl,
C.sub.3-10 cycloalkyloxy, C.sub.3-10cycloalkylthio, C.sub.3-10
cycloalkenyl, C.sub.7-10 cycloalkynyl, or heterocyclic;
[0070] R.sup.6 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.1-18 alkylthio, C.sub.1-18 alkylsulfoxide, C.sub.1-18
alkylsulfone, C.sub.1-18 halo-alkyl, C.sub.2-18 halo-alkenyl,
C.sub.2-18 halo-alkynyl, C.sub.1-18 halo-alkoxy, C.sub.1-18
halo-alkylthio, C.sub.3-10 cycloalkyl, C.sub.3-10cycloalkenyl,
C.sub.7-10 cycloalkynyl, halogen, OH, CN, cyanoalkyl,
--CO.sub.2R.sup.18, NO.sub.2, --NR.sup.7R.sup.8, C.sub.1-18
haloalkyl, C(.dbd.O)R.sup.18, C(.dbd.S)R.sup.18, SH, aryl, aryloxy,
arylthio, arylsulfoxide, arylsulfone, arylsulfonamide,
aryl(C.sub.1-18)alkyl, aryl(C.sub.1-18)alkyloxy,
aryl(C.sub.1-18)alkylthi- o, heterocyclic, C.sub.1-18 hydroxyalkyl,
where each may be optionally substituted with at least 1
R.sup.19;
[0071] R.sup.7 and R.sup.8 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.1-18 alkenyl, aryl,
C.sub.3-10cycloalkyl, C.sub.4-10 cycloalkenyl, heterocyclic,
--C(.dbd.O)R.sup.12; --C(.dbd.S)R.sup.12, an amino acid residue
linked through a carboxyl group thereof, or where R.sup.7 and
R.sup.8 together with the nitrogen form a heterocyclic;
[0072] R.sup.9 and R.sup.18 are independently selected from
hydrogen, OH, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.3-10
cycloalkyl, C.sub.4-10 cycloalkenyl, C.sub.1-18 alkoxy,
--NR.sup.15R.sup.16, aryl, an amino acid residue linked through an
amino group of the amino acid, CH.sub.2OCH(.dbd.O)R.sup.9a, or
CH.sub.2C(.dbd.O)OR.sup.9a where R.sup.9a is C.sub.1-C.sub.12
alkyl, C.sub.6-C.sub.20 aryl, C.sub.6-C.sub.20 alkylaryl or
C.sub.6-C.sub.20 aralkyl;
[0073] R.sup.10 and R.sup.11 are independently selected from the
group consisting of hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, aryl,
--C(.dbd.O)R.sup.12, heterocyclic, or an amino acid residue;
[0074] R.sup.12 is selected from the group consisting of hydrogen,
C.sub.1-18 alkyl, C.sub.2-18 alkenyl, aryl, C.sub.3-10 cycloalkyl,
C.sub.4-10 cycloalkenyl, or an amino acid residue;
[0075] R.sup.13 and R.sup.14 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, aryl,
C.sub.3-10cycloalkyl, C.sub.4-10 cycloalkenyl, --C(.dbd.O)R.sup.12,
--C(.dbd.S)R.sup.12, or an amino acid residue;
[0076] R.sup.15 and R.sup.16 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10cycloalkyl, C.sub.4-10 cycloalkenyl, or an amino
acid residue;
[0077] R.sup.17 is M-Q-, wherein M is a C.sub.3-10 cycloalkyl
optionally substituted with 1 or more R.sup.19, and Q is a bond, or
C.sub.1-10 alkyl optionally substituted with 1 or more
R.sup.19;
[0078] R.sup.19 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.2-18 alkynyl, C.sub.1-18 alkoxy,
C.sub.2-18 alkenyloxy, C.sub.2-18 alkynyloxy, C.sub.1-18 alkylthio,
C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl, C.sub.4-10
cycloalkynyl, halogen, --OH, --CN, cyanoalkyl, --NO.sub.2,
--NR.sup.20R.sup.21, C.sub.1-18 haloalkyl, C.sub.1-18 haloalkyloxy,
--C(.dbd.O)R.sup.18, --C(.dbd.O)OR.sup.18,
--OalkenylC(.dbd.O)OR.sup.18, --OalkylC(.dbd.O)NR.sup.20R.sup.21,
--OalkylOC(.dbd.O)R.sup.18, --C(.dbd.S)R.sup.18, SH,
--C(.dbd.O)N(C.sub.1-6 alkyl), --N(H)S(O)(O)(C.sub.1-6 alkyl),
aryl, heterocyclic, C.sub.1-18alkylsulfone, arylsulfoxide,
arylsulfonamide, aryl(C.sub.1-18)alkyloxy, aryloxy, aryl(C.sub.1-18
alkyl)oxy, arylthio, aryl(C.sub.1-18)alkylthio or
aryl(C.sub.1-18)alkyl, where each may be optionally substituted
with 1 or more .dbd.O, NR.sup.20R.sup.21, CN, C.sub.1-18 alkoxy,
heterocyclic, C.sub.1-18 haloalkyl, heterocyclic alkyl,
heterocyclic connected to R.sup.17 by alkyl, alkoxyalkoxy or
halogen;
[0079] R.sup.20 and R.sup.21 are independently selected from
hydrogen, C.sub.1-18 alkyl, C.sub.2-18 alkenyl, C.sub.2-18 alkynyl,
aryl, C.sub.3-10 cycloalkyl, C.sub.4-10 cycloalkenyl,
--C(.dbd.O)R.sup.12, or --C(.dbd.S)R.sup.12;
[0080] R.sup.22 is selected from hydrogen, --OH, C.sub.1-18 alkyl,
C.sub.2-18 alkenyl, C.sub.1-18 alkoxy, --NR.sup.23R.sup.24, aryl,
C.sub.3-10 cycloalkyl, and C.sub.4-10 cycloalkenyl;
[0081] R.sup.23 and R.sup.24 are independently selected from
hydrogen, C.sub.1-18 alkyl, or a heterocyclic formed by taking
C.sub.2-3 alkyl together with N of R.sup.22, which heterocyclic is
optionally substituted with OH or aryl, or an amino acid residue
linked through a carboxyl group of the amino acid;
[0082] R.sup.25 and R.sup.26 are not present, or are independently
selected from hydrogen, C.sub.1-18 alkyl, C.sub.3-10cycloalkyl,
aryl, heterocyclic, where each is optionally independently
substituted with 1 to 4 of C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo,
CH.sub.2OH, benzyloxy, and OH; and
[0083] R.sup.27 is selected from hydrogen, C.sub.1-18 alkyl,
C.sub.3-10cycloalkyl, (C.sub.3-10 cycloalkyl)-C.sub.1-6alkyl, aryl,
and aryl C.sub.1-18 alkyl, and
[0084] the salts, tautomers, isomers and solvates thereof.
[0085] Yet another embodiment of the present invention provides
compounds having the formula (B), 5
[0086] wherein:
[0087] the dotted lines represent an optional double bond, provided
that no two double bonds are adjacent to one another, and that the
dotted lines represent at least 3, optionally 4 double bonds; and
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.25, X and Y are
as disclosed above.
[0088] An embodiment of the present invention provides compounds of
the formula (B) wherein Y is a single bond, and R.sup.1 is
aryl.
[0089] Another embodiment of the present invention provides
compounds of formula (B) wherein X is C.sub.1-C.sub.10 alkylene,
C.sub.2-10 alkenylene or C.sub.2-10 alkynylene.
[0090] Another embodiment of the present invention provides
compounds of formula (B) wherein R.sup.3 is heterocylic.
[0091] Another embodiment of the present invention provides
compounds of formula (B) wherein R.sup.3 is heterocyclic
substituted with R.sup.17 where Q is a bond and M is aryl.
[0092] Another embodiment of the present invention provides
compounds of formula (B) wherein Y is a single bond, and R.sup.1 is
phenyl.
[0093] Another embodiment of the present invention provides
compounds of formula (B) wherein R.sup.3 is isoxazole substituted
with R.sup.17 where Q is a bond and M is aryl.
[0094] Another embodiment of the present invention provides
compounds of formula (B) wherein R.sup.3 is isoxazole substituted
with R.sup.17 where Q is a bond and M is phenyl.
[0095] Yet another embodiment of the present invention provides
compounds having the formula (C), 6
[0096] wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.25, X and Y are as disclosed above.
[0097] An embodiment of the present invention provides compounds of
the formula (C) wherein Y is a single bond, and R.sup.1 is
aryl.
[0098] Another embodiment of the present invention provides
compounds of formula (C) wherein X is C.sub.1-C.sub.10 alkylene,
C.sub.2-10 alkenylene or C.sub.2-10 alkynylene.
[0099] Another embodiment of the present invention provides
compounds of formula (C) wherein R.sup.3 is heterocylic.
[0100] Another embodiment of the present invention provides
compounds of formula (C) wherein R.sup.3 is heterocyclic
substituted with R.sup.17 where Q is a bond and M is aryl.
[0101] Another embodiment of the present invention provides
compounds of formula (C) wherein Y is a single bond, and R.sup.1 is
phenyl.
[0102] Another embodiment of the present invention provides
compounds of formula (C) wherein R.sup.3 is isoxazole substituted
with R.sup.17 where Q is a bond and M is aryl.
[0103] Another embodiment of the present invention provides
compounds of formula (C) wherein R.sup.3 is isoxazole substituted
with R.sup.17 where Q is a bond and M is phenyl.
[0104] The compounds of formula (A) are optionally combined with
pharmacologically acceptable excipients.
[0105] The compounds of formula (A) are administered in
therapeutically effective amounts to subjects (humans or animals)
in need of antiviral therapy, in particular for inhibiting the
infection, growth or replication of Flaviviridae and
Picornaviridae, especially BVDV, HCV and Coxsackie virus.
[0106] The invention further relates to a method of screening
antiviral compounds which comprises providing a compound of formula
(A) and determining the anti-viral activity of said compound.
[0107] Also within the scope of the invention is a metabolite of
the compounds of formula (A) made by the process of administering a
compound of formula (A) to a subject and recovering the metabolite
from the subject.
[0108] The invention also comprises a method for structure-activity
determination of analogues of formula (A) compounds 7
[0109] wherein the substituents are defined in WO 2004/005286,
comprising
[0110] (A) preparing a compound of formula (A) in which at least
one substituent is not disclosed by WO 2004/005286; and
[0111] (B) determining the anti-HCV activity of the compound of
step (a).
DETAILED DECRIPTION OF THE INVENTION
[0112] "Alkyl" means saturated hydrocarbon moiety where the moiety
may be cyclic, cyclic or a combination of acyclic and cyclic
portions. The acyclic portion may contain 1 to 3 carbon atoms, and
each ring may contain 3 to 6 carbon atoms (for example,
3-methylcyclohexyl). Within this definition, the term "cycloalkyl"
refers to the saturated hydrocarbon moieties that are cyclic.
Examples of "alkyl" include methyl, ethyl, 1-propyl, 2-propyl,
1-butyl, 2-methyl-1-propyl(i-Bu), 2-butyl (s-Bu) 2-methyl-2-propyl
(t-Bu), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl,
3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl,
2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl,
4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl,
2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl, cyclopropyl, cyclobutyl,
cyclopentyl, cycloheptyl, cyclooctyl and the like, or a C.sub.7-10
polycyclic saturated hydrocarbon radical having from 7 to 10 carbon
atoms such as, for instance, norbornyl, fenchyl,
trimethyltricycloheptyl or adamantyl.
[0113] "Alkenyl" means a hydrocarbon moiety with at least one site
of double bond unsaturation where the moiety may be acyclic, cyclic
or a combination of acyclic and cyclic portions. The acyclic
portion may contain 1 to 3 carbon atoms, and each cyclic portion
may contain 3 to 6 carbon atoms. A site of double bond unsaturation
may be in a acyclic portion, a cyclic portion. In the instance of a
moiety having a combination of acyclic and cyclic portions, there
may be a site of double bond unsaturation in each of the portions.
Within this definition, the term "cycloalkenyl" refers to the
double bond unsaturated hydrocarbon moieties that are cyclic.
Examples the term "alkenyl" include, but are not limited to,
ethylene or vinyl (--CH.dbd.CH.sub.2), allyl
(--CH.sub.2CH.dbd.CH.sub.2), cyclopentenyl (--C.sub.5H.sub.7),
5-hexenyl (--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH.sub.2),
1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl,
1-cyclohex-1-enyl, 1-cyclohex-2-enyl, and 1-cyclohex-3-enyl. The
double bond optionally is in the cis or trans configuration.
[0114] "Alkynyl" means a hydrocarbon moiety with a least one site
of triple bond unsaturation where the moiety may be acyclic, cyclic
or a combination of acyclic and cyclic portions. The acyclic
portion may contain contain 1 to 3 carbon atoms, and each cyclic
portion may contain 7 or more carbon atoms. Within this definition,
the term "cycloalkynl" refers to triple bond unsaturated
hydrocarbon moieties that are cyclic. Examples of the term
"alkynyl" include, but are not limited to, --C.ident.CH,
--CH.sub.2C.dbd.CH, --CH.sub.2C--C-cyclohexyl, or
--CH.sub.2-cycloheptynyl.
[0115] The suffix "-ene" used in connection with alkyl, alkenyl and
alkynyl groups refers to such groups with at least 2 sites of
substitution. Such polyvalent hydrocarbon radicals include, but are
not limited to, methylene (--CH.sub.2--) 1,2-ethylene
(--CH.sub.2CH.sub.2--), 1,3-propylene
(--CH.sub.2CH.sub.2CH.sub.2--), 1,4-butylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--), 1,2-ethylene
(--CH.dbd.CH--), --C.quadrature.C--, propargyl
(--CH.sub.2C.quadrature.C--), and 4-pentynyl
(--CH.sub.2CH.sub.2CH.sub.2C.quadrature.CH--).
[0116] "Aryl" means an aromatic hydrocarbon containing 1 or more
rings, generally 1, 2 or 3, with 4 to 6 carbon atoms in each,
ordinarily 5 or 6 carbon atoms.
[0117] "Arylalkyl," "arylalkenyl" and "arylalkynyl" means an alkyl,
alkenyl or alkynyl radical, respectively, in which one of the
hydrogen atoms, typically a terminal or sp3 carbon atom, is
replaced with an aryl radical. Typical arylalkyl groups include,
but are not limited to, benzyl, 2-phenylethan-1-yl,
2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl,
2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and
the like.
[0118] As noted, carbocycles optionally are found as single rings
or multiple ring systems. Ordinarily the hydrocarbons of the
compounds of formula (A) are single rings. Monocyclic carbocycles
generally have 3 to 6 ring atoms, still more typically 5 or 6 ring
atoms. Bicyclic carbocycles typically have 7 to 12 ring atoms, e.g.
arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or
10 ring atoms arranged as a bicyclo [5,6] or [6,6] system.
[0119] If the number of carbon atoms is unspecified for a
hydrocarbon, typically the number of carbon atoms will range from 1
to 18, except that the number of carbons typically will range from
2 to 18 for unsaturated hydrocarbons and from 6 to 10 for aryl.
[0120] "Heterocyclic" or "heterocycle" means any 4, 5, 6, 7, 8 or 9
membered single or fused ring system containing one or more
heteroatoms selected from the group consisting of O, N or S.
Heterocycles optionally are entirely aromatic, entirely saturated,
or contain 1 or more intra-ring sites of unsaturation, typically
double bonds. Multiple heterocyclic rings (one or more of which
contains a heteroatom) are bridged or spiro. Generally, the
heterocyclic rings will be aromatic, and usually they are single
rings. Examples of heterocycles include oxazacyloalkyl,
morpholinyl, dioxacycloalkyl, thiacycloalkenyl, pyridyl,
dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl,
tetrahydrothiophenyl, furanyl, thienyl, pyrrolyl, pyranyl,
pyrazolyl, pyrazolidinyl, pyrazolinyl, imidazolyl, tetrazolyl,
benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl,
isoquinolinyl, benzimidazolyl, piperidinyl, piperazinyl,
pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl,
bis-tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl,
2H,6H-1,5,2-dithiazinyl, thianthrenyl, pyranyl, isobenzofuranyl,
chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl, isothiazolyl,
isothiazoledinyl, isoxazolyl, oxazolinyl, pyrazinyl, pyridazinyl,
pyrimidinyl, pyrrolidinyl, pyrrolinyl, indolizinyl, isoindolyl,
3H-indolyl, 1H-indazoly, purinyl, 4H-quinolizinyl, isoquinolyl,
quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl,
cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl,
.beta.-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl,
phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl,
phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl,
imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl,
isoindolinyl, quinuclidinyl, oxazolidinyl, benzotriazolyl,
benzisoxazolyl, oxindolyl, benzoxazolinyl, benzothienyl,
benzothiazolyl and isatinoyl. Other suitable heterocycles are
exemplified in Rigaudy et al., Nomenclature of Organic Chemistry,
Sections A-H (1979) at pp. 53-76 and Fletcher et al., Nomenclature
of Organic Compounds, Adv. Chem. Ser. 126 (1974) at pp 49-64.
[0121] The location on the heterocycle which provides the point of
attachment(s) to the rest of the compound of this invention is not
critical, but those skilled in the art will recognize substitution
sites that are optimal for compound stability and/or ease of
synthesis. Carbon bonded heterocycles typically are bonded at
position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of
a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2,
3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan,
tetrahydrofuran, thiofuran, thiophene, pyrrole or
tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or
thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or
isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4
of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or
position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more
typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl,
4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl,
5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl,
5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl,
5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or
5-thiazolyl.
[0122] Nitrogen containing heterocycles are bonded at nitrogen or a
carbon, typically a carbon atom. These include, for example,
position 1 of aziridine, 1-aziridyl, 1-azetedyl, 1-pyrrolyl,
1-imidazolyl, 1-pyrazolyl, 1-piperidinyl, 2-pyrroline, 3-pyrroline,
2-imidazoline, 3-imidazoline, 9-carbazole, 4-morpholine, 9-alpha or
13-carboline, 2-isoindole, 2-pyrazoline and 3-pyrazoline, and by
analogy, azetidine, pyrrole, pyrrolidine piperidine, piperazine,
indole, pyrazoline, indoline, imidazole, imidazolidine, 1H-indazole
and isoindoline. These and other N-containing heterocycles are
well-known to those skilled in the art, and their linkage sites are
a matter of discretion.
[0123] Sulfur containing heterocycles are bonded through carbon or
sulfur. They include oxidized states such as --S(.dbd.O)(.dbd.O).
In general, they are linked in the compounds of formula (A)
analogous to N-containing heterocycles.
[0124] "Alkoxy", "cycloalkoxy", "aryloxy", "arylalkyloxy", "oxy
heterocycle", "thioalkyl", "thiocycloalkyl", "arylthio", and
"arylalkylthio" means substituents wherein an alkyl, cycloalkyl,
aryl, or arylalkyl, respectively, are attached to an oxygen atom or
a sulfur atom through a single bond, such as but not limited to
methoxy, ethoxy, propoxy, butoxy, thioethyl, thiomethyl, phenyloxy,
benzyloxy, mercaptobenzyl and the like.
[0125] "Halogen" means any atom selected from the group consisting
of fluorine, chlorine, bromine and iodine.
[0126] Any substituent designation that is found in more than one
site in a compound of this invention shall be independently
selected.
[0127] When a group is stated to be substituted with "one or more"
of another group, this typically means 1 to 3 substituents,
ordinarily 1, 2 or 3 substitutents.
[0128] Those of skill in the art will also recognize that the
compounds of the invention may exist in many different protonation
states, depending on, among other things, the pH of their
environment. While the structural formulae provided herein depict
the compounds in only one of several possible protonation states,
it will be understood that these structures are illustrative only,
and that the invention is not limited to any particular protonation
state--any and all protonated forms of the compounds are intended
to fall within the scope of the invention.
Amino Acids
[0129] "Amino-acid" refers to a radical derived from a molecule
having the chemical formula H.sub.12N--CHR.sup.28--COOH, wherein
R.sup.28 is a side group of a naturally-occurring or known
synthetic amino-acid. The amino acids optionally are substituted
with hydrocarbon typically of 1 to 8 carbons at one or more
carboxyl or amino groups, whether those groups are on the side
chain or are free after linking the amino acid to the remainder of
the compound of this invention.
[0130] Optionally the amino acid residue is a hydrophobic residue
such as mono- or di-alkyl or aryl amino acids, cycloalkylamino
acids and the like. Optionally, the residue does not contain a
sulfhydryl or guanidino substituent.
[0131] Naturally-occurring amino acid residues are those residues
found naturally in plants, animals or microbes, especially proteins
thereof. Polypeptides most typically will be substantially composed
of such naturally-occurring amino acid residues. These amino acids
are glycine, alanine, valine, leucine, isoleucine, serine,
threonine, cysteine, methionine, glutamic acid, aspartic acid,
lysine, hydroxylysine, arginine, histidine, phenylalanine,
tyrosine, tryptophan, proline, asparagine, glutamine and
hydroxyproline. Additionally, unnatural amino acids, for example,
valanine, phenylglycine and homoarginine are also included.
[0132] Generally, only one of any site in the parental molecule is
substituted with an amino acid, although it is within the scope of
this invention to introduce amino acids at more than one permitted
site. In general, the .alpha.-amino or .alpha.-carboxyl group of
the amino acid are bonded to the remainder of the molecule, i.e.,
carboxyl or amino groups in the amino acid side chains generally
are not used to form the amide bonds with the parental compound
(although these groups may need to be protected during synthesis of
the conjugates).
[0133] The amino acid esters optionally are hydrolyzable in vivo or
in vitro under acidic (pH <3) or basic (pH >10) conditions.
Optionally, they are substantially stable in the gastrointestinal
tract of humans but are hydrolyzed enzymatically in blood or in
intracellular environments.
[0134] R.sup.28 usually is C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6
alkyl substituted with amino, carboxyl, amide, carboxyl (as well as
esters, as noted above), hydroxyl, C.sub.6-C.sub.7 aryl,
guanidinyl, imidazolyl, indolyl, sulfhydryl, sulfoxide, and/or
alkylphosphate. R.sup.28 also is nitrogen to form a proline residue
taken together with the amino acid .alpha.- However, R.sup.28 is
generally the side group of the naturally-occurring amino acid
disclosed above, for example H, --CH.sub.3, --CH(CH.sub.3).sub.2,
--CH.sub.2--CH(CH.sub.3).sub.2, --CHCH.sub.3--CH.sub.2-CH.sub.3,
--CH.sub.2--C.sub.6H.sub.5, --CH.sub.2CH.sub.2--S--CH.sub.3,
--CH.sub.2OH, --CH(OH)--CH.sub.3, --CH.sub.2--SH,
--CH.sub.2--C.sub.6H.sub.4OH, --CH.sub.2--CO--NH.sub.2,
--CH.sub.2--CH.sub.2--CO--NH.sub.2, --CH.sub.2--COOH,
--CH.sub.2--CH.sub.2-COOH, --(CH.sub.2).sub.4--NH.sub.2 and
--(CH2).sub.3--NH--C(NH.sub.2)--NH.sub.2. R.sup.28 also includes
1-guanidinoprop-3-yl, benzyl, 4-hydroxybenzyl, imidazol-4-yl,
indol-3-yl, methoxyphenyl and ethoxyphenyl.
Exemplary Embodiments
[0135] R.sup.1 is generally aryl or aromatic heterocyle substituted
with 1, 2 or 3 R.sup.6 wherein R.sup.6 is halogen, C.sub.1-18
alkoxy; or C.sub.1-18 haloalkyl. Typically, R.sup.1 is phenyl
substituted with 1, 2 or 3 halogens, usually fluoro.
[0136] Y generally is a single bond, O, C.sub.1-6 alkylene,
C.sub.2-6 alkenylene, C.sub.2-6 alkynylene or one of said groups
containing 1 to 3, usually 1, heteroatoms selected from O, S or
NR.sup.11. Examples include --O(CH.sub.2).sub.1-5--,
--(CH.sub.2).sub.1-4--O--(CH.sub.2).sub.1-4--,
--S--(CH.sub.2).sub.1-5--,
--(CH.sub.2).sub.1-4--S--(CH.sub.2).sub.1-4--,
--NR.sup.11--(CH.sub.2).sub.1-5--,
--(CH.sub.2).sub.1-4--NR.sup.11--(CH.s- ub.2).sub.1-4 or C.sub.3-10
cycloalkylidene. Typically, Y is --OCH.sub.2--, --CH.sub.2O--,
C.sub.1-2 alkylene, C.sub.2-3 alkenylene, C.sub.2-3 alkynylene, 0
or a bond, but usually a bond.
[0137] In general, YR.sup.1 is not any one of H, an unsubstituted
C.sub.3-10 cycloalkyl or C1-C6 alkyl. Typically YR.sup.1 is halo or
halomethyl-substituted (typically trihalomethyl) phenyl (and
usually 1 to 2 substituents in ortho or meta).
[0138] X usually is alkylene, alkynylene or alkenylene, typically
alkylene, or said hydrocarbons having an intrachain heteroatom,
typically O or S. Examples include --CH.sub.2--, --CH(CH.sub.3)--,
--CH.sub.2--CH.sub.2--, --CH.sub.2--CH.sub.2-CH.sub.2--,
--CH.sub.2--CH.sub.2-CH.sub.2--CH.sub.2,
--(CH.sub.2).sub.2-4--O--(CH.sub- .2).sub.2-4--,
--(CH.sub.2).sub.2-4--S--(CH.sub.2).sub.2-4--,
--(CH.sub.2).sub.2-4--NR.sup.10--(CH.sub.2).sub.2-4--, C.sub.3-10
cycloalkylidene, C.sub.2-6 alkenylene (such as
--CH.dbd.CH--CH.sub.2--) and C.sub.2-6 alkynylene. Usually, X is
methylene.
[0139] R.sup.3 generally is aryl or a heterocycle, typically an
aromatic heterocycle. The heterocycle generally will contain 1, 2
or 3 N, S or O atoms in the ring, usually is linked to X through a
ring carbon atom and typically contains 4 to 6, usually 5, total
ring atoms. The R.sup.3 aryl or heterocycle ordinarily is
substituted with 1, 2 or 3, usually 1, R.sup.17. R.sup.3 optionally
is not indolyl.
[0140] When R.sup.3 is substituted with R.sup.17 then R.sup.17
typically is aryl or a heterocycle further substituted with 1 or
more, usually 1, 2 or 3, R.sup.19.
[0141] R.sup.17 is M-Q in some embodiments of the invention. M is a
ring. This means any cyclic organic structure, whether carbocyclic
or heterocyclic, and whether saturated, unsaturated or aromatic or
single or fused ring systems. M is chosen from rings that are
structurally stable in biological systems. In general, M is a aryl
or aromatic heterocycle where heterocycle is defined above.
[0142] Q is a spacer group, and is not critical. Typically it is
not cyclic and contains from no to 3 atoms, generally C, O or S,
usually C or 0.
[0143] R.sup.17 typically is selected from the group consisting of
C.sub.3-10 cycloalkyl, C.sub.3-10 cycloalkenyl, C.sub.7-10
cycloalkynyl, halogen, aryl, aryloxy, arylthio, arylsulfoxide,
arylsulfone, arylsulfonamide, arylalkyl; arylalkyloxy (optionally
an benzyloxy); arylalkylthio (optionally a benzylthio); a
heterocycle; C.sub.1-18 hydroxyalkyl, but typically is an aryl or a
heterocycle, and where each of said aryl, aryloxy, arylthio,
arylsulfoxide, arylsulfone, arylsulfonamide, arylalkyl,
arylalkyloxy, arylalkylthio, or heterocycle is optionally
substituted with 1 or more R.sup.19. R.sup.17 generally is
positioned distally to X. Optionally, R.sup.17 is not
C(O)R.sup.18.
[0144] R.sup.9 and R.sup.18 typically are H, OH or alkyl. R.sup.18
optionally is not NR.sup.15R.sup.16.
[0145] R.sup.5 typically is H.
[0146] R.sup.6 generally is halogen. Optionally, R.sup.6 is not
C(O)R.sup.18.
[0147] R.sup.7, R.sup.8, R.sup.10, R.sup.11, R.sup.13, R.sup.14,
R.sup.15, R.sup.16, R.sup.20, R.sup.21, R.sup.23 and R.sup.24
typically are independently H or C.sub.1-18 alkyl.
[0148] R.sup.12 and R.sup.22 typically are independently OH or
alkyl.
[0149] R.sup.19 usually is H; C.sub.1-18 alkyl; C.sub.2-18 alkenyl;
C.sub.2-18 alkynyl; C.sub.1-18 alkoxy; alkenyloxy; alkynyloxy;
C.sub.1-18alkylthio; C.sub.3-10 cycloalkyl; C.sub.4-10
cycloalkenyl; C.sub.4-10 cycloalkynyl; halogen; OH; CN; cyanoalkyl;
NO.sub.2; NR.sup.20R.sup.21; haloalkyl; haloalkyloxy;
C(.dbd.O)R.sup.18; C(.dbd.O)OR.sup.18; OalkenylC(--O)OR.sup.18;
--OalkylC(--O)NR.sup.20R.sup- .21; aryl; heterocycle;
--OalkylOC(.dbd.O)R.sup.18; C(.dbd.O)N(C.sub.1-6 alkyl),
N(H)S(O)(O)(C.sub.1-6 alkyl); arylalkyloxy; aryloxy; arylalkyloxy;
and arylalkyl; each of which is unsubstituted or substituted with 1
or more .dbd.O; NR.sup.20R.sup.21; CN; alkoxy; heterocycle;
haloalkyl- or alkyl-substituted heterocycle; heterocycle linked to
R.sup.17 by alkyl; alkoxyalkoxy or halogen. R.sup.18 as a
subtituent in here is generally not H. R.sup.19 typically is
independently halogen, N(R.sup.20 R.sup.21), alkoxy or
halo-substituted alkyl or alkoxy.
[0150] R.sup.25 and R.sup.26 usually are not present but if they
are then typically they are cyclopentyl or cyclohexyl. If the
compound is substituted at R.sup.25 or R.sup.26, either R.sup.2 or
R.sup.4 is selected from (.dbd.O), (--S), and (.dbd.NR.sup.27),
usually .dbd.O.
[0151] M typically is an aromatic ring, usually single or two fused
rings, and containing 4 to 10 atoms. Usually, M is hydrocarbon, but
also optionally comprises 1 to 3 N, O and/or S heteroatoms.
[0152] Q usually is a hydrocarbon chain, typically a normal or
secondary alkylene, which optionally comprises at least one oxy or
thio ester. Generally Q is 1 to 6 atoms, usually 1 to 3. Q
typically is not substituted with R.sup.19, but if it is then
typically it is substituted with one R.sup.19. R.sup.19 as
substituted on Q usually is halogen, nitro or cyano. Substituents
optionally are designated with or without bonds. Regardless of bond
indications, if a substituent is polyvalent (based on its position
in the structure referred to), then any and all possible
orientations of the substituent are intended.
[0153] Haloalkyl or haloalkyloxy typically are --CF3 or --OCF3.
[0154] The present invention provides a compound of Formula (A) of
the following the structure, 8
[0155] having antiviral activity as determined following the
procedures taught throughout the Specification, such as in Part B
"Methodology For Determination Of Antiviral And Cytostatic
Activity" in the Examples Section. Preparation of this compound is
taught throughout the Specification, such as in Example 6.
[0156] The present invention further provides a compound of Formula
(A) of the following structure, 9
[0157] having antiviral activity as determined following the
procedures taught throughout the Specification, such as in Part B
"Methodology For Determination Of Antiviral And Cytostatic
Activity" in the Examples Section. Preparation of this compound is
taught throughout the Specification, such as in Example 8A.
[0158] Formula (A) depicts optional single or double bonds. It will
be understood that the bonds are present such that the aromatic
nature of the nucleus of formula (A) is preserved, i.e., these
formulas are intended to embrace all possible tautomers. For
example R.sup.25 or R.sup.26 will be absent if the ring N to which
they are bonded as indicated in the formula is linked to a flanking
ring carbon atom by a double bond. On the other hand, R.sup.25 or
R.sup.26 may be present when the N atom to which it is bonded as
indicated in the formula is linked to its flanking carbon atoms by
single bonds only; in this case aromaticity is accommodated by
other substituents, e.g. where R.sup.2 or R.sup.4 is oxo.
[0159] The term "prodrug" as used herein refers to any compound
that when administered to a biological system generates the drug
substance, i.e. active ingredient, as a result of spontaneous
chemical reaction(s), enzyme catalyzed chemical reaction(s),
photolysis, and/or metabolic chemical reaction(s). A prodrug is
thus a covalently modified analog or latent form of a
therapeutically-active compound.
Prodrugs
[0160] Certain of the compounds herein when substituted with
appropriate selected functionalities are capable of acting as
prodrugs. These are labile functional groups which separate from an
active inhibitory compound during metabolism, systemically, inside
a cell, by hydrolysis, enzymatic cleavage, or by some other process
(Bundgaard, Hans, "Design and Application of Prodrugs" in Textbook
of Drug Design and Development (1991), P. Krogsgaard-Larsen and H.
Bundgaard, Eds. Harwood Academic Publishers, pp. 113-191). These
prodrug moieties can serve to enhance solubility, absorption and
lipophilicity to optimize drug delivery, bioavailability and
efficacy. A "prodrug" is thus a covalently modified analog of a
therapeutically-active compound. A prodrug moiety of course can be
therapeutically active in its own right.
[0161] Exemplary prodrug moieties include the hydrolytically
sensitive or labile esters (--CO.sub.2R') of carboxylic acids
(--CO.sub.2H) or other functional groups with an acidic proton
which is bound to the imidazo[4,5-c]pyridine compounds of the
invention. The R' group of such hydrolytically sensitive or labile
esters may include: (i) acyloxymethyl esters
--CH.sub.2C(.dbd.O)R.sup.9a; and (ii) acyloxymethyl carbonates
--CH.sub.2C(.dbd.O)OR.sup.9a where R.sup.9a is C.sub.1-C.sub.6
alkyl, C.sub.1-C.sub.6 substituted alkyl, C.sub.6-C.sub.20 aryl or
C.sub.6-C.sub.20 substituted aryl. A close variant of the
acyloxyalkyl ester, the alkoxycarbonyloxyalkyl ester (carbonate),
may also enhance oral bioavailability as a prodrug moiety in the
compounds of the invention. An exemplary acyloxymethyl ester R
group is pivaloyloxymethoxy, (POM)
--CH.sub.2C(.dbd.O)C(CH.sub.3).sub.3. An exemplary acyloxymethyl
carbonate prodrug moiety is pivaloyloxymethylcarbonate (POC)
--CH.sub.2C(.dbd.O)OC(CH.sub.3).sub.3. Cleavable moieties capable
of acting as prodrug functionalities are optionally linked at any
tolerant site on the compound of this invention, for example
R.sup.3 and any of its substituents.
Excluded Compounds
[0162] The present invention excludes all compounds expressly
disclosed in any prior art reference (to the extent the reference
is effective as novelty- or inventive step/obviousness-defeating as
the case may be) set forth in this application (as well as any
compounds disclosed in any reference patent family member) and and
any other compounds over which the claims of this application are
not novel or do not posses an inventive step or are obvious under
applicable law.
[0163] The present invention excludes, as required, compounds
according to the general formula (A) where
[0164] (a) Any of the substituents X, Y, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5 are a cephalosporin or wherein the substituents X,
Y, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 are an azabicyclo
group, more particularly
5-Thia-1-aza-bicyclo[4.2.0]oct-2-en-8-one;
[0165] (b) The compound is
5-(2-piperidin-1-yl-ethyl)-2-(4-hydroxyphenyl)--
1H-imidazo[4,5-c]pyridin-5-ium bromide (X=ethyl, Y=bond,
R.sup.1=phenyl substituted in para with OH, R.sup.2=H,
R.sup.3=piperidinyl, and R.sup.4, R.sup.5H) (as disclosed in
example 52 of EP 1132381);
[0166] (c) The compound is
4-[5-(2-{4-[Bis-(4-fluorophenyl)-methyl]-pipera-
zin-1-yl}-ethyl)-5H-imidazo[4,5-c]pyridin-2-yl]phenol (X=ethyl,
Y=bond, R.sup.1=phenyl substituted in para with OH, R.sup.2=H,
R.sup.3=heterocycle with 2 N heteroatoms, wherein one N is
substituted with an arylalkyl consisting of CH(Phenyl).sub.2,
wherein each phenyl carries an F in para) (as disclosed in example
54 of EP 1132381);
[0167] (d) The compound is
4-[5-(3-{4-[Bis-(4-fluorophenyl)-methyl]-pipera-
zin-1-yl}-propyl).sub.5H-imidazo[4,5-c]pyridin-2-yl]phenol
(X=butyl, Y=bond, R.sup.1=phenyl substituted in para with OH,
R.sup.2=H, R.sup.3=heterocycle with 2 N heteroatoms, wherein one N
is substituted with an arylalkyl consisting of CH(Phenyl).sub.2,
wherein each phenyl carries an F in para) (as disclosed in example
55 of EP 1132381);
[0168] (e) The compound is
5-(phenylmethyl)-5H-imidazo[4,5-c]pyridine wherein phenyl is
substituted with CONR.sup.15R.sup.16 and R.sup.15 is a branched C3
alkyl and R.sup.16 is phenyl (X=--CH.sub.2--; Y=bond;
R.sup.1=hydrogen; R.sup.2=H; R.sup.3=phenyl substituted with 1
C(.dbd.O)R.sup.18, wherein R.sup.18 is NR.sup.15R.sup.16, with
R.sup.15 and R.sup.16 a branched C.sub.6 alkyl; R.sup.4H) (as
disclosed in example 35 of U.S. Pat. No. 5,302,601);
[0169] (f) The compound is
6-(5H-imidazo[4,5-c]pyridin-5-yl-methyl)-N-(1me-
thylethyl)-N-phenyl-3-pyridinecarboxamide (X=--CH.sub.2--; Y=bond;
R.sup.1=hydrogen; R.sup.2=H, R.sup.3=pyridine substituted with 1
R.sup.6, wherein R.sup.6=1 C=0 R.sup.18, wherein R.sup.18 is
NR.sup.15R.sup.16, wherein R.sup.15=isopropyl and R.sup.16=phenyl)
(as disclosed in example 6 of U.S. Pat. No. 4,990,518);
[0170] (g) The compound is a compound wherein X=--CH.sup.2--;
Y=bond; R.sup.1=hydrogen; R.sup.2=H, R.sup.3=5-6 membered
heterocycle, in particular a pyridinyl or furanyl, substituted with
1 R.sup.17 wherein R.sup.17=C(.dbd.O)R.sup.18, and wherein
R.sup.18=NR.sup.15R.sup.16 and R.sup.15 and R.sup.16 are either a
C.sub.1-18 alkyl, in particular methyl, ethyl or isopropyl,
C.sub.2-18 alkenyl, in particular 2-methyl allyl, or a C.sub.3-10
cycloalkyl, in particular cyclopentyl or cyclohexyl (as disclosed
in U.S. Pat. No. 4,990,518);
[0171] (h) The compound is a compound wherein X=--CH.sup.2--;
Y=bond; R.sup.1=hydrogen; R.sup.2=H, R.sup.3=5-6 membered
heterocycle, in particular a pyridinyl or furanyl, substituted with
1 R.sup.17 wherein R.sup.17=C(.dbd.O)R.sup.18, and wherein
R.sup.18=C.sub.3-10cycloalkyl or C.sub.4-10 cycloalkenyl.
[0172] (i) The compound is
2,6-bis(1,1,-dimethylethyl)-4-[[2-(5H-imidazo-[-
4,5-c]pyridin-5-yl)ethyl]thio]-phenol hydrate and/or
2,6-bis(1,1,-dimethylethyl)-4-[[2-(5H-imidazo-[4,5-c]pyridin-5-yl)propyl]-
thio]-phenol hydrate (X=CH.sup.2--CH.sup.2--;
[0173] Y=bond; R.sup.1=hydrogen, R.sup.2=H, R.sup.3=thioaryl
substituted with three R.sup.6, wherein R.sup.6=2 branched
C.sub.4alkyl in meta and OH in para) (as disclosed in example 6 of
WO96/12703);
[0174] (j) The compound is
5-[2-(Biphenyl-4-yloxy)-ethyl]-5H-imidazo[4,5-c- ]pyridine
(X=CH.sub.2CH.sub.2, Y=bond, R.sup.1=hydrogen, R.sup.2=H,
R.sup.3=phenoxy substituted with 1 R.sup.17 in para, wherein
R.sup.17=benzyl; R.sup.4=H) (as disclosed in WO96/11192);
[0175] (k) The compound is
5-[2-(4-Phenoxy-phenoxy)-ethyl]-5H-imidazo[4,5-- c]pyridine
(X=CH.sub.2CH.sub.2, Y=bond, R.sup.1=hydrogen, R.sup.2=H,
R.sup.3=phenoxy substituted with 1 R.sup.17 in para, wherein
R.sup.17=phenoxy; R.sup.4=H) (as disclosed in WO96/11192);
[0176] (l) The compound is
[5-(4-Fluorobenzyl)-5H-imidazo[4,5-c]pyridin-2-- yl]-methylamine
(X=CH.sub.2, Y=NR.sup.11, wherein R.sup.11=methyl,
R.sup.1=R.sup.2=H, R.sup.3=phenyl substituted with 1 R.sup.17 in
para, wherein R.sup.6 is F, R.sup.4=H, R.sup.5=H) (as disclosed in
EP76530);
[0177] (m) The compound is
2,6-bis(1,1,-dimethylethyl)-4-[[3-(5H-imidazo-[-
4,5-c]pyridin-5-yl)propyl]thio]-phenol hydrate
(X.dbd.CH.sub.2--CH.sub.2-C- H.sub.2, Y=bond; R.sup.1=hydrogen,
R.sup.2=H, R.sup.3-thiophenyl substituted with 3 R.sup.6, wherein
R.sup.6=2 branched C4 alkyl in meta and OH in para) (as disclosed
in WO96/12703);
[0178] (n) The compound is
5-[2-(4-Phenylmethyloxy-phenoxy)-ethyl]-5H-imid- azo[4,5-c]pyridine
(X=CH.sub.2CH.sub.2, Y=bond, R.sup.1=hydrogen, R.sup.2=H,
R.sup.3=phenoxy substituted with 1 R.sup.17 in para, wherein
R.sup.17=benzyl oxy) (as disclosed in WO96/11192);
[0179] (o) The compound is
5-[3-(4-Phenoxy-phenoxy)-propyl]-5H-imidazo[4,5- -c]pyridine
(X=CH.sub.2CH.sub.2CH.sub.2, Y=bond, R.sup.1=hydrogen, R.sup.2=H,
R.sup.3=phenoxy substituted with 1 R.sup.6 in para, wherein
R.sup.6=phenoxy substituted in para with F; R.sup.4=H) (as
disclosed in WO96/11192);
[0180] (p) The compound is
5-{2-[4-(4-Fluorophenoxy)-phenoxy]-ethyl}-5H-im-
idazo[4,5-c]pyridine (X=CH.sub.2CH.sub.2, Y-bond, R.sup.1=hydrogen,
R.sup.2=H, R.sup.3=phenoxy substituted with 1 R.sup.1 in para,
wherein R.sup.6=phenoxy, substituted in para with F; R.sup.4=H) (as
disclosed in WO96/11192);
[0181] (q) The compound is
5-[3-(4-Phenylmethyl-phenoxy)-propyl]-5H-imidaz- o[4,5-c]pyridine
(X=CH.sub.2CH.sub.2CH.sub.2, Y=bond, R.sup.1-=hydrogen, R.sup.2=H,
R.sup.3=phenoxy substituted with 1 R.sup.6 in para, wherein
R.sup.6=benzyl; R.sup.4=H) (as disclosed in WO96/11192);
[0182] (r) The compound is
(1H-Indol-3-yl)-[3-(2-methyl-5H-imidazo[4,5-c]p-
yridine-5-carbonyl)-phenyl]-methanone (X=--(C.dbd.O)-- or SO.sub.2,
Y=CH.sub.2, R.sup.1=H, R.sup.2=H, R.sup.3-=phenyl substituted with
1 R.sup.6, wherein R.sup.6 is C(.dbd.O)R.sup.18, wherein R.sup.18
is indole) (as disclosed in U.S. Pat. No. 5,486,525);
[0183] (s) The compound is 4 or
3-[(2-methyl-5H-imidazo[4,5-c]pyridin-5-yl- )methyl]-benzoic acid
alkylester or 5-[4 or 3-(alkoxycarbonyl-phenyl)-meth-
yl]-2-methyl-5H-imidazo[4,5-c]pyridine, in particular 4 or
3-[(2-methyl-5H-imidazo[4,5-c]pyridin-5-yl)methyl]-methyl ester
(X=CH.sub.2, Y=CH.sub.2, R.sup.1=H, R.sup.2=H, R.sup.3=phenyl
substituted at the para or meta position with one R.sup.17, wherein
R.sup.17 is (C.dbd.O)R.sup.15, wherein R.sup.18=alkoxy) (as
disclosed in U.S. Pat. No. 5,486,525)
[0184] (t) The compound is
5-[(fluorophenyl)methyl]-2-amino-5-H-imidazo[4,- 5-c]-pyridine
(XR.sup.3=fluorobenzyl, Y=NR.sup.11 with R.sup.1=methyl, R.sup.1=H,
R.sup.2, R.sup.3, R.sup.4=H) (as disclosed in U.S. Pat. No.
5,137,896);
[0185] (u) The compound is
((5-[4-(Fluorophenyl)methyl]-5-H-imidazo[4,5-c]- -pyridine-2-yl)
methyl)-carbamate, methyl ester (XR.sup.3=fluorobenzyl,
Y=C(.dbd.O)R.sup.12 with R.sup.12=methyl, R.sup.1H, R.sup.2,
R.sup.3, R.sup.4=H)(as disclosed in U.S. Pat. No. 5,137,896);
[0186] (v) The compound is
5-(4-Chlorophenylmethyl)-2-(piperidin-1-ylmethy-
l)-5H-imidazo[4,5-c]pyridine and its dihydrochloride salt
(XR.sup.3=chlorobenzyl, Y=--CH.sub.2--, R.sup.1=piperidinyl) (as
disclosed in Justus Liebigs Annalen der Chemie (1971), 747,
158-171);
[0187] (w) The compound is
5-(4-Chlorophenylmethyl)-2-(4-methyl-piperazin--
1-ylmethyl)-5H-imidazo[4,5-c]pyridine (XR.sup.3=chlorobenzyl,
Y=CH.sub.2--, R.sup.1=piperazinyl, R.sup.6=methyl) (as disclosed in
Journal of the Chemical Society [section B]: Physical Organic
(1966), 4, 285-291);
[0188] (x) Compounds, particularly compound 9 on page 160, Cleve et
al. "Liebigs Ann. Chem. 747:158-171 (1971);
[0189] (y) Compounds, particularly compounds 19 and 20, of Kiyama
et al. "Chem. Pharm. Bull. 43(3):450-460 (1995); and
[0190] (z) Compounds, particularly compound 14, of Medereski et al.
"Tet. Lt." 48(48):10549-10558 (1992)
[0191] The compounds of the invention optionally exclude those
compounds according to the general formula (A) as described above,
wherein (a) Y R.sup.1 is not phenyl para substituted with OH, or
(b) is H, an unsubstituted C.sub.3-10 cycloalkyl, or
C.sub.1-6alkyl.
[0192] The compounds of the invention optionally exclude those
compounds according to the general formula (A) as described above,
wherein R.sup.1 is not H, Y is not NR.sup.11 with R.sup.11
C.sub.1-6 alkyl or methyl, and/or YR.sup.1 is not
monomethylamino.
[0193] The compounds of the invention optionally exclude those
compounds according to the general formula (A) as described above,
wherein R.sup.1 is a phenyl substituted with 1R.sup.6, R.sup.6 is
C(.dbd.O)R.sup.18 and R.sup.18 is t-butoxy.
[0194] The compounds of the invention optionally exclude those
compounds according to the general formula (A) as described above,
wherein R.sup.1 is not piperidinyl and is not piperazinyl
substituted with methyl.
[0195] The compounds of this invention exclude those compounds
disclosed by WO 2004/005286, in particular the compounds in table 8
thereof.
[0196] The compounds of this invention optionally exclude those in
which XR.sup.3 is the definitional equivalent to the substructure
--CH2)n--Y--C(O)--N(R1)(R2) set forth on column 1, line 49 to
column 2 line 38 of U.S. Pat. No. 5,302,601 and the comparable
disclosure in any member of the patent family of U.S. Pat. No.
5,302,601, which disclosure is herewith expressly incorporated by
reference.
[0197] The compounds of this invention optionally exclude those in
which R.sup.5 contains any of the substituents designated as
<<Ar>> in WO 00/39127, in particular aryl, aryl
phenoxy, or benzyl.
[0198] The compounds of this invention optionally do not include
the compounds of Example 35 of U.S. Pat. No. 5,302,601, Example 6
of U.S. Pat. No. 4,990,518, Examples 1 to 5 of U.S. Pat. No.
4,988,707, Examples 1-5 of U.S. Pat. No. 5,208,241, Example 39 of
U.S. Pat. No. 5,137,896, the azabenzimidazole compound of WO
99/27929, Examples 1-20 and 45 of U.S. Pat. No. 5,227,384, Examples
3 and/or 11 of WO 96/12703 and/or compounds 340A, 347C, 349C, 351C,
355C and/or 356 C of WO 96/11192.
[0199] The compounds of this invention optionally exclude those in
which XR.sup.3 is equivalent to the substructure
--(CH.sub.2)n-Het-C(O)--N(R.su- p.1)(R.sup.2) set forth on column
1, line 41 to column 2 line 24 of U.S. Pat. No. 4,990,518.
[0200] The compounds of this invention do not include the compounds
expressly disclosed in the patents listed in the Background of the
Invention above, in Chemical Abstracts acc no. 1987:18435 and in
Chemical Abstracts acc no. 1983:594812.
[0201] The compounds of this invention do not include the compounds
expressly disclosed in Justus Liebigs Annalen der Chemie (1971),
747, 158-171 or in the Journal of the Chemical Society [section B]:
Physical Organic (1966), 4, 285-291.
[0202] Optionally, the compounds of this invention exclude those
compounds wherein YR.sup.1 is one of the substituents designated
R.sup.13 in column 5, lines 22-38 of U.S. Pat. No. 5,486,525 and/or
R.sup.2 and/or R.sup.5 are one of the substituents collectively
designated R.sup.14 and R.sup.15 in column 5, lines 38-53 of U.S.
Pat. No. 5,486,525.
[0203] Optionally, the compounds of this invention exclude the
compounds found in any patent family member of any published or
issued patent specifically recited in this application.
[0204] Finally, the compounds of this invention optionally also
exclude the methylene homologues of the foregoing known compounds
excluded from the scope of this invention. It is understood that a
compound optionally excluded also includes the salts thereof.
Utilities
[0205] The compounds of this invention, or the metabolites produced
from these compounds in vivo, have a large number of uses. They are
useful in immunology, chromatography, diagnostics and therapeutics,
among other fields.
[0206] The compounds of formula (A) are conjugated to immunogenic
polypeptides as a reagent for eliciting antibodies capable of
binding specifically to the polypeptide, to the compounds or to
their metabolic products which retain immunologically recognized
epitopes (sites of antibody binding). These immunogenic
compositions therefore are useful as intermediates in the
preparation of antibodies for use in diagnostics, quality control,
or the like, or in assays for the compounds of formula (A) or their
novel metabolic products. The compounds are useful for raising
antibodies against otherwise non-immunogenic polypeptides, in that
the compounds serve as haptenic sites stimulating an immune
response which cross-reacts with the unmodified conjugated
protein.
[0207] Conjugates of the compounds of formula (A) with immunogenic
polypeptides such as albumin or keyhole limpet hemocyanin generally
are useful as immunogens. The polypeptides are conjugated at the
same sites denoted for amino acids. The metabolic products
described above may retain a substantial degree of immunological
cross reactivity with the compounds of the invention. Thus, the
antibodies of this invention will be capable of binding to the
unprotected compounds of the invention without binding to the
protected compounds. Alternatively the metabolic products will be
capable of binding to the protected compounds and/or the
metabolitic products without binding to the protected compounds of
the invention, or will be capable of binding specifically to any
one or all three. The antibodies desirably will not substantially
cross-react with naturally-occurring materials. Substantial
cross-reactivity is reactivity under specific assay conditions for
specific analytes sufficient to interfere with the assay
results.
[0208] The immunogens of this invention contain the compound of
this invention presenting the desired epitope in association with
an immunogenic substance. Within the context of the invention such
association means covalent bonding to form an immunogenic conjugate
(when applicable) or a mixture of non-covalently bonded materials,
or a combination of the above. Immunogenic substances include
adjuvants such as Freund's adjuvant, immunogenic proteins such as
viral, bacterial, yeast, plant and animal polypeptides, in
particular keyhole limpet hemocyanin, serum albumin, bovine
thyroglobulin or soybean trypsin inhibitor, and immunogenic
polysaccharides. Typically, the compound having the structure of
the desired epitope is covalently conjugated to an immunogenic
polypeptide or polysaccharide by the use of a polyfunctional
(ordinarily bifunctional) cross-linking agent. Methods for the
manufacture of hapten immunogens are conventional per se, and any
of the methods used heretofore for conjugating haptens to
immunogenic polypeptides or the like are suitably employed here as
well, taking into account the functional groups on the precursors
or hydrolytic products which are available for cross-linking and
the likelihood of producing antibodies specific to the epitope in
question as opposed to the immunogenic substance.
[0209] Typically the polypeptide is conjugated to a site on the
compound of the invention distant from the epitope to be
recognized.
[0210] The conjugates are prepared in conventional fashion. For
example, the cross-linking agents N-hydroxysuccinimide, succinic
anhydride or alkN=C=Nalk are useful in preparing the conjugates of
this invention. The conjugates comprise a compound of the invention
attached by a bond or a linking group of 1-100, typically, 1-25,
more typically 1-10 carbon atoms to the immunogenic substance. The
conjugates are separated from starting materials and by products
using chromatography or the like, and then are sterile filtered and
vialed for storage.
[0211] Animals are typically immunized against the immunogenic
conjugates or derivatives and antisera or monoclonal antibodies
prepared in conventional fashion.
[0212] The compounds of this invention are useful as linkers,
spacers or affinity (typically hydrophobic) moieties in preparing
affinity absorption matrices. The compounds of the invention
optionally are bound covalently to an insoluble matrix and used for
affinity chromatography separations, depending on the nature of the
groups of the compounds, for example compounds with pendant aryl
groups are useful in making hydrophobic affinity columns.
[0213] They also are useful as linkers and spacers in preparing
immobilized enzymes for process control, or in making immunoassay
reagents. The compounds herein contain functional groups that are
suitable as sites for cross-linking desired substances. For
example, it is conventional to link affinity reagents such as
hormones, peptides, antibodies, drugs, and the like to insoluble
substrates. These insolublized reagents are employed in known
fashion to absorb binding partners for the affinity reagents from
manufactured preparations, diagnostic samples and other impure
mixtures. Similarly, immobilized enzymes are used to perform
catalytic conversions with facile recovery of enzyme. Bifunctional
compounds are commonly used to link analytes to detectable groups
in preparing diagnostic reagents.
[0214] The compounds of this invention are labeled with detectable
moieties such biotin, radioisotopes, enzymes and the like for
diagnostic purposes. Suitable techniques for accomplishing the
labeling of the compounds of formula (A) are well known and will be
apparent to the artisan from consideration of this specification as
a whole. For example, one suitable site for labeling is R17 or
R19.
[0215] More typically, however, the compounds of the invention are
employed for the treatment or prophylaxis of viral infections such
as yellow fever virus, Dengue virus, hepatitis B virus, hepatitis G
virus, Classical Swine Fever virus or the Border Disease Virus, but
more particularly flaviviral or picornaviral infections, in
particular, HCV and BVDV.
[0216] The therapeutic compound(s) of this invention are
administered to a subject mammal (including a human) by any means
well known in the art, i.e. orally, intranasally, subcutaneously,
intramuscularly, intradermally, intravenously, intra-arterially,
parenterally or by catheterization. The therapeutically effective
amount of the compound(s) is a flaviviral or picornaviral growth
inhibiting amount. More preferably, it is a flaviviral or
picornaviral replication inhibiting amount or a flaviviral or
picoruaviral enzyme inhibiting amount of the compounds of formula
(A). This is believed to correspond to an amount which ensures a
plasma level of between about 1 .mu.g/ml and 100 mg/ml, optionally
of 10 mg/ml. This optionally is achieved by administration of a
dosage of in the range of 0.001 mg to 60 mg, preferably 0.01 mg to
10 mg, preferably 0.1 mg to 1 mg per day per kg bodyweight for
humans. These are starting points for determining the optimal
dosage of the compound of this invention. The actual amount will
depend upon many factors known to the artisan, including
bioavailability of the compound, whether it contains a prodrug
functionality, its metabolism and distribution in the subject and
its potency, among others. It typically is necessary to determine
the proper dosing in the clinical setting, and this is well within
the skill of the ordinary artisan. The therapeutically effective
amount of the compound(s) of this invention optionally are divided
into several sub-units per day or are administered at daily or more
than one day intervals, depending upon the pathologic condition to
be treated, the patient's condition and the nature of the compound
of this invention.
[0217] As is conventional in the art, the evaluation of a
synergistic effect in a drug combination may be made by analyzing
the quantification of the interactions between individual drugs,
using the median effect principle described by Chou et al. in Adv.
Enzyme Reg. (1984) 22:27 or tests such as, but not limited to, the
isobologram method, as previously described by Elion et al. in J.
Biol. Chem. (1954) 208:477-488 and by Baba et al. in Antimicrob.
Agents Chemother. (1984) 25:515-517, using EC.sub.50 for
calculating the fractional inhibitory concentration.
[0218] Suitable anti-viral agents for inclusion in combination
antiviral compositions or for coadministration in a course of
therapy include, for instance, interferon alpha, ribavirin, a
compound falling within the scope of disclosure of EP 1162196, WO
03/010141, WO 03/007945 and WO 03/010140, a compound falling within
the scope of disclosure of WO 00/204425, and other patents or
patent applications within their patent families, in amounts of 1
to 99.9% by weight compound of this invention, preferably from 1 to
99% by weight, more preferably from 5 to 95% by weight as can be
readily determined by one skilled in the art. Such co-administered
agents need not be formulated in the same dosage form as the
compound of the invention. They optionally are simply administered
to the subject in the course of treatment along with a course of
treatment with a compound of formula (A).
[0219] The present invention further provides veterinary
compositions comprising at least one active ingredient as above
defined together with a veterinary carrier therefore, for example
in the treatment of BVDV. Veterinary carriers are materials useful
for the purpose of administering the composition and are excipients
which are otherwise inert or acceptable in the veterinary art and
are compatible with the compound of this invention. These
veterinary compositions may be administered orally, parenterally or
by any other desired route.
Salts
[0220] The term "pharmaceutically acceptable salts" as used herein
means the therapeutically active non-toxic salt forms formed by the
compounds of formula (A). Such salts may include those derived by
combination of appropriate cations such as alkali and alkaline
earth metal ions or ammonium and quaternary amino ions with an acid
anion moiety, typically a carboxylic acid.
[0221] The compounds of the invention may bear multiple positive or
negative charges. The net charge of the compounds of the invention
may be either positive or negative. Any associated counter ions are
typically dictated by the synthesis and/or isolation methods by
which the compounds are obtained. Typical counter ions include, but
are not limited to ammonium, sodium, potassium, lithium, halides,
acetate, trifluoroacetate, etc., and mixtures thereof. It will be
understood that the identity of any associated counter ion is not a
critical feature of the invention, and that the invention
encompasses the compounds in association with any type of counter
ion. Moreover, as the compounds can exist in a variety of different
forms, the invention is intended to encompass not only forms of the
compounds that are in association with counter ions (e.g., dry
salts), but also forms that are not in association with counter
ions (e.g., aqueous or organic solutions).
[0222] Metal salts typically are prepared by reacting the metal
hydroxide with a compound of this invention. Examples of metal
salts which are prepared in this way are salts containing Li+, Na+,
Ca+2 and Mg+2 and K+. A less soluble metal salt can be precipitated
from the solution of a more soluble salt by addition of the
suitable metal compound. In addition, salts may be formed from acid
addition of certain organic and inorganic acids to basic centers,
typically amines, or to acidic groups. Examples of such appropriate
acids include, for instance, inorganic acids such as hydrohalogen
acids, e.g. hydrochloric or hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid and the like; or organic acids such as, for
example, acetic, propanoic, hydroxyacetic, benzoic,
2-hydroxypropanoic, 2-oxopropanoic, lactic, fumaric, tartaric,
pyruvic, maleic, malonic, malic, salicylic (i.e. 2-hydroxybenzoic),
p-aminosalicylic, isethionic, lactobionic, succinic oxalic and
citric acids; organic sulfonic acids, such as methanesulfonic,
ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and
inorganic acids, such as hydrochloric, sulfuric, phosphoric and
sulfamic acids, C1-C6 alkylsulfonic, benzenesulfonic,
p-toluenesulfonic, cyclohexanesulfamic, and the like. Preferred
salts include mesylate and HCl.
[0223] The compounds of this invention include the solvates formed
with the compounds of formula (A) and their salts, such as for
example hydrates, alcoholates and the like. The compositions herein
comprise compounds of the invention in their un-ionized, as well as
zwitterionic form, and combinations with stoichiometric amounts of
water as in hydrates.
[0224] Also included within the scope of this invention are the
salts of the compounds of formula (A) with one or more amino acids
as described above. The amino acid typically is one bearing a side
chain with a basic or acidic group, e.g., lysine, arginine or
glutamic acid, or a neutral group such as glycine, serine,
threonine, alanine, isoleucine, or leucine.
[0225] Salts of acids or bases which are not physiologically
acceptable may also find use, for example, in the preparation or
purification of a compound of formula (A). All salts, whether or
not derived form; a physiologically acceptable acid or base, are
within the scope of the present invention.
Isomers
[0226] The term "isomers" as used herein means all possible
isomeric forms, including tautomeric and stereochemical forms,
which the compounds of formula (A) may possess, but not including
position isomers. Typically, the structures shown herein exemplify
only one tautomeric or resonance form of the compounds, but the
corresponding alternative configurations are contemplated as well.
Unless otherwise stated, the chemical designation of compounds
denotes the mixture of all possible stereochemically isomeric
forms, said mixtures containing all diastereomets and enantiomers
(since the compounds of formula (A) may have one or more chiral
centers), as well as the stereochemically pure or enriched isomers.
More particularly, stereogenic centers may have either the R- or
S-configuration, and double or triple bonds optionally are in
either the cis- or trans-configuration.
[0227] Enriched isomeric forms of a compound of this invention are
defined as a single isomer substantially free of the compound's
other enantiomers or diastereomers. In particular, the term
"stereoisomerically enriched" or "chirally enriched" relates to
compounds having a single stereoisomeric proportion of at least
about 80% (i.e. at least 90% of one isomer and at most 10% of the
other possible isomers), preferably at least 90%, more preferably
at least 94% and most preferably at least 97%. The terms
"enantiomerically pure" and "diastereomerically pure" contain
undetectable levels of any other isomer.
[0228] Separation of stereoisomers is accomplished by standard
methods known to those in the art. One enantiomer of a compound of
the invention can be separated substantially free of its opposing
enantiomer by a method such as formation of diastereomers using
optically active resolving agents ("Stereochemistry of Carbon
Compounds," (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H.,
(1975) J. Chromatogr., 113:(3) 283-302). Separation of isomers in a
mixture can be accomplished by any suitable method, including: (1)
formation of ionic, diastereomeric salts with chiral compounds and
separation by fractional crystallization or other methods, (2)
formation of diastereomeric compounds with chiral derivatizing
reagents, separation of the diastereomers, and conversion to the
pure enantiomers, or (3) enantiomers can be separated directly
under chiral conditions. Under method (1), diastereomeric salts can
be formed by reaction of enantiomerically pure chiral bases such as
brucine, quinine, ephedrine, strychnine,
a-methyl-b-phenylethylamine (amphetamine), and the like with
asymmetric compounds bearing an acidic functionality, such as
carboxylic acid and sulfonic acid.
[0229] The diastereomeric salts optionally are induced to separate
by fractional crystallization or ionic chromatography. For
separation of the optical isomers of amino compounds, addition of
chiral carboxylic or sulfonic acids, such as camphorsulfonic acid,
tartaric acid, mandelic acid, or lactic acid can result in
formation of the diastereomeric salts. Alternatively, by method
(2), the substrate to-be resolved may be reacted with one
enantiomer of a chiral compound to form a diastereomeric pair
(Eliel, E. and Wilen, S. (1994). Stereochemistry of Organic
Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric
compounds can be formed by reacting asymmetric compounds with
enantiomerically pure chiral derivatizing reagents, such as menthyl
derivatives, followed by separation of the diastereomers and
hydrolysis to yield the free, enantiomerically enriched xanthene. A
method of determining optical purity involves making chiral esters,
such as a menthyl ester or Mosher ester,
a-methoxy-a-(trifluoromethyl)phenyl acetate (Jacob III. (1982) J.
Org. Chem. 47:4165), of the racemic mixture, and analyzing the NMR
spectrum for the presence of the two atropisomeric diastereomers.
Stable diastereomers can be separated and isolated by normal- and
reverse-phase chromatography following methods for separation of
atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96/15111). Under
method (3), a racemic mixture of two asymmetric enantiomers is
separated by chromatography using a chiral stationary phase.
Suitable chiral stationary phases are, for example,
polysaccharides, in particular cellulose or amylose derivatives.
Commercially available polysaccharide based chiral stationary
phases are ChiralCeI.TM. CA, OA, OB5, OC5, OD, OF, OG, OJ and OK,
and Chiralpak.TM. AD, AS, OP(+) and OT(+). Appropriate eluents or
mobile phases for use in combination with said polysaccharide
chiral stationary phases are hexane and the like, modified with an
alcohol such as ethanol, isopropanol and the like. ("Chiral Liquid
Chromatography" (1989) W. J. Lough, Ed. Chapman and Hall, New York;
Okamoto, (1990). "Optical resolution of dihydropyridine enantiomers
by High-performance liquid chromatography using phenylcarbamates of
polysaccharides as a chiral stationary phase", J. of Chromatogr.
513:375-378).
Metabolites
[0230] The present invention also provides the in vivo metabolic
products of the compounds described herein, to the extent such
products are novel and unobvious over the prior art. Such products
may result for example from the oxidation, reduction, hydrolysis,
amidation, esterification and the like of the administered
compound, primarily due to enzymatic processes. Accordingly, the
invention includes novel and unobvious compounds produced by a
process comprising contacting a compound of this invention with a
mammal for a period of time sufficient to yield a metabolic product
thereof. Such products typically are identified by preparing a
radiolabelled (e.g. C14 or H3) compound of the invention,
administering it parenterally in a detectable dose (e.g. greater
than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig,
monkey, or to man, allowing sufficient time for metabolism to occur
(typically about 30 seconds to 30 hours) and isolating its
conversion products from the urine, blood or other biological
samples. These products are easily isolated since they are labeled
(others are isolated by the use of antibodies capable of binding
epitopes surviving in the metabolite). The metabolite structures
are determined in conventional fashion, e.g. by MS or NMR analysis.
In general, analysis of metabolites is done in the same way as
conventional drug metabolism studies well-known to those skilled in
the art. The conversion products, so long as they are not otherwise
found in vivo, are useful in diagnostic assays for therapeutic
dosing of the compounds of the invention even if they possess no
antiviral activity of their own.
Formulations
[0231] The compounds of the invention optionally are formulated
with conventional pharmaceutical carriers and excipients, which
will be selected in accord with ordinary practice. Tablets will
contain excipients, glidants, fillers, binders and the like.
Aqueous formulations are prepared in sterile form, and when
intended for delivery by other than oral administration generally
will be isotonic. Formulations optionally contain excipients such
as those set forth in the "Handbook of Pharmaceutical Excipients"
(1986) and include ascorbic acid and other antioxidants, chelating
agents such as EDTA, carbohydrates such as dextrin,
hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid
and the like.
[0232] Subsequently, the term "pharmaceutically acceptable carrier"
as used herein means any material or substance with which the
active ingredient is formulated in order to facilitate its
application or dissemination to the locus to be treated, for
instance by dissolving, dispersing or diffusing the said
composition, and/or to facilitate its storage, transport or
handling without impairing its effectiveness. The pharmaceutically
acceptable carrier may be a solid or a liquid or a gas which has
been compressed to form a liquid, i.e. the compositions of this
invention can suitably be used as concentrates, emulsions,
solutions, granulates, dusts, sprays, aerosols, suspensions,
ointments, creams, tablets, pellets or powders.
[0233] Suitable pharmaceutical carriers for use in the said
pharmaceutical compositions and their formulation are well known to
those skilled in the art, and there is no particular restriction to
their selection within the present invention. They may also include
additives such as wetting agents, dispersing agents, stickers,
adhesives, emulsifying agents, solvents, coatings, antibacterial
and antiftungal agents (for example phenol, sorbic acid,
chlorobutanol), isotonic agents (such as sugars or sodium chloride)
and the like, provided the same are consistent with pharmaceutical
practice, i.e. carriers and additives which do not create permanent
damage to mammals. The pharmaceutical compositions of the present
invention may be prepared in any known manner, for instance by
homogeneously mixing, coating and/or grinding the active
ingredients, in a one-step or multi-steps procedure, with the
selected carrier material and, where appropriate, the other
additives such as surface-active agents may also be prepared by
micronisation, for instance in view to obtain them in the form of
microspheres usually having a diameter of about 1 to 10 gm, namely
for the manufacture of microcapsules for controlled or sustained
release of the active ingredients.
[0234] Suitable surface-active agents, also known as emulgent or
emulsifier, to be used in the pharmaceutical compositions of the
present invention are non-ionic, cationic and/or anionic materials
having good emulsifying, dispersing and/or wetting properties.
Suitable anionic surfactants include both water-soluble soaps and
water-soluble synthetic surface-active agents. Suitable soaps are
alkaline or alkaline-earth metal salts, unsubstituted or
substituted ammonium salts of higher fatty acids
(C.sub.10-C.sub.22), e.g. the sodium or potassium salts of oleic or
stearic acid, or of natural fatty acid mixtures obtainable form
coconut oil or tallow oil. Synthetic surfactants include sodium or
calcium salts of polyacrylic acids; fatty sulphonates and
sulphates; sulphonated benzimidazole derivatives and
alkylarylsulphonates. Fatty sulphonates or sulphates are usually in
the form of alkaline or alkaline-earth metal salts, unsubstituted
ammonium salts or ammonium salts substituted with an alkyl or acyl
radical having from 8 to 22 carbon atoms, e.g. the sodium or
calcium salt of lignosulphonic acid or dodecylsulphonic acid or a
mixture of fatty alcohol sulphates obtained from natural fatty
acids, alkaline or alkaline-earth metal salts of sulphuric or
sulphonic acid esters (such as sodium lauryl sulphate) and
sulphonic acids of fatty alcohol/ethylene oxide adducts. Suitable
sulphonated benzimidazole derivatives preferably contain 8 to 22
carbon atoms. Examples of alkylarylsulphonates are the sodium,
calcium or alcoholamine salts of dodecylbenzene sulphonic acid or
dibutyl-naphthalenesulphonic acid or a naphthalene-sulphonic
acid/formaldehyde condensation product. Also suitable are the
corresponding phosphates, e.g. salts of phosphoric acid ester and
an adduct of p-nonylphenol with ethylene and/or propylene oxide, or
phospholipids. Suitable phospholipids for this purpose are the
natural (originating from animal or plant cells) or synthetic
phospholipids of the cephalin or lecithin type such as e.g.
phosphatidylethanolamine, phosphatidylserine,
phosphatidylglycerine, lysolecithin, cardiolipin,
dioctanylphosphatidyl-choline, dipalritoylphoshatidyl-choline and
their mixtures.
[0235] Suitable non-ionic surfactants include polyethoxylated and
polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty
acids, aliphatic amines or amides containing at least 12 carbon
atoms in the molecule, alkylarenesulphonates and
dialkylsulphosuccinates, such as polyglycol ether derivatives of
aliphatic and cycloaliphatic alcohols, saturated and unsaturated
fatty acids and alkylphenols, said derivatives preferably
containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in
the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the
alkyl moiety of the alkylphenol. Further suitable non-ionic
surfactants are water-soluble adducts of polyethylene oxide with
poylypropylene glycol, ethylenediaminopolypropylene glycol
containing 1 to 10 carbon atoms in the alkyl chain, which adducts
contain 20 to 250 ethyleneglycol ether groups and/or 10 to 100
propyleneglycol ether groups. Such compounds usually contain from 1
to 5 ethyleneglycol units per propyleneglycol unit. Representative
examples of non-ionic surfactants are
nonylphenol-polyethoxyethanol, castor oil polyglycolic ethers,
polypropylene/polyethylene oxide adducts, tributylphenoxypolyetho-
xyethanol, polyethyleneglycol and octylphenoxypolyethoxyethanol.
Fatty acid esters of polyethylene sorbitan (such as polyoxyethylene
sorbitan trioleate), glycerol, sorbitan, sucrose and
pentaerythritol are also suitable non-ionic surfactants.
[0236] Suitable cationic surfactants include quaternary ammonium
salts, particularly halides, having 4 hydrocarbon radicals
optionally substituted with halo, phenyl, substituted phenyl or
hydroxy; for instance quaternary ammonium salts containing as
N-substituent at least one C8C22 alkyl radical (e.g. cetyl, lauryl,
palmityl, myristyl, oleyl and the like) and, as further
substituents, unsubstituted or halogenated lower alkyl, benzyl
and/or hydroxy-lower alkyl radicals.
[0237] A more detailed description of surface-active agents
suitable for this purpose may be found for instance in
"McCutcheon's Detergents and Emulsifiers Annual" (MC Publishing
Crop., Ridgewood, New Jersey, 1981), "Tensid-Taschenbucw`, 2 d ed.
(Hanser Verlag, Vienna, 1981) and "Encyclopaedia of Surfactants,
(Chemical Publishing Co., New York, 1981).
[0238] Compounds of the invention and their physiologically
acceptable salts (hereafter collectively referred to as the active
ingredients) may be administered by any route appropriate to the
condition to be treated, suitable routes including oral, rectal,
nasal, topical (including ocular, buccal and sublingual), vaginal
and parenteral (including subcutaneous, intramuscular, intravenous,
intradermal, intrathecal and epidural). The preferred route of
administration may vary with for example the condition of the
recipient.
[0239] While it is possible for the active ingredients to be
administered alone it is preferable to present them as
pharmaceutical formulations. The formulations, both for veterinary
and for human use, of the present invention comprise at least one
active ingredient, as above described, together with one or more
pharmaceutically acceptable carriers therefore and optionally other
therapeutic ingredients. The carrier(s) optimally are "acceptable"
in the sense of being compatible with the other ingredients of the
formulation and not deleterious to the recipient thereof. The
formulations include those suitable for oral, rectal, nasal,
topical (including buccal and sublingual), vaginal or parenteral
(including subcutaneous, intramuscular, intravenous, intradermal,
intrathecal and epidural) administration. The formulations may
conveniently be presented in unit dosage form and may be prepared
by any of the methods well known in the art of pharmacy. Such
methods include the step of bringing into association the active
ingredient with the carrier which constitutes one or more accessory
ingredients. In general the formulations are prepared by uniformly
and intimately bringing into association the active ingredient with
liquid carriers or finely divided solid carriers or both, and then,
if necessary, shaping the product.
[0240] Formulations of the present invention suitable for oral
administration may be presented as discrete units such as capsules,
cachets or tablets each containing a predetermined amount of the
active ingredient; as a powder or granules; as solution or a
suspension in an aqueous liquid or a non-aqueous liquid; or as an
oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The
active ingredient may also be presented as a bolus, electuary or
paste.
[0241] A tablet may be made by compression or molding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared by compressing in a suitable machine the active ingredient
in a free-flowing form such as a powder or granules, optionally
mixed with a binder, lubricant, inert diluent, preservative,
surface active or dispersing agent. Molded tablets may be made by
molding in a suitable machine a mixture of the powdered compound
moistened with an inert liquid diluent. The tablets may optionally
be coated or scored and may be formulated so as to provide slow or
controlled release of the active ingredient therein. For infections
of the eye or other external tissues e.g. mouth and skin, the
formulations are optionally applied as a topical ointment or cream
containing the active ingredient(s) in an amount of, for example,
0.075 to 20% w/w (including active ingredient(s) in a range between
0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w,
etc), preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w.
When formulated in an ointment, the active ingredients may be
employed with either a paraffinic or a water-miscible ointment
base. Alternatively, the active ingredients may be formulated in a
cream with an oil-in-water cream base. If desired, the aqueous
phase of the cream base may include, for example, at least 30% w/w
of a polyhydric alcohol, i.e. an alcohol having two or more
hydroxyl groups such as propylene glycol, butane 1,3-diol,
mannitol, sorbitol, glycerol and polyethylene glycol (including
PEG400) and mixtures thereof. The topical formulations may
desirably include a compound which enhances absorption or
penetration of the active ingredient through the skin or other
affected areas. Examples of such dermal penetration enhancers
include dimethylsulfoxide and related analogs.
[0242] The oily phase of the emulsions of this invention may be
constituted from known ingredients in a known manner. While the
phase may comprise merely an emulsifier (otherwise known as an
emulgent), it desirably comprises a mixture of at least one
emulsifier with a fat or an oil or with both a fat and an oil.
Optionally, a hydrophilic emulsifier is included together with a
lipophilic emulsifier which acts as a stabilizer. It is also
preferred to include both an oil and a fat. Together, the
emulsifier(s) with or without stabilizer(s) make up the so-called
emulsifying wax, and the wax together with the oil and fat make up
the so-called emulsifying ointment base which forms the oily
dispersed phase of the cream formulations.
[0243] The choice of suitable oils or fats for the formulation is
based on achieving the desired cosmetic properties, since the
solubility of the active compound in most oils likely to be used in
pharmaceutical emulsion formulations is very low. Thus the cream
should optionally be a non-greasy, non-staining and washable
product with suitable consistency to avoid leakage from tubes or
other containers. Straight or branched chain, mono- or dibasic
alkyl esters such as di-isoadipate, isocetyl stearate, propylene
glycol diester of coconut fatty acids, isopropyl myristate, decyl
oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate
or a blend of branched chain esters known as Crodamol CAP may be
used, the last three being preferred esters. These may be used
alone or in combination depending on the properties required.
Alternatively, high melting point lipids such as white soft
paraffin and/or liquid paraffin or other mineral oils can be
used.
[0244] Formulations suitable for topical administration to the eye
also include eye drops wherein the active ingredient is dissolved
or suspended in a suitable carrier, especially an aqueous solvent
for the active ingredient. The active ingredient is optionally
present in such formulations in a concentration of 0.5 to 20%,
advantageously 0.5 to 10% particularly about 1.5% w/w. Formulations
suitable for topical administration in the mouth include lozenges
comprising the active ingredient in a flavored basis, usually
sucrose and acacia or tragacanth; pastilles comprising the active
ingredient in an inert basis such as gelatin and glycerin, or
sucrose and acacia; and mouthwashes comprising the active
ingredient in a suitable liquid carrier.
[0245] Formulations for rectal administration may be presented as a
suppository with a suitable base comprising for example cocoa
butter or a salicylate. Formulations suitable for nasal
administration wherein the carrier is a solid include a coarse
powder having a particle size for example in the range 20 to 500
microns (including particle sizes in a range between 20 and 500
microns in increments of 5 microns such as 30 microns, 35 microns,
etc), which is administered in the manner in which snuff is taken,
i.e. by rapid inhalation through the nasal passage from a container
of the powder held close up to the nose. Suitable formulations
wherein the carrier is a liquid, for administration as for example
a nasal spray or as nasal drops, include aqueous or oily solutions
of the active ingredient. Formulations suitable for aerosol
administration may be prepared according to conventional methods
and may be delivered with other therapeutic agents.
[0246] Formulations suitable for vaginal administration may be
presented as pessaries, tampons, creams, gels, pastes, foams or
spray formulations containing in addition to the active ingredient
such carriers as are known in the art to be appropriate.
[0247] Formulations suitable for parenteral administration include
aqueous and non-aqueous sterile injection solutions which may
contain anti-oxidants, buffers, bacteriostats and solutes which
render the formulation isotonic with the blood of the intended
recipient; and aqueous and non-aqueous sterile suspensions which
may include suspending agents and thickening agents. The
formulations may be presented in unit-dose or multi-dose
containers, for example sealed ampoules and vials, and may be
stored in a freeze-dried (lyophilized) condition requiring only the
addition of the sterile liquid carrier, for example water for
injections, immediately prior to use. Extemporaneous injection
solutions and suspensions may be prepared from sterile powders,
granules and tablets of the kind previously described.
[0248] Preferred unit dosage formulations are those containing a
daily dose or unit daily sub-dose, as herein above recited, or an
appropriate fraction thereof, of an active ingredient.
[0249] It should be understood that in addition to the ingredients
particularly mentioned above the formulations of this invention may
include other agents conventional in the art having regard to the
type of formulation in question, for example those suitable for
oral administration may include flavoring agents.
[0250] Compounds of the invention can be used to provide controlled
release pharmaceutical formulations containing as active ingredient
one or more compounds of the invention ("controlled release
formulations") in which the release of the active ingredient can be
controlled and regulated to allow less frequency dosing or to
improve the pharmacokinetic or toxicity profile of a given
invention compound. Controlled release formulations adapted for
oral administration in which discrete units comprising one or more
compounds of the invention can be prepared according to
conventional methods.
[0251] Additional ingredients may be included in order to control
the duration of action of the active ingredient in the composition.
Control release compositions may thus be achieved by selecting
appropriate polymer carriers such as for example polyesters,
polyamino acids, polyvinyl pyrrolidone, ethylene-vinyl acetate
copolymers, methylcellulose, carboxymethylcellulose, protamine
sulfate and the like. The rate of drug release and duration of
action may also be controlled by incorporating the active
ingredient into particles, e.g. microcapsules, of a polymeric
substance such as hydrogels, polylactic acid,
hydroxymethylcellulose, polymethyl methacrylate and the other
above-described polymers. Such methods include colloid drug
delivery systems like liposomes, microspheres, microemulsions,
nanoparticles, nanocapsules and so on. Depending on the route of
administration, the pharmaceutical composition may require
protective coatings. Pharmaceutical forms suitable for
injectionable use include sterile aqueous solutions or dispersions
and sterile powders for the extemporaneous preparation thereof.
Typical carriers for this purpose therefore include biocompatible
aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene
glycol and the like and mixtures thereof.
[0252] In view of the fact that, when several active ingredients
are used in combination, they do not necessarily bring out their
joint therapeutic effect directly at the same time in the mammal to
be treated, the corresponding composition may also be in the form
of a medical kit or package containing the two ingredients in
separate but adjacent repositories or compartments. In the latter
context, each active ingredient may therefore be formulated in a
way suitable for an administration route different from that of the
other ingredient, e.g. one of them may be in the form of an oral or
parenteral formulation whereas the other is in the form of an
ampoule for intravenous injection or an aerosol.
Synthetic Methods
[0253] The compounds of formula (A) are prepared using a series of
chemical reactions well known to those skilled in the art,
altogether making up the process for preparing said compounds and
exemplified further. The processes described further are only meant
as examples and by no means are meant to limit the scope of the
present invention.
[0254] The invention also relates to methods of making the
compositions of the invention. The compositions are prepared by any
of the applicable techniques of organic synthesis. Many such
techniques are well known in the art. However, many of the known
techniques are elaborated in "Compendium of Organic Synthetic
Methods" (John Wiley & Sons, New York), Vol. 1, Ian T. Harrison
and Shuyen Harrison, 1971; Vol. 2, Ian T. Harrison and Shuyen
Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol.
4, Leroy G. Wade, Jr., 1980; Vol. 5, Leroy G. Wade, Jr., 1984; and
Vol. 6, Michael B. Smith; as well as March, J., "Advanced Organic
Chemistry, Third Edition", (John Wiley & Sons, New York, 1985),
"Comprehensive Organic Synthesis. Selectivity, Strategy &
Efficiency in Modem Organic Chemistry. In 9 Volumes", Barry M.
Trost, Editor-in-Chief (Pergamon Press, New York, 1993
printing).
[0255] Exemplary methods for the preparation of the compositions of
the invention are provided below. These methods are intended to
illustrate the nature of such preparations, and are not intended to
limit the scope of applicable methods.
[0256] Generally, the reaction conditions such as temperature,
reaction time solvents, workup procedures, and the like, will be
those common in the art for the particular reaction to be
performed. The cited reference material, together with material
cited therein, contains detailed descriptions of such conditions.
Typically the temperatures will be -100.degree. C. to 200.degree.
C., solvents will be aprotic or protic, and reaction times will be
10 seconds to 10 days. Workup typically consists of quenching any
unreacted reagents followed by partition between a water/organic
layer system (extraction) and separating the layer containing the
product. Oxidation and reduction reactions are typically carried
out at temperatures near room temperature (about 20.degree. C.),
although for metal hydride reductions frequently the temperature is
reduced to 0.degree. C. to -100.degree. C., solvents are typically
aprotic for reductions and may be either protic or aprotic for
oxidations. Reaction times are adjusted to achieve desired
conversions.
[0257] Condensation reactions are typically carried out at
temperatures near room temperature, although for non-equilibrating,
kinetically controlled condensations reduced temperatures
(0.degree. C. to -100.degree. C.) are also common. Solvents can be
either protic (common in equilibrating reactions) or aprotic
(common in kinetically controlled reactions).
[0258] Standard synthetic techniques such as azeotropic removal of
reaction by-products and use of anhydrous reaction conditions (e.g.
inert gas environments) are common in the art and will be applied
when applicable.
[0259] General aspects of these exemplary methods are described
below. Each of the products of the following processes is
optionally separated, isolated, and/or purified prior to its use in
subsecquent processes.
[0260] The terms "treated", "treating", "treatment", and the like,
mean contacting, mixing, reacting, allowing to react, bringing into
contact, and other terms common in the art for indicating that one
or more chemical entities is treated in such a manner as to convert
it to one or more other chemical entities. This means that
"treating compound one with compound two" is synonymous with
"allowing compound one to react with compound two", "contacting
compound one with compound two", "reacting compound one with
compound two", and other expressions common in the art of organic
synthesis for reasonably indicating that compound one was
"treated", "reacted", "allowed to react", etc., with compound
two.
[0261] "Treating" indicates the reasonable and usual manner in
which organic chemicals are allowed to react. Normal concentrations
(0.01M to 10M, typically 0.1M to 1M), temperatures (-100.degree. C.
to 250.degree. C., typically -78.degree. C. to 150.degree. C., more
typically -78.degree. C. to 100.degree. C., still more typically
0.degree. C. to 100.degree. C.), reaction vessels (typically glass,
plastic, metal), solvents, pressures, atmospheres (typically air
for oxygen and water insensitive reactions or nitrogen or argon for
oxygen or water sensitive), etc., are intended unless otherwise
indicated. The knowledge of similar reactions known in the art of
organic synthesis is used in selecting the conditions and apparatus
for "treating" in a given process. In particular, one of ordinary
skill in the art of organic sysnthesis selects conditions and
apparatus reasonably expected to successfully carry out the
chemical reactions of the described processes based on the
knowledge in the art.
[0262] Modification of the exemplified schemes and examples leads
to various analogs of the specific exemplary materials produced
above. The above citations describing suitable methods of organic
synthesis are applicable to such modifications.
[0263] In the exemplary schemes it may be advantageous to separate
reaction products from one another and/or from starting materials.
The desired products of each step or series of steps is separated
and/or purified (hereinafter separated) to the desired degree of
homogeneity by the techniques common in the art. Typically such
separations involve multiphase extraction, crystallization from a
solvent or solvent mixture, distillation, sublimation, or
chromatography. Chromatography can involve any number of methods
including, for example, size exclusion or ion exchange
chromatography, high, medium, or low pressure liquid
chromatography, small scale and preparative thin or thick layer
chromatography, as well as techniques of small scale thin layer and
flash chromatography.
[0264] Another class of separation methods involves treatment of a
mixture with a reagent selected to bind to or render otherwise
separable a desired product, unreacted starting material, reaction
by product, or the like. Such reagents include adsorbents or
absorbents such as activated carbon, molecular sieves, ion exchange
media, or the like. Alternatively, the reagents can be acids in the
case of a basic material, bases in the case of an acidic material,
binding reagents such as antibodies, binding proteins, selective
chelators such as crown ethers, liquid/liquid ion extraction
reagents (LIX), or the like.
[0265] Selection of appropriate methods of separation depends on
the nature of the materials involved. For example, boiling point,
and molecular weight in distillation and sublimation, presence or
absence of polar functional groups in chromatography, stability of
materials in acidic and basic media in multiphase extraction, and
the like. One skilled in the art will apply techniques most likely
to achieve the desired separation.
[0266] Suitable methods for making the compounds of this invention
also are found in WO 2004/005286, in particular schemes 1-13
therein.
[0267] Another synthetic route to
5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyrid- ine and analogues is
shown in scheme 1. 10
[0268] The following list includes carboxylic acid reactants which
may be employed in the condensation, ring closure reaction of
Scheme 1. The compounds so produced 10 will bear the residue of the
acid at the site of YR.sup.1. Optionally, the remainder of the
molecule will be as in any of the compounds of examples 2-7.
1 Acid MW 11 258.117 12 179.199 13 258.117 14 124.099 15 158.103 16
156.204 17 174.558 18 189.173 19 191.013 20 113.072 21 214.219 22
146.144 23 152.148 24 137.137 25 244.22 26 174.158 27 164.159 28
200.213 29 190.12 30 200.213 31 191.013 32 252.272 33 165.191 34
250.256 35 214.219 36 216.21 37 206.118 38 216.21 39 194.229 40
277.116 41 164.159 42 215.251 43 178.23 44 215.251 45 125.126 46
126.114 47 112.084 48 129.139 49 128.151 50 143.165 51 124.099 52
124.099 53 200.213 54 127.099 55 201.201 56 126.114 57 112.088 58
222.238 59 124.099 60 174.158 61 174.158 62 230.266 63 240.257 64
221.279 65 166.175 66 257.107 67 137.137 68 223.614 69 204.267 70
140.141 71 141.101 72 176.17 73 154.139 74 188.128 75 173.17 76
262.21 77 173.17 78 187.197 79 178.21 80 178.15 81 187.197 82
176.17 83 173.17 84 157.556 85 154.139 86 234.2 87 112.088 88
170.138 89 192.169 90 187.197
[0269] The following list includes alkylating reagents which may be
employed in the pyridyl alkylation reaction of Scheme 1. Here, the
residue of the alkylating agent is located at the X R.sup.3 site of
the compound of this invention. Optionally, the remainder of the
compound will be as found in any of the compounds of examples
2-7.
2 Alkylating reagent MW 91 195.475 92 203.053 93 168.666 94 223.471
95 154.639 96 253.109 97 154.639 98 203.053 99 145.588 100 203.053
101 190.672 102 273.478 103 338.832 104 269.059 105 205.039 106
223.471 107 325.225 108 289.478 109 262.579 110 269.059 111 228.721
112 253.06 113 207.016 114 253.06 115 307.03 116 253.06 117 199.09
118 221.043 119 175.057 120 285.567 121 154.639 122 344.203 123
216.663 124 261.569 125 218.682 126 212.078 127 275.144 128 195.57
129 198.648 130 299.113 131 294.907 132 228.077 133 244.144 134
193.632 135 222.084 136 223.471 137 152.623 138 255.961 139 118.523
140 252.11 141 255.138 142 190.039 143 328.828 144 176.012 145
202.611 146 237.099 147 281.123 148 238.087 149 170.638 150 239.623
151 257.023 152 198.648 153 257.023 154 350.235 155 257.023 156
252.11 157 257.023 158 236.111 159 257.023 160 320.206 161 257.023
162 228.995 163 255.032 164 273.478 165 174.63 166 203.053 167
186.637 168 214.036 169 247.134 170 203.053 171 190.672 172 214.036
173 204.676 174 285.913 175 257.023 176 241.462 177 262.579 178
283.251 179 224.646 180 177.064 181 194.62 182 267.922 183 262.617
184 350.235 185 237.042 186 350.235 187 275.144 188 196.7 189
186.637 190 199.09 191 169.035 192 199.09 193 229.065 194 199.09
195 250.727 196 199.09 197 324.526 198 253.06 199 261.569 200
258.103 201 262.617 202 331.052 203 273.699 204 88.5365 205 249.127
206 132.988 207 131.561 208 102.563 209 210.581 210 144.644 211
303.154 212 144.044 213 223.471 214 296.239 215 179.02 216 172.098
217 273.478 218 158.071 219 257.023 220 170.082 221 257.023 222
186.081 223 241.12 224 184.109 225 166.61 226 149.663 227 205.995
228 248.195 229 188.613 230 313.064 231 277.696 232 158.071 233
133.602 234 186.124 235 208.647 236 230.133 237 272.144 238 129.589
239 219.052 240 167.038 241 229.065 242 243 209.699 244 245 226.648
246 247 132.613 248 249 207.659 250 251 223.471 252 253 276.549 254
255 168.047 256 257 162.566 258 259 224.646 260 261 186.637 262 263
154.639 264 265 277.16 266 267 263.133 268 269 231.088 270 271
200.648 272 273 215.727 274 275 291.469 276 277 273.478 278 279
237.498 280 281 237.498 282 283 223.471
[0270] Scheme 2 shows a synthetic route to
5-biarylmethyl-2-phenyl-5H-imid- azo[4,5-c]pyridines and
5-benzyl-2-biaryl-5H-imidazo[4,5-c]pyridines. 284
[0271] Scheme 3 shows a synthetic route to
5-(alkoxybenzyl)-2-phenyl-5H-im- idazo[4,5-c]pyridines and
5-benzyl-2-alkoxybenzyl-5H-imidazo[4,5-c]pyridin- es. R, R', and R"
can be any alkyl, benzylic or heterobenzylic groups. 285
[0272] Analogous compounds may be synthesized in the same fashion
as in the foregoing schemes by varying the starting materials,
intermediates, solvents and conditions as will be known by those
skilled in the art.
EXAMPLES
Part A
Compound Synthesis
Example 1
2-(2,3-difluorophenyl)-3H-imidazo[4,5-c]pyridine
[0273] 286
[0274] Phosphorous pentoxide (24.56 g) was dissolved in
methanesulfonic acid (165.8 mL) at 50.degree. C. with stirring. To
the solution, 3,4-diaminopyridine (12.3 g, 0.1 mmoles) and
2,3-difluorobenzoic acid (19.4 g, 0.12 moles) were added. The
reaction mixture was heated to 190.degree. C. for 3 hours. The
reaction was done three times. The reaction mixtures was cooled to
50.degree. C. and poured into ice with stirring. At this stage, all
three batches were combined. The reaction mixture was neutralized
by the addition of NaOH with stirring until the pH is 8. Solid
material precipitated out of solution, was collected by filtration
and air-dried. The final product was re-crystallized from
ethanol/water twice to yield 36 g of
2-(2,3-difluorophenyl)-3H-imidazo[4,- 5-c]pyridine. 1H 300 Mhz
(CD.sub.3OD) sigma 7.3-7.42 (m, 1p); 7.43-7.58 (m, 1p); 7.70 (d,
1p); 8.0 (m, 1p); 8.34 (d, 1p); and 8.95 (s, 1p). LC/MS data
M/z=232.
[0275] Following the above taught procedure and substituting
2-fluorobenzoic acid in place of 2,3-difluorobenzoic acid, the
compound 2-(2-fluorophenyl)-3H-imidazo[4,5-c]pyridine can be
prepared.
Example 2
5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)
20-5H-imidazo[4,5-c]pyridine
[0276] 287
[0277] To a suspension of
2-(2-fluorophenyl)-3H-imidazo[4,5-c]pyridine (11.0 g, 50.0 mmoles)
in DMF was added a 10% (w/v) solution of aqueous NaOH. To this
solution, 5-(chloromethyl)-3-(4-chlorophenyl)isoxazole (13.68 g,
60.0 mmoles) dissolved in DMF was added. The reaction mixture was
stirred at room temperature and monitored every half hour by LCMS.
The reaction was stopped at 4 hours, after LCMS showed no progress
between at 2 hour and 4 hour monitor points. The reaction product
was triturated with first with water and then with EtoAc
(3.times.). The material was crystallized by dissolving the
material in MeOH with heat, followed by precipitation with water.
This crystallization process was then repeated yielding
5((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fl-
uorophenyl)-5H-imidazo[4,5-c]pyridine (15.385 g, 38 mmole) as white
crystal at a yield of 74%. 1H 300 Mhz (d.sub.6-DMSO) sigma 6.02 (s,
2p); 7.13 (s, 1p); 7.26-7.35 (m, 2p); 7.43-7.52 (m, 1p); 7.56 (d,
2p); 7.84 (d, 1); 7.89 (d, 2p); 8.24 (d, 1); 8.28-8.36 (m, 1p); and
9.19 (s, 1p). LCMS data M/Z=405.31.
Example 3A
5-(4-(trifluoromethoxy)benzyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]pyr-
idine
[0278] 288
[0279] First, 2-(2,3-difluorophenyl)-3H-imidazo[4,5-c]pyridine (20
g, 86.6 mmole) was added to 430 mL of DMF; Some of the solid
material did not dissolve. To this solution was added 43 mL of a
10% NaOH (w/v) solution. With vigorous stirring, the un-dissolved
material went into solution. The resulting solution was divided
into 30 equal portions of 16.3 mL, 3 mmole of
2-(2,3-difluorophenyl)-3H-imidazo[4,5-c]pyridine so as to fit into
a microwave reaction vessel. To each reaction vessel was added of
11-(chloromethyl)-4-(trifluoromethoxy)benzene (693 mg, 3 mmole).
Each reaction mixture was microwaved for 1 minute at 110.degree. C.
Following the completion of all the microwave reactions, all of the
reaction vessels were combined (one was lost due to breakage of the
vessel) into three batches for workup. For each batch, DMF was
removed by vacuum, and the resulting material was washed three
times with deionized water. The resulting crude material was
dissolved in CH.sub.2Cl.sub.2, Purified using a 330 g SiO.sub.2
column (Redisep (Isco) 0% to 0%/5 min to 10% B/30 min to 20%/5
min), and the resulting material was re-crystallized from
ethanol/H.sub.2O. The three batches yielded 14 g, 33.5 mmole of
5-(4-(trifluoromethoxy)benzyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]py-
ridine. 1H 300 Mhz (CD.sub.3OD) sigma 5.79 (s, 2p); 7.25-7.35 (m,
1p); 7.37 (d, 2p); 7.38-7.42 (m, 2p); 7.55 (d, 2p); 7.88-7.95 (m,
1p); 8.25 (d, 1p); and 9.05 (s, 1p). LC/MS M/z=406.23.
Example 3B
[0280] Following the above-taught procedure, and substituting
1-(chloromethyl)-2,4 difluorobenzene in place of
1-(chloromethyl)-4-(trif- luoromethoxy)benzene, the compound
5-(4-iodobenzyl)-2-(2,3-difluorophenyl)- -5H-imidazo[4,5-c]pyridine
can be prepared.
Example 4
5-(2,4-difluoro-biphenyl)methyl-2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]py-
ridine
[0281] 289
[0282] 2,4-difluorophenylboronic acid (196 mg, 1.24 mmole) was
added to a solution of
5-(4-iodobenzyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]pyri- dine
(460 mg, 1.03 mmole) in DMF (10 mL). Na.sub.2CO.sub.3 was dissolved
in H.sub.2O, added to the DMF solution and stirred. Pd(PPh3).sub.4
was then added to the DMF reaction mixture. The reaction mixture
was heated in a microwave at 200.degree. C. for 2 minutes. After
extractive work-up using ethyl acetate/water, the crude product was
purified in two batches using an Isco 40 g SiO.sub.2 column (0 to
10% B/20 min, A=CH.sub.2Cl.sub.2, B=MeOH, flow rate=40 ml/min) for
each purification. The pure product fractions were combined and
concentrated. The resulting solid was re-crystallized from
CH.sub.2Cl/hexane. The collected crystals were dried under high
vacuum overnight resulting in
5-(2,4-difluoro-biphenyl)methyl-2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]p-
yridine (223 mg, 0.515 mmole) at 50% yield. 1H 300 Mhz (CD.sub.3OD)
sigma 5.8 (s, 2p); 7.0-7.1 (m, 2p); 7.25-7.35 (m, 1p); 7.35-7.45
(m, 1p); 7.45-7.60 (m, Sp); 7.85 (d, 1p); 7.85-8.0 (m, 1p); 8.3 (d,
1p); and 9.10 (s, 1p). LC/MS data M/z=434.18.
Example 5
5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2,3-difluorophenyl)-5H-imid-
azo[4,5-c]pyridine
[0283] 290
[0284] To a solution of azabenzimidazole (10 g, 43.3 mmole) in DMF
was added 10% (w/v) aqueous NaOH followed by a solution of
5-(chloromethyl)-3-(4-chlorophenyl)-isoxazole (11.8 g, 51.9 mmole)
in DMF. The reaction mixture was stirred at room temperature for 7
hours, and then concentrated. The solid material was treated with
EtOAc/H.sub.2O, and collected by filtering. The solid material was
then tritrated with H.sub.2O and EtOAc, and air-dried. The solid
was further purified by re-crystallization from MeOH to obtain
5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2,3-difluorophenyl)-5H-imi-
dazo[4,5-c]pyridine (8.5 g, 20.1 mmole) at 46.6% yield. 1H 300 Mhz
(DMSO-d.sub.6) sigma 6.03 (s, 2p); 7.12 (s, 1p); 7.25-7.35 (m, 1p);
7.44-7.53 (m, 1p); 7.55 (d, 2p); 7.88 (d, 3p); 8.11-8.18 (m, 1p);
8.24-8.29 (dd, 1p); and 9.23 (s, 1p). LC/MS data M/z=423.34,
425.22.
Example 6
5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5-
H-imidazo[4,5-c]pyridine
[0285] 291
2,4-(bis-trifluoromethyl)benzaldoxime
[0286] To aromatic aldehyde (0.021 mol) suspended in EtOH/H.sub.2O
(1:2, 230 mL, 0.09 M) was added hydroxylamine hydrochloride (1.58
g, 0.023 mol) and cooled to 4.degree. C. To this solution was added
aqueous NaOH 50% w/w (4.13 mL, 0.052 mol) dropwise. After stirring
for 1.5 h at room temperature, the reaction mixture was acidified
with 2N aqueous HCl and extracted with CH.sub.2Cl.sub.2 (3.times.50
mL). The organic solution was washed with saturated aqueous NaCl
and dried over sodium sulfate. Removal of solvent gave crude oxime
(5.3 g, quant.) that was used directly in the next step.
2,4-(bis-trifluoromethyl)phenyl chloromethyl isoxazole
[0287] 2,4-(bis-trifluoromethyl)benzaldoxime (9.75 g, 0.038 mol)
was suspended in CH.sub.2Cl.sub.2 (45 mL, 0.85 M) and cooled to
4.degree. C. Propargyl chloride (2.72 mL, 0.038 mol) was added to
the reaction solution followed by dropwise addition of NaOCl
(10-13. % free chlorine, 37.6 mL, 0.061 mol). The reaction mixture
was stirred at 4.degree. C. for 15 min then heated to reflux for 3
h. After cooling to room temperature, the reaction was partitioned
between CH.sub.2Cl.sub.2 and H.sub.2O. The organic layer was
separated, washed with saturated aqueous NaCl, and dried over
sodium sulfate. After removal of solvent, the crude product
chloromethylisoxazole was purified by column chromatography on
silica (10% CH.sub.2Cl.sub.2/hexanes)(6.5 g, 0.020 mol).
5-((3-(2,4-trifluoromethylphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)--
5H-imidazo[4,5-c]pyridine
[0288] To imidazopyridine (14.28 g, 0.067 mol) suspended in DMF (40
mL) was added aqueous NaOH 10% w/w (32.2 mL, 0.080 mol) dropwise
followed by addition of the chloromethyl isoxazole from the
previous step (26.3 g, 0.080 mol) in DMF (16 mL). After stirring
for 12 h at room temperature, solvents were evaporated to give
crude product as a tan solid. The crude solid was triturated with
H.sub.2O (7.times.) and crystallized (2.times.) from MeOH/H.sub.2O
(2:1) to provide pure title product.
[0289] NMR; 300 Mhz D.sub.6MSO
[0290] Chemical Shift, Multiplicity, # of Protons:
[0291] 6.1, s, 2
[0292] 7.0, s, 1
[0293] 7.3, t, 2
[0294] 7.4-7.5, m, 1
[0295] 7.8-7.9, d, 1
[0296] 7.9-8.0, d, 1
[0297] 8.2-8.4, m, 4
[0298] 9.2, s, 1
Example 7
5-((3-(4-trifluoromethy-2-fluorophenyl)isoxazol-5-yl)methyl)-2-(2-fluoroph-
enyl)-5H-imidazo[4,5-c]pyridine
[0299]
3 Isoxazole synthesis 292 293 Compound MW Amount Moles Equivalents
A 207.13 9.3 g 0.044 1 NaOCl (10% 74.44 43.0 mL 0.44 1.6 free Cl)
Propargyl chloride 74.51 3.14 mL 0.044 1 Dichloromethane 48.7
mL
[0300] "A" was suspended in dichloromethane at 0.degree. C. and
NaOCl was added at 0.degree. C. with vigorous stirring, followed by
propargyl chloride. Reaction stirred at 0.degree. C. for 5 min 10
and then heated to reflux for 2 h. It was then cooled to room
temperature, washed with water, dried over sodium sulfate and
concentrated in vacuo to obtain a yellow solid. It was purified on
the combiflash on a silica gel column, eluting with 3-50% ethyl
acetate-hexanes. 4.5 g of shiny white solid obtained.
4 294 295 Compound MW Amount mMoles Equivalents A 279.62 2.0 g 7.6
1.2 B 213.21 1.373 g 6.4 1 10% w/v aq 2.26 mL NaOH DMF 13.73 mL +
6.56 mL "B" was suspended in 13.73 mL DMF and 10% (w/v) aq. NaOH
was added to it. "A" was dissolved in 6.56 mL DMF and this solution
was added to the above with stirring. The reaction was stirred at
room temperature for 5 hours. DMF was removed by concentrating in
vacuo and the solid obtained was triturated with water two times
and then with ethyl acetate. The solid thus obtained was
recrystallized from methanol-water to obtain 533 mg of the desired
compound.
[0301] NMR (DMSO) Data:
[0302] Chemical Shift, Multiplicity, # of Protons:
[0303] 6.14, s, 2
[0304] 7.18, d, 1
[0305] 7.28-7.36, m, 2
[0306] 7.44-7.54, m, 1
[0307] 7.70-7.76, d, 1
[0308] 7.86-7.90, d, 1
[0309] 7.90-7.96, d, 1
[0310] 8.08-8.16, t, 1
[0311] 8.28-8.36, t, 2
[0312] 9.24, s, 1
Example 8A
5-((3-(2-trifluoromethy-4-fluorophenyl)isoxazol-5-yl)methyl)-2-(2-fluoroph-
enyl)-5H-imidazo[4,5-c]pyridine
[0313] 296
[0314] To a solution of azabenzimidazole (12.7 g, 59.6 mmole) in
DMF (120 mL) was added 10% (w/v) aqueous NaOH (30.5 mL, 76.6 mmole)
followed by a solution of
5-(chloromethyl)-3-(2-triflouromethyl-4-flourophenyl)-isoxazo- le
(21.3 g, 76.6 mmole) in DMF (60 mL). The reaction mixture was
stirred at room temperature for 18 hours, and then concentrated.
The material was precipitated from MeOH/H.sub.2O, and collected by
filtering. The solid material was recrystallized from EtoAc/hexanes
to obtain
5-((3-(2-trifluoromethy-4-fluorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorop-
henyl)-5H-imidazo[4,5-c]pyridine in 69% yield.
[0315] NMR Data
[0316] 300 Mhz D.sub.6MSO
[0317] Chemical Shift, Multiplicity, # of Protons:
[0318] 6.15, s, 2
[0319] 6.91, s, 1
[0320] 7.3, t, 2
[0321] 7.42-7.52, m, 1
[0322] 7.65-7.9, m, 2
[0323] 7.84-7.9, m, 2
[0324] 8.22-8.45, m, 2
[0325] 9.19, s, 1
Example 8B
Salts of
5-((3-(2-trifluoromethy-4-fluorophenyl)isoxazol-5-yl)methyl)-2-(2-
-fluorophenyl)-5H-imidazo[4,5-c]pyridine
[0326] Methanesulfonic Acid Salt
[0327]
5-((3-(2-trifluoromethy-4-fluorophenyl)isoxazol-5-yl)methyl)-2-(2-f-
luorophenyl)-5H-imidazo[4,5-c]pyridine free base (200 mg) was
slurried in 2.0 mL acetone. Methanesulfonic acid (42.6 mg) was
added and the mixture was warmed to .about.60.degree. C. Water was
added in small increments until a solution was formed (110 .mu.L
required). The solution was cooled to ambient temperature and
stirred overnight. The slurry was cooled in an ice bath before
being filtered and washed with acetone. The solid obtained was
dried at 40.degree. C. to give 149 mg of the desired salt. DSC
endotherm 213.1.degree. C. NMR was consistent with the desired
structure.
[0328] HCl Salt
[0329]
5-((3-(2-trifluoromethy-4-fluorophenyl)isoxazol-5-yl)methyl)-2-(2-f-
luorophenyl)-5H-imidazo[4,5-c]pyridine free base (200 mg) was
slurried in 2.0 mL acetone. Concentrated hydrochloric acid (46 mg)
was added and the mixture was warmed to .about.60.degree. C. Water
was added to the thick slurry in small increments until a solution
was formed (100 .mu.L required). The solution was cooled to ambient
20 temperature and stirred overnight. The slurry was cooled in an
ice bath before being filtered and washed with acetone. The solid
obtained was dried at 40.degree. C. to give 80 mg of the desired
salt. DSC endotherm 241.5.degree. C. NMR consistent with the
desired structure.
Example 8B
Formulation of
5-((3-(2-trifluoromethy-4-fluorophenyl)isoxazol-5-yl)methyl-
)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine salts
[0330] Either salt of Example 7B was mixed 1:1 by weight in dry
pregelatinized starch. 100 mg of the mixture was loaded into a hard
gel capsule.
[0331] Additional compounds of this invention were made by the
methods of procedures A, C, D, E and F.
[0332] Procedure A; Alkylation 297
[0333] For compounds prepared in an array format, 100 um of the
scaffold (in this case
2-(2,3-Difluoro-phenyl)-3H-imidazo[4,5-c]pyridine) was used for
each reaction. The total amount of
2-(2,3-Difluoro-phenyl)-3H-imidazo- [4,5-c]pyridine was dissolved
in enough DMF to give 500 ul/reaction. To each solution was added
60 .mu.L of 10% (w/v)NaOH/H.sub.2O. The alkylating agents were
dissolved in DMF at a concentration 480 .mu.mole/mL and 250 .mu.L
of these solutions were added to the respective reaction. Each
reaction was then heated to 110.degree. C. for 1 min using
microwave irradiation. After cooling, the reactions were filtered
through a 0.45 um filter. Each compound was then purified by mass
based fractionation on a C-18 reverse phase column using 0.1%
TFA/H.sub.2O and 0.1% TFA/Acetonitrile as the eluting solvents.
Each compound was identified by its mass spectrum and purity was
determined by UV absorbance at 254 mn. The HPLC fractions were
concentrated by centrifugal evaporation and weighed to determine
quantity collected.
[0334] Procedure C; Suzuki Boronic Acid 298
[0335] The aryl boronic acid (1.2 eq.) was added to a solution of
5-(4-iodobenzyl)-2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]pyridine
(1 eq.) in DMF. Na.sub.2CO.sub.3 (2eq) was dissolved in H.sub.2O,
added to the DMF solution and stirred. Pd(PPh3)4 (5 mole %) was
then added to the DMF reaction mixture. The reaction mixture was
heated in a microwave at 200.degree. C. for 2 minutes. The reaction
mixture was applied to a 1 g solid phase extraction cartridge
(C-18) and the column was washed with 3.times.2 mL of methanol. The
eluents were filtered through a 0.45 um filter and then
concentrated to dryness. The resulting material was redissolved in
DMF, and purified by reverse phase HPLC/MS.
[0336] Procedure D
[0337] General Procedure for Oxime Formation
[0338] To aromatic aldehyde suspended in EtOH/H.sub.2O (1:2) was
added hydroxylamine hydrochloride (1.1 equiv.) and cooled to
4.degree. C. To this solution was added aqueous NaOH 50% w/w (2.5
equiv.) dropwise. After stirring for 1.5 h at room temperature, the
reaction mixture was acidified with 2N aqueous HCl and extracted
with CH.sub.2Cl.sub.2. The organic solution was washed with
saturated aqueous NaCl and dried over sodium sulfate. Removal of
solvent gave crude oxime that was used directly in the next
step.
[0339] General Procedure for Cycloaddition
[0340] Oxime was suspended in CH.sub.2Cl.sub.2 and cooled to
4.degree. C. Propargyl chloride (1 equiv.) was added to the
reaction solution followed by dropwise addition of NaOCl (10-13%
free chlorine, 1 equiv.). The reaction mixture was stirred at
4.degree. C. for 15 min then heated to reflux for 3 h. After
cooling to room temperature, the reaction was partitioned between
CH.sub.2Cl.sub.2 and H.sub.2O. The organic layer was separated,
washed with saturated aqueous NaCl, and dried over sodium sulfate.
After removal of solvent, the crude product was purified by
trituration (hexanes) or by column chromatography on silica (10%
CH.sub.2Cl.sub.2/hexanes).
[0341] General Procedure for Alkylation
[0342] To imidazopyridine suspended in DMF was added aqueous NaOH
10% w/w (1.2 equiv.) dropwise followed by addition of chloromethyl
isoxazole (1.2 equiv.) in DMF. After stirring for 12 h at room
temperature, solvents were evaporated to give crude product as a
tan solid. The crude solid was triturated with H.sub.2O and
crystallized from MeOH/H.sub.2O (2:1) to provide pure final
product.
[0343] Procedure E; Suzuki Bromides 299
[0344] The aryl bromide (1.2 eq.) was added to a solution of
4-((2-(2,3-difluorophenyl)-5H-imidazo[4,5-c]pyridin-5-yl)methyl)phenylbor-
onic acid (1 eq.) in DMF. Na.sub.2CO.sub.3 (2eq) was dissolved in
H.sub.2O, added to the DMF solution and stirred.
Pd(PPh.sub.3).sub.4 (5 mole %) was then added to the DMF reaction
mixture. The reaction mixture was heated in a microwave at
200.degree. C. for 2 minutes. The reaction mixture was applied to a
1 g solid phase extraction cartridge (C-18) and the column was
washed with 3.times.2 mL of methanol. The eluents were filtered
through a 0.45 um filter and then concentrated to dryness. The
resulting material was redissolved in DMF, and purified by reverse
phase HPLC/MS.
[0345] Procedure F
[0346] Preparation of Biphenyl Array 300301
[0347] The appropriately substituted
4'-[2-(2,3-Difluoro-phenyl)-imidazo[4-
,5-c]pyridin-5-ylmethyl]-biphenyl-4-ol (5) scaffold was prepared by
first treating 2-(2,3-Difluoro-phenyl)-3H-imidazo[4,5-c]pyridine)
(1) with 1-bromomethyl-4-iodobenzene (2) in DMF using aqueous
sodium hydroxide as base. The resulting
2-(2,3-Difluoro-phenyl)-5-(4-iodo-benzyl)-5H-imidazo[-
4,5-c]pyridine (3) (1 equivalent) was treated with three different
substituted 4-hydroxyphenyl boronic acids ((4-hydroxyphenyl)boronic
acid, 4-Hydroxy-2-(trifluoromethyl)phenyl boronic acid and
(4-hydroxy-2-methylphenyl)boronic acid) and
(4-Fluoro-2-hydroxy)phenylbor- onic acid (1.1 equivalents) under
Suzuki coupling conditions (sodium carbonate, water, palladium
tetrakis(triphenyl)phosphine) to afford the appropriately
substituted 4'-[2-(2,3-Difluoro-phenyl)-imidazo[4,5-c]pyrid-
in-5-ylmethyl]-biphenyl-4-ol or
-[2-(2,3-Difluoro-phenyl)-imidazo[4,5-c]py-
ridin-5-ylmethyl]-biphenyl-2-ol. The products were precipitated in
ethyl acetate and filtered over a medium frit followed by washing
with water to afford the pure product (5).
[0348] For compounds prepared in array format of the general type
(7), 50 .mu.M of the scaffold (5) in 250 .mu.L DMF was used for
each reaction. To each reaction was added 1.4 equivalents of Cesium
Carbonate. The alkylating agents (6) were added as a 0.4M solution
(0.05 mMoles) in DMF. The reactions were shaken at 60.degree. C.
for 4 hours and monitored by analytical LC/MS. Each reaction was
filtered through a 0.45 .mu.M filter and purified by mass-based
fractionation on a C-18 reverse phase column using 0.1% TFA/water
and 0.1% TFA/acetonitrile as the eluting solvents. Each compound
was identified by its mass spectrum and purity was determined by
its UV absorbance at 254 nm. The HPLC fractions were concentrated
in vacuo and weighed to afford the product (7) as its
trifluoroacetate salt.
[0349] The compounds produced according to these procedures and
examples, and certain of their properties, are described in the
Table below. The substituent designated "C" is methyl.
5 Obs. Structures Purity MW MW Method Example 9 302 95 387.340
388.340 A Example 10 303 90 395.440 396.440 A Example 11 304 90
413.431 414.431 A Example 12 305 92 404.451 405.451 A Example 13
306 95 407.451 408.451 A Example 14 307 85 405.479 406.479 A
Example 15 308 90 389.331 390.331 A Example 16 309 90 431.418
432.418 A Example 17 310 93 404.834 405.834 A Example 18 311 90
370.389 371.389 A Example 19 312 95 389.331 390.331 A Example 20
313 95 389.331 390.331 A Example 21 314 95 389.331 390.331 A
Example 22 315 97 355.777 356.777 A Example 23 316 90 407.451
408.451 A Example 24 317 90 461.134 462.134 A Example 25 318 90
401.404 402.404 A Example 26 319 95 371.377 372.377 A Example 27
320 95 439.375 440.375 A Example 28 321 90 405.822 406.822 A
Example 29 322 90 427.485 428.485 A Example 30 323 85 456.833
457.833 A Example 31 324 95 439.375 440.375 A Example 32 325 90
386.454 387.454 A Example 33 326 90 392.480 393.480 A Example 34
327 95 361.301 362.301 A Example 35 328 92 369.804 370.804 A
Example 36 329 90 405.785 406.785 A Example 37 330 92 421.785
422.785 A Example 38 331 90 401.367 402.367 A Example 39 332 90
351.814 352.814 A Example 40 333 92 423.812 424.812 A Example 41
334 98 339.391 340.391 A Example 42 335 92 449.408 450.408 A
Example 43 336 95 422.825 423.825 A Example 44 337 93 388.380
389.380 A Example 45 338 95 479.124 480.124 A Example 46 339 97
419.394 420.394 A Example 47 340 94 389.367 390.367 A Example 48
341 92 457.366 458.366 A Example 49 342 90 363.778 364.778 A
Example 50 343 92 445.476 446.476 A Example 51 344 95 457.366
458.366 A Example 52 345 95 472.443 473.443 A Example 53 346 95
404.444 405.444 A Example 54 347 95 395.393 396.393 A Example 55
348 90 410.470 411.470 A Example 56 349 92 457.329 458.329 A
Example 57 350 93 353.350 354.350 A Example 58 351 95 423.776
424.776 A Example 59 352 95 439.775 440.775 A Example 60 353 92
419.357 420.357 A Example 61 354 90 390.222 391.222 A Example 62
355 90 405.330 406.330 A Example 63 356 90 431.421 432.421 A
Example 64 357 0 422.441 423.441 A Example 65 358 90 425.442
426.442 A Example 66 359 95 431.876 432.876 C Example 67 360 95
442.429 443.429 C Example 68 361 95 411.458 412.458 C Example 69
362 95 411.458 412.458 C Example 70 363 95 411.458 412.458 C
Example 71 364 95 415.422 416.422 C Example 72 365 95 403.457
404.457 C Example 73 366 90 441.485 442.485 C Example 74 367 95
465.430 466.430 C Example 75 368 95 431.876 432.876 C Example 76
369 95 415.422 416.422 C Example 77 370 95 441.485 442.485 C
Example 78 371 95 441.485 442.485 C Example 79 372 95 443.522
444.522 C Example 80 373 95 387.392 388.392 C Example 81 374 95
433.412 434.412 C Example 82 375 95 439.469 440.469 C Example 83
376 95 439.469 440.469 C Example 84 377 95 425.485 426.485 C
Example 85 378 95 465.430 466.430 C Example 86 379 95 465.430
466.430 C Example 87 380 95 415.422 416.422 C Example 88 381 95
466.321 467.321 C Example 89 382 95 433.412 434.412 C Example 90
383 95 533.428 534.428 C Example 91 384 95 466.321 467.321 C
Example 92 385 90 425.485 426.485 C Example 93 386 90 457.484
458.484 C Example 94 387 90 447.492 448.492 C Example 95 388 90
489.529 490.529 C Example 96 389 90 457.484 458.484 C Example 97
390 90 425.485 426.485 C Example 98 391 90 425.485 426.485 C
Example 99 392 90 440.500 441.500 C Example 100 393 90 429.449
430.449 C Example 101 394 90 437.902 438.902 C Example 102 395 90
437.453 438.453 C Example 103 396 90 453.517 454.517 C Example 104
397 90 481.429 482.429 C Example 105 398 90 481.429 482.429 C
Example 106 399 90 453.517 454.517 C Example 107 400 90 449.867
450.867 C Example 108 401 90 466.321 467.321 C Example 109 402 90
422.441 423.441 C Example 110 403 90 433.412 434.412 C Example 111
404 90 442.429 443.429 C Example 112 405 90 427.458 428.458 C
Example 113 406 90 427.458 428.458 C Example 114 407 90 425.485
426.485 C Example 115 408 90 439.512 440.512 C Example 116 409 90
466.321 467.321 C Example 117 410 90 503.556 504.556 C Example 118
411 90 443.522 444.522 C Example 119 412 90 422.441 423.441 C
Example 120 413 90 475.521 476.521 C Example 121 414 90 433.412
434.412 C Example 122 415 90 503.556 504.556 C Example 123 416 90
429.449 430.449 C Example 124 417 90 453.540 454.540 C Example 125
418 90 466.321 467.321 C Example 126 419 90 456.456 457.456 C
Example 127 420 90 481.429 482.429 C Example 128 421 90 483.522
484.522 C Example 129 422 90 445.448 446.448 C Example 130 423 90
392.870 393.870 A Example 131 424 90 358.425 359.425 A Example 132
425 90 392.486 393.486 A Example 133 426 90 453.540 454.540 C
Example 134 427 90 546.582 547.582 C Example 135 428 90 445.448
446.448 C Example 136 429 0 456.378 457.378 A Example 137 430 95
472.378 473.378 A Example 138 431 95 423.812 424.812 A Example 139
432 99 457.270 458.270 D Example 140 433 98 472.378 473.378 D
Example 141 434 98 524.377 525.377 D Example 142 435 0 474.369
475.369 D Example 143 436 99 454.387 455.387 D Example 144 437 98
474.369 475.369 D Example 145 438 98 485.266 486.266 D Example 146
439 95 442.351 443.351 D Example 147 440 90 420.397 421.397 D
Example 148 441 90 402.407 403.407 D Example 149 442 98 448.433
449.433 D Example 150 443 98 474.369 475.369 D Example 151 444 96
439.280 440.280 D Example 152 445 98 454.387 455.387 D Example 153
446 98 506.386 507.386 D Example 154 447 98 456.378 457.378 D
Example 155 448 98 436.397 437.397 D Example 156 449 98 456.378
457.378 D Example 157 450 98 467.276 468.276 D Example 158 451 98
430.442 431.442 D Example 159 452 98 456.378 457.378 D Example 160
453 85 473.725 474.725 D Example 161 454 98 488.832 489.832 D
Example 162 455 98 540.831 541.831 D Example 163 456 98 490.823
491.823 D Example 164 457 98 470.842 471.842 D Example 165 458 98
490.823 491.823 D Example 166 459 98 501.721 502.721 D Example 167
460 90 415.422 416.422 C Example 168 461 90 483.420 484.420 C
Example 169 462 90 499.419 500.419 C Example 170 463 90 445.448
446.448 C Example 171 464 90 461.513 462.513 C Example 172 465 90
451.402 452.402 C Example 173 466 90 465.430 466.430 C Example 174
467 90 481.429 482.429 C Example 175 468 90 427.458 428.458 C
Example 176 469 90 443.522 444.522 C Example 177 470 90 433.412
434.412 C Example 178 471 90 431.876 432.876 C Example 179 472 90
515.874 516.874 C Example 180 473 90 461.903 462.903 C Example 181
474 90 477.967 478.967 C Example 182 475 90 467.857 468.857 C
Example 183 476 90 501.410 502.410 C Example 184 477 90 397.431
398.431 C Example 185 478 95 479.556 480.556 E Example 186 479 95
423.469 424.469 E Example 187 480 95 441.485 442.485 E Example 188
481 95 455.468 456.468 E Example 189 482 95 469.495 470.495 E
Example 190 483 95 483.522 484.522 E Example 192 484 95 436.468
437.468 E Example 193 485 95 475.475 476.475 E Example 194 486 95
453.496 454.496 E Example 195 487 95 463.438 464.438 E Example 196
488 95 464.479 465.479 E Example 199 489 90 415.422 416.422 C
Example 200 490 90 483.420 484.420 C Example 201 491 90 499.419
500.419 C Example 202 492 90 445.448 446.448 C Example 203 493 90
461.513 462.513 C Example 204 494 90 451.402 452.402 C Example 205
495 90 397.431 398.431 C Example 206 496 90 465.430 466.430 C
Example 207 497 90 481.429 482.429 C Example 208 498 90 427.458
428.458 C Example 209 499 90 443.522 444.522 C Example 210 500 90
433.412 434.412 C Example 211 501 90 431.876 432.876 C Example 212
502 90 499.875 500.875 C Example 213 503 90 477.967 478.967 C
Example 214 504 95 462.506 463.506 E Example 215 505 95 421.840
422.840 A Example 216 506 95 403.850 404.850 A Example 217 507 95
417.422 418.422 A Example 218 508 95 399.431 400.431 A Example 219
509 95 434.400 435.400 A Example 220 510 95 416.409 417.409 A
Example 221 511 98 424.361 425.361 D Example 222 512 85 406.370
407.370 D Example 223 513 98 440.815 441.815 D Example 224 514 90
553.493 554.493 F Example 225 515 90 567.520 568.520 F Example 226
516 90 579.575 580.575 F Example 227 517 84 551.521 552.521 F
Example 228 518 100 537.537 538.537 F Example 229 519 92 551.564
552.564 F Example 230 520 100 593.646 594.646 F Example 231 521 81
567.520 568.520 F Example 232 522 78 539.510 540.510 F Example 233
523 77 583.563 584.563 F Example 234 524 85 549.548 550.548 F
Example 235 525 85 579.531 580.531 F Example 236 526 82 593.558
594.558 F Example 237 527 90 535.521 536.521 F Example 238 528 85
551.564 552.564 F Example 239 529 85 595.574 596.574 F Example 240
530 80 551.564 552.564 F Example 241 531 85 535.521 536.521 F
Example 242 532 85 577.603 578.603 F Example 243 533 100 595.574
596.574 F Example 244 534 83 533.505 534.505 F Example 245 535 90
487.529 488.529 F Example 246 536 90 501.556 502.556 F Example 247
537 90 501.556 502.556 F Example 248 538 90 501.556 502.556 F
Example 249 539 90 539.485 540.485 F Example 250 540 90 483.497
484.497 F Example 251 541 90 483.566 484.566 F Example 252 542 90
513.549 514.549 F Example 253 543 90 485.538 486.538 F Example 254
544 90 529.592 530.592 F Example 255 545 90 525.560 526.560 F
Example 256 546 90 481.550 482.550 F Example 257 547 90 541.603
542.603 F Example 258 548 90 481.550 482.550 F Example 259 549 90
541.603 542.603 F Example 260 550 90 479.534 480.534 F Example 261
551 90 522.559 523.559 F Example 262 552 90 469.539 470.539 F
Example 263 553 90 471.511 472.511 F Example 264 554 90 515.565
516.565 F Example 265 555 90 511.533 512.533 F Example 266 556 90
467.523 468.523 F Example 267 557 90 527.576 528.576 F Example 268
558 90 521.494 522.494 F Example 269 559 80 465.507 466.507 F
Example 270 560 90 453.496 454.496 F Example 271 561 90 470.483
471.483 F Example 272 562 90 495.577 496.577 F Example 273 563 90
481.550 482.550 F Example 274 564 90 610.644 611.644 F Example 275
565 90 506.560 507.560 F Example 276 566 90 485.538 486.538 F
Example 277 567 90 595.574 596.574 F Example 278 568 90 521.494
522.494 F Example 279 569 90 538.481 539.481 F Example 280 570 90
563.576 564.576 F Example 281 571 85 565.548 566.548 F Example 282
572 90 580.606 581.606 F Example 283 573 90 549.548 550.548 F
Example 284 574 85 678.643 679.643 F Example 285 575 90 574.558
575.558 F Example 286 576 90 588.585 589.585 F Example 287 577 90
659.599 660.599 F Example 288 578 90 617.547 618.547 F Example 289
579 90 572.542 573.542 F Example 290 580 90 553.537 554.537 F
Example 291 581 90 629.514 630.514 F Example 292 582 85 571.502
572.502 F Example 293 583 80 545.566 546.566 F Example 294 584 90
471.486 472.486 F Example 295 585 90 488.473 489.473 F Example 296
586 90 628.635 629.635 F Example 297 587 90 524.550 525.550 F
Example 298 588 90 538.577 539.577 F Example 300 589 90 503.529
504.529 F Example 301 590 90 579.506 580.506 F Example 302 591 90
521.494 522.494 F Example 303 592 90 541.603 542.603 F Example 304
593 90 467.523 468.523 F Example 305 594 90 483.566 484.566 F
Example 306 595 90 509.604 510.604 F Example 307 596 90 511.577
512.577 F Example 308 597 90 495.577 496.577 F Example 309 598 90
520.587 521.587 F Example 310 599 90 534.614 535.614 F Example 311
600 90 605.627 606.627 F Example 312 601 90 563.576 564.576 F
Example 313 602 90 499.565 500.565 F Example 314 603 90 575.543
576.543 F Example 315 604 90 791.891 792.891 F Example 316 605 95
486.405 487.405 D Example 317 606 90 417.397 418.397 A Example 318
607 90 396.787 397.787 A Example 319 608 90 387.34 A Example 320
609 90 371.34 A Example 321 610 90 400.23 A Example 322 611 90
401.37 A Example 323 612 90 405.33 A Example 324 613 90 345.42 A
Example 325 614 90 409.47 A Example 326 615 90 403.40 A Example 327
616 90 363.41 A Example 328 617 90 389.33 A Example 329 618 90
359.45 A Example 330 619 90 385.37 A Example 331 620 90 417.37 A
Example 332 621 90 421.78 A Example 333 622 90 466.24 A Example 334
623 90 393.90 A Example 335 624 90 416.68 A Example 336 625 90
405.79 A Example 337 626 90 463.68 A Example 338 627 90 379.87 A
Example 339 628 90 423.81 Example 340 629 90 419.39 Example 341 630
90 403.39 Example 342 631 90 418.41 D Example 343 632 90 402.41 D
Example 344 633 90 378.34 D Example 345 634 90 394.41 D Example 346
635 90 431.45 D Example 347 636 90 464.48 D Example 348 637 90
467.28 D Example 349 638 90 494.51 D Example 350 639 90 434.47 D
Example 351 640 90 432.43 D Example 352 641 90 432.43 D Example 353
642 90 436.40 D Example 354 643 90 440.82 D Example 355 644 90
446.46 D Example 356 645 90 480.48 D Example 357 646 90 391.38 D
Example 358 647 90 446.46 D Example 359 648 90 440.82 D Example 360
649 90 478.48 D Example 361 650 90 428.85 D Example 362 651 90
460.49 D Example 363 652 90 428.47 D Example 364 653 90 444.44 D
Example 365 654 90 474.51 D Example 366 655 90 473.30 D Example 367
656 90 378.34 D Example 368 657 90 500.55 D Example 369 658 90
500.55 D Example 370 659 90 488.54 D Example 371 660 90 488.53 D
Example 372 661 90 487.4 D Example 373 662 90 417.4 C
Example 374
Isoxazole Analogues
[0350] 663
[0351] To a stirred solution of 4-ethoxy-benzaldehyde (3.000 g) in
50% ethanol (7 mL) ice (10 g) and hydroxylamine hydrochloride
(2.100 g) were added, followed by 30% aqueous sodium hydroxide
solution (3.5 mL). After completion of the reaction (1 h)
hydrochloric acid was added to adjust pH to 1 and the suspension
was cooled on an ice bath and filtered. The crude oxime can be used
for the next step without purification. Alternatively, it can be
recrystallized from a mixture of diisopropyl ether and ethyl
acetate. Yield: 71%.
[0352] To a solution of propargyl chloride (655 mg, 1 equ.) and
triethylamine (35 mg, 0.1 equ.) in dichloromethane (9.5 mL) were
subsequently added with cooling 10% aqueous sodium hypochlorite
solution (9.5 mL, 1.5 equ.) and then a solution of the oxime (1.40
g, .about.1.3 M in dichloromethane) over a period of 15 minutes and
stirring was continued for an additional hour. The reaction was
monitored by TLC (silicagel, eluent: 5% MeOH in dichloromethane).
After completion the reaction mixture was extracted 3 times with 30
mL dichloromethane. The combined organic phases were dried over
anhydrous sodium sulphate and evaporated under reduced pressure.
The crude 5-(chloromethyl)-3-(4-ethoxy- phenyl)-isoxazole was
purified by column chromatography (silicagel, ethyl
acetate/petroleum ether=1:9). Yield: 1.1 g.
[0353] A mixture of 3,4-diaminopyridine (2.00 g),
2,3-difluorobenzoic acid (1 equivalent) and polyphosphoric acid (50
g) was heated at 180.degree. C. for 4 h with stirring. Then the
mixture was cooled to ambient temperature and poured into
ice/water. The resulting mixture was neutralized by addition of
solid NaOH. The crude 2-(2,3-difluorophenyl)-1
(3)H-imidazo[4,5-c]pyridine was collected by filtration, washed
with water and dried. It was used in the next step without further
purification. Yield: 88%.
[0354] 2-(2,3-Difluorophenyl)-1(3)H-imidazo[4,5-c]pyridine (0.500
g) was dissolved in dry DMF (5 mL) and the resulting solution was
cooled to 0.degree. C. Aqueous 50% sodium hydroxide (1.5
equivalents) was added and the mixture was stirred for 15 min. Then
5-(chloromethyl)-3-(4-ethoxyphen- yl)-isoxazole (1.2 equivalents)
was added and the resulting mixture was stirred for 24 h at room
temperature. Finally, water (50 mL) was added, the precipitate was
collected by filtration and dried to give the crude product.
[0355] Recrystallized from ethyl acetate; colorless crystals;
yield: 35%
[0356] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (d, 1H, H4,
J=1.2 Hz), 8.28 (dd, 1H, H6, J=6.6, 1.2 Hz), 8.15 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=6.6 Hz), 7.77 (AA'BB', 2H, benzyl-H),
7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.07-7.00 (m, 3H,
arom. H), 6.02 (s, 2H, CH.sub.2), 4.06 (q, 2H, OCH.sub.2, J=6.9
Hz), 1.32 (t, 3H, CH.sub.3, J=6.9 Hz).
[0357] The following examples were prepared by analogy to the above
procedure: 664
[0358] Starting from 4-methoxybenzaldehyde.
[0359] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.2 Hz), 8.28 (dd, 1H, H6, J=6.6, 1.2 Hz), 8.15 (m, 1H,
phenyl-H), 7.88 (d, 1H, H7, J=6.6 Hz), 7.79 (AA'BB', 2H, benzyl-H),
7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.09-7.00 (m, 3H,
arom. H), 6.01 (s, 2H, CH.sub.2), 3.80 (s, 3H, OCH.sub.3). 665
[0360] Starting from 4-methylbenzaldehyde.
[0361] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (br s, 1H,
H4), 8.29 (d, 1H, H6, J=6.7 Hz), 8.14 (m, 1H, phenyl-H), 7.88 (d,
1H, H7, J=6.7 Hz), 7.58-7.27 (m, 6H, arom. H), 7.00 (s, 1H,
isoxazole-H), 6.04 (s, 2H, CH.sub.2), 2.41 (s, 3H, CH.sub.3).
666
[0362] Starting from 2-furaldehyde
[0363] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (br s, 1H,
H4), 8.28 (d, 1H, H6, J=6.7 Hz), 8.15 (m, 1H, phenyl-H), 7.90-7.87
(m, 2H, arom. H), 7.51 (m, 1H, phenyl-H), 7.32 (m, 1H, phenyl-H),
7.15 (d, 1H, furane-H, J=3.6 Hz), 6.96 (s, 1H, isoxazole-H), 6.68
(m, 1H, furane-H), 6.02 (s, 2H, CH.sub.2). 667
[0364] Starting from thiophene-2-carboxaldehyde
[0365] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.6 Hz), 8.27 (dd, 1H, H6, J=7.0, 1.6 Hz), 8.14 (m, 1H,
phenyl-H), 7.88 (d, 1H, H7, J=7.0 Hz), 7.75-7.70 (m, 2H, arom. H),
7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.19 (dd, 1H,
thiophene-H), 7.06 (s, 1H, isoxazole-H), 6.02 (s, 2H, CH.sub.2).
668
[0366] Starting from 4-dimethylaminobenzaldehyde
[0367] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.6 Hz), 8.27 (dd, 1H, H6, J=7.0, 1.6 Hz Hz), 8.14 (m, 1H,
phenyl-H), 7.88 (d, 1H, H7, J=7.0 Hz), 7.65 (AA'BB', 2H, benzyl-H),
7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 6.98 (s, 1H,
isoxazole-H), 6.76 (AA'BB', 2H, benzyl-H), 5.75 (s, 2H, CH.sub.2),
2.95 (s, 6H, N(CH.sub.3).sub.2). 669
[0368] Starting from 4-biphenylcarboxaldehyde
[0369] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.25 (d, 1H, H4,
J=1.6 Hz), 8.30 (dd, 1H, H6, J=7.0, 1.6 Hz), 8.16 (m, 1H,
phenyl-H), 7.98-7.70 (m, 7H, arom. H), 7.57-7.26 (m, 5H, arom. H),
7.18 (s, 1H, isoxazole-H), 6.05 (s, 2H, CH.sub.2). 670
[0370] Starting from 4-bromobenzaldehyde
[0371] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.6 Hz), 8.28 (dd, 1H, H6, J=7.0, 1.6 Hz), 8.16 (m, 1H,
phenyl-H), 7.90-7.68 (m, 4H, arom. H), 7.51 (m, 1H, phenyl-H), 7.31
(m, 1H, phenyl-H), 7.15 (s, 1H, isoxazole-H), 6.05 (s, 2H,
CH.sub.2). 671
[0372] Starting from 4-benzyloxybenzaldehyde
[0373] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.6 Hz), 8.27 (dd, 1H, H6, J=7.0, 1.6 Hz Hz), 8.15 (m, 1H,
phenyl-H), 7.90-7.76 (m, 3H, arom. H), 7.57-7.26 (m, 7H, arom. H),
7.15-7.05 (m, 3H, arom. H), 6.01 (s, 2H, N--CH.sub.2), 5.16 (s, 2H,
O--CH.sub.2). 672
[0374] Starting from 4-(methylthio)benzaldehyde
[0375] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.2 Hz), 8.28 (dd, 1H, H6, J=6.6, 1.2 Hz), 8.15 (m, 1H,
phenyl-H), 7.88 (d, 1H, H7, J=6.6 Hz), 7.79 (AA'BB', 2H, benzyl-H),
7.50 (m, 1H, phenyl-H), 7.38-7.25 (m, 3H, arom. H), 7.10 (s,1H,
isoxazole-H), 6.03 (s, 2H, CH.sub.2), 2.51 (s, 3H, SCH.sub.3).
673
[0376] Starting from 2-fluoro-4-methoxybenzaldehyde
[0377] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.26 (d, 1H, H4,
J=1.2 Hz), 8.30 (dd, 1H, H6, J=6.6, 1.2 Hz), 8.14 (m, 1H,
phenyl-H), 7.88 (d, 1H, H7, J=6.6 Hz), 7.80 (m, 1H, benzyl-H,),
7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.04-6.71 (m, 3H,
arom. H), 6.03 (s, 2H, CH.sub.2), 3.82 (s, 3H, OCH.sub.3). 674
[0378] Prepared as described above, starting from
4-chloro-2-fluorobenzald- ehyde.
[0379] .sup.1H NMR (200 MHz, DMSO-d.sub.6) L 9.26 (d, 1H, H4, J=1.4
Hz), 8.30 (dd, 1H, H6, J=6.8, 1.4 Hz), 8.14 (m, 1H, phenyl-H),
7.90-7.87 (m, 2H, arom. H), 7.66 (dd, 1H, arom. H, J=10.8, 1.8 Hz),
7.53-7.41 (m, 2H, arom. H), 7.31 (m, 1H, phenyl-H), 7.10 (d, 1H,
isoxazole-H, J=2.7 Hz), 6.06 (s, 2H, CH.sub.2). 675
[0380] Starting from 4-propoxybenzaldehyde
[0381] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.2 Hz), 8.29 (dd, 1H, H6, J=6.6, 1.2 Hz), 8.14 (m, 1H,
phenyl-H), 7.88 (d, 1H, H7, J=6.6 Hz), 7.78 (AA'BB', 2H, benzyl-H),
7.49 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.06-7.00 (m, 3H,
arom. H), 6.01 (s, 2H, CH.sub.2), 3.97 (t, 2H, OCH.sub.2, J=6.5
Hz), 1.73 (hex, 2H, CH.sub.2), 0.97 (t, 3H, CH.sub.3, J=7.3 Hz).
676
[0382] Starting from 4-phenoxybenzaldehyde
[0383] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.25 (d, 1H, H4,
J=1.2 Hz), 8.29 (dd, 1H, H6, J=6.6, 1.2 Hz), 8.16 (m, 1H,
phenyl-H), 7.92-7.83 (m, 3H, arom. H), 7.58-7.05 (m, 10H, arom. H),
6.04 (s, 2H, CH.sub.2). 677
[0384] Starting from 1-methylpyrrole-2-carboxaldehyde
[0385] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (d, 1H, H4,
J=1.2 Hz), 8.28 (dd, 1H, H6, J=6.8, 1.2 Hz), 8.16 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=6.8 Hz), 7.50 (m, 1H, phenyl-H), 7.31
(m, 1H, phenyl-H), 6.98 (dd, 1H, pyrrole-H), 6.92 (s, 1H,
isoxazole-H), 6.68 (dd, 1H, pyrrole-H), 6.12 (dd, 1H, pyrrole-H),
6.00 (s, 2H, CH.sub.2). 678
[0386] Starting from 4-isopropoxybenzaldehyde.
[0387] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (d, 1H, H4,
J=1.4 Hz), 8.28 (dd, 1H, H6, J=7.0, 1.4 Hz), 8.15 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=7.0 Hz), 7.76 (AA'BB', 2H, benzyl-H),
7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.05-6.98 (m, 3H,
arom. H), 6.01 (s, 2H, CH.sub.2), 4.67 (hept, 1H, OCH, J=6.2 Hz),
1.26 (d, 6H, (CH.sub.3).sub.2, J=6.2 Hz). 679
[0388] Synthesized as described above, starting from
5-chlorothiophene-2-carboxaldehyde.
[0389] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.4 Hz), 8.27 (dd, 1H, H6, J=7.0, 1.4 Hz), 8.14 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=7.0 Hz), 7.63 (d, 1H, thiophene-H,
J=4.0 Hz), 7.51 (m, 1H, phenyl-H), 7.37-7.24 (m, 2H, arom. H), 7.07
(s, 1H, isoxazole-H), 6.03 (s, 2H, CH.sub.2). 680
[0390] Synthesized as described above, starting from
5-bromothiophene-2-carboxaldehyde.
[0391] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.4 Hz), 8.27 (dd, 1H, H6, J=6.6, 1.4 Hz), 8.14 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=6.6 Hz), 7.59 (d, 1H, thiophene-H,
J=3.6 Hz), 7.50 (m, 1H, phenyl-H), 7.36-7.27 (m, 2H, arom. H), 7.06
(s, 1H, isoxazole-H), 6.02 (s, 2H, CH.sub.2). 681
[0392] Synthesized as described above, starting from
4-butoxybenzaldehyde (prepared by alkylation of
4-hydroxybenzaldehyde).
[0393] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (d, 1H, H4,
J=1.2 Hz), 8.28 (dd, 1H, H6, J=6.6, 1.2 Hz), 8.15 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=6.6 Hz), 7.78 (AA'BB', 2H, benzyl-H),
7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.07-7.01 (m, 3H,
arom. H), 6.01 (s, 2H, CH.sub.2), 4.01 (t, 2H, OCH.sub.2, J=6.5
Hz), 1.72 (m, 2H, CH.sub.2), 1.42 (m, 2H, CH.sub.2), 0.93 (t, 3H,
CH.sub.3, J=7.2 Hz). 682
[0394] Synthesized as described above, starting from
4-propoxybenzaldehyde and using
2-(2-fluorophenyl)-1(3)H-imidazo[4,5-c]pyridine instead of
2-(2,3-difluorophenyl)-1 (3)H-imidazo[4,5-c]pyridine.
[0395] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .quadrature. 9.18 (d,
1H, H4, J=1.2 Hz), 8.38-8.23 (m, 2H, arom. H), 7.85 (d, 1H, H7,
J=6.6 Hz), 7.78 (AA'BB', 2H, benzyl-H), 7.54-7.25 (m, 3H,
phenyl-H), 7.06-7.00 (m, 3H, arom. H), 6.00 (s, 2H, CH.sub.2), 3.98
(t, 2H, OCH.sub.2, J=6.6 Hz), 1.73 (hex, 2H, CH.sub.2), 0.97 (t,
3H, CH.sub.3, J=7.3 Hz). 683
[0396] Starting from 4-allyloxybenzaldehyde
[0397] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.2 Hz), 8.27 (dd, 1H, H6, J=6.7, 1.2 Hz), 8.14 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=6.7 Hz), 7.79 (AA'BB', 2H, benzyl-H),
7.50 (m, 1H, phenyl-H), 7.31 (m, 1H, phenyl-H), 7.09-7.00 (m, 3H,
arom. H), 6.15-5.98 (m, 3H), 5.45-5.24 (m, 2H), 4.62 (d, 2H, J=4.8
Hz). 684
[0398] A mixture of 5-(chloromethyl)-3-(4-chlorophenyl)-isoxazole
(2.00 g), NCS (11.75 g, 10 equivalents), glacial acetic acid (35
mL) and 20 drops of concentrated sulphuric acid is heated to reflux
for 3 days. After cooling to room temperature dichloromethane (100
mL) is added, and the resulting mixture is extracted with water
(2.times.100 mL) and saturated aqueous sodium bicarbonate solution
(2.times.100 mL). Then the organic phase was dried over anhydrous
sodium sulphate and evaporated. The crude product, thus obtained,
was purified by column chromatography (silica gel, eluent:
petroleum ether/ethyl acetate=19/1) to give 1.14 g.
[0399] The final step was performed as described above.
Recrystallized from a mixture of ethyl acetate and ethanol. Yield:
60%.
[0400] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .quadrature. 9.20 (d,
1H, H4, J=1.4 Hz), 8.25 (dd, 1H, H6, J=6.8, 1.4 Hz), 8.15 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=6.8 Hz), 7.83 (AA'BB', 2H, benzyl-H),
7.66 (AA'BB', 2H, benzyl-H), 7.51 (m, 1H, phenyl-H), 7.31 (m, 1H,
phenyl-H), 6.14 (s, 2H, CH.sub.2). 685
[0401] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.18 (d, 1H, H4,
J=1.4 Hz), 8.22 (dd, 1H, H6, J=6.8, 1.4 Hz), 8.14 (m, 1H,
phenyl-H), 7.89 (d, 1H, H7, J=6.8 Hz), 7.80 (AA'BB', 2H, benzyl-H),
7.65 (AA'BB', 2H, benzyl-H), 7.49 (m, 1H, phenyl-H), 7.30 (m, 1H,
phenyl-H), 6.11 (s, 2H, CH.sub.2).
[0402] Synthesized in analogy to the chloroisoxazole derivative
374u: 4 equ. NBS, 2.5 h reflux, yield: 91%.
Example 375
[0403] 686
[0404] To a solution of 500 mg 3-methyl-1-phenylpyrazole in 4 mL
carbontetrachloride is added in portions at 70.degree. C. a mixture
of 678 mg (1.2 equi.) NBS and AIBN (62.3 mg, 0.12 equ.). The
resulting mixture is heated at reflux for an additional 15 minutes
and then cooled to room temperature. The precipitate is filtered
off and the filtrate is concentrated to precipitate the crude
product (380 mg), which--after collecting by filtration and
drying--was used in the next step without further purification.
[0405] The final step was performed as described above.
Recrystallized from ethyl acetate.
[0406] Yield: 35%.
Example 376
imidazo[4,5-c]pyridin-4-one analogues
[0407] 687
[0408] A mixture of 4-chloro-3-nitro-pyridin-2-one (1.00 g),
4-(trifluoromethyl)benzyl chloride (1.226 g), anhydrous potassium
carbonate (0.871 g) and anhydrous DMF (10 mL) was stirred at
ambient temperature for 24 hours. Then water (100 mL) was added and
the resulting precipitate was collected by filtration, washed with
water and dried. Yield: 58.2%
4-chloro-3-nitro-1-(4-trifluoromethyl)benzyl-pyridin-2-one.
[0409] 4-Chloro-3-nitro-1-(4-trifluoromethyl)benzyl-pyridin-2-one
(500 mg) was dissolved in anhydrous THF (10 mL). Then concentrated
aqueous ammonia (7.5 mL) was added and the resulting mixture was
stirred at room temperature for 24 hours. Water (50 mL) was added
and the resulting precipitate was collected by filtration, washed
with water and dried. Yield: 45.8% of
4-amino-3-nitro-1-(4-trifluoromethyl)benzyl-pyridin-2-one- .
[0410] A mixture of
4-amino-3-nitro-1-(4-trifluoromethyl)benzyl-pyridin-2-- one (1.400
g), saturated aqueous ammoniumchloride solution (9.4 mL), zink
powder (1.400 g) and methanol (235 mL) was stirred at room
temperature for 1 hour. Then additional zink powder (1.400 g) was
added and the resulting mixture was stirred for an additional 23
hours. After evaporation of the solvent water (30 mL) was added and
the pH was adjusted to 8-9 by addition of 2N NaOH. The resulting
mixture was extracted with ethyl acetate (3.times.30 mL) and the
combined organic phases were washed with water (30 mL), dried over
anhydrous sodium sulphate and evaporated. Yield: 53.4%
3,4-diamino-1-(4-trifluoromethyl)be- nzyl-pyridin-2-one.
[0411] A mixture of
3,4-diamino-1-(4-trifluoromethyl)benzyl-pyridin-2-one (0.200 mg),
2,3-difluorobenzaldehyde (100 mg), sodium pyrosulfite (0.134 g) and
N,N-dimethylacetamide (4.6 mL) was heated at 130.degree. C. for 24
hours. Then water (30 mL) was added and the resulting precipitate
was collected by filtration, washed with water and dried. The crude
product was purified by column chromatography (silicagel, eluent:
dichloromethane/methanol=12/1) and then recrystallized from a
mixture of diisopropyl ether and ethyl acetate. Yield: 16.8%.
[0412] Melting point: 279-283.degree. C.
[0413] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 13.05 (br s, 1H,
NH), 7.88 (m, 1H, phenyl-H), 7.74-7.32 (m, 7H, arom. H), 6.69 (br
d, 1H, H7, J=6.0 Hz), 5.34 (s, 2H, CH.sub.2).
Example 377
[0414] 688
[0415] A mixture of
2-(2,3-difluorophenyl)-1(3)H-imidazo[4,5-c]pyridine (2.00 g), 50 mg
methyltrioxorhenium, 100 mL methanol and 30% aqueous hydrogen
peroxide (4 mL) was stirred at room temperature for 4 days. Then,
additional 50 mg of methyltrioxorhenium and 30% hydrogen peroxide
(4 mL) were added and the resulting mixture was stirred for another
2 days. After evaporation of the methanol water (200 mL) was added
and the pH was adjusted to 9 by addition of 2N NaOH. The resulting
precipitate was filtered, dried and recrystallized from a mixture
of ethyl acetate (20 mL) and ethanol (53 mL) to give 1.208 g
(56.5%) of 2-(2,3-difluorophenyl)-1(3)H-imidazo[4,5-c]pyridine
5-oxide.
[0416] 2-(2,3-Difluorophenyl)-1(3)H-imidazo[4,5-c]pyridine 5-oxide
(1.00 g) was dissolved in dry tetrahydrofurane (100 mL) and
MeMgBr-solution (14 mL, 3M in diethyl ether) was added dropwise
under argon. The resulting mixture was stirred for 1.5 hours at
ambient temperature. Then water (100 mL) was added slowly and the
pH was adjusted to 8.5. Extraction with ethyl acetate (3.times.70
mL), drying of the combined organic phases over anhydrous sodium
sulphate and evaporation of the solvent afforded 0.630 g (60%) of
crude 2-(2,3-difluorophenyl)-4-methyl-1(3)H-imidazo[4,5-c]pyridi-
ne. Recrystallization from a mixture of diisopropyl ether (20 mL)
and ethyl acetate (34 mL) gave 240 mg (24.2%) of pure
2-(2,3-difluorophenyl)-- 4-methyl-1(3)H-imidazo[4,5-c]pyridine.
[0417] The final step was performed as described above.
Purification by column chromatography (silica gel, eluent:
dichloromethane/methanol=20/1)- . Yield: 22.4%.
[0418] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 8.25 (d, 1H, H6,
J=6.8 Hz), 8.11 (m, 1H, phenyl-H), 7.89 (AA'BB', 2H, benzyl-H),
7.77 (d, 1H, H7, J=6.8 Hz), 7.60-7.41 (m, 3H, arom. H), 7.30 (m,
1H, phenyl-H), 7.12 (s, 1H, isoxazole-H), 6.05 (s, 2H, CH.sub.2),
3.05 (s, 3H, CH.sub.3).
Example 378
Synthesis of 7-Substituted Analogues
[0419] 689
[0420] 3-Methyl-4-nitropyridine 1-oxide (5.85 g) was dissolved in
glacial acetic acid (115 mL) and hydrogenated in a Parr
hydrogenation apparatus (catalyst: 220 mg
PtO.sub.2.times.2H.sub.2O, 50 psi) at ambient temperature for 2.5
h. Then the catalyst was filtered off and the solvent was
evaporated. After addition of 150 mL of water the pH was adjusted
to 12 by addition of 2N NaOH. The resulting solution was extracted
10 times with 100 mL of dichloromethane (containing 5% methanol).
The combined organic phases were dried over anhydrous sodium
sulphate and evaporated to give 3.81 g (83.6%) of
4-amino-3-methylpyridine.
[0421] 4-Amino-3-methylpyridine (3.00 g) was dissolved with
icecooling in concentrated sulfuric acid (36 mL). Then, fuming
nitric acid (4,72 g) was added dropwise. After stirring at room
temperature for 1 h, the solution was heated at 60.degree. C. for
14 hours. After cooling to ambient temperature, the reaction
mixture was poured on ice and the resulting solution was adjusted
to pH 13 by addition of solid KOH. The precipitate was filtered
off, washed with water and dried. Yield: 1.198 g (31.3%)
4-amino-3-methyl-5-nitropyridine.
[0422] A mixture of 4-amino-3-methyl-5-nitropyridine (1.198 g),
iron powder (1.748 g), ethanol (52 mL) and hydrochloric acid (13
mL) was heated to reflux for 3 hours. After cooling to room
temperature the ethanol was distilled off and the resulting
suspension was diluted with water to 50 mL and the pH was adjusted
to 13 by addition of 2N NaOH. Extraction with ethyl acetate
(3.times.70 mL), drying of the combined organic phases of anhydrous
sodium sulphate and evaporation of the solvent afforded 0.579 g
(60%) of 3,4-diamino-5-methylpyridine.
[0423] The cyclization with 2,3-difluorbenzoic acid in PPA was
performed as described above. Purified by column chromatography
(silica gel, eluent: dichloromethan/methanol=12/1). Yield:
22.2%.
[0424] The final step was performed as described above.
Recrystallized from a mixture of ethyl acetate and ethanol. Yield:
42.9% 378a.
[0425] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.14 (d, 1H, H4,
J=1.2 Hz), 8.17-8.10 (m, 2H, arom. H), 7.90 (AA'BB', 2H, benzyl-H),
7.60-7.42 (m, 3H, arom. H), 7.32 (m, 1H, phenyl-H), 7.15 (s, 1H,
isoxazole-H), 5.99 (s, 2H, CH.sub.2), 2.58 (s, 3H, CH.sub.3).
[0426] The following compounds were prepared in analogy to the
above procedures: 690
[0427] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.32 (d, 1H, H4,
J=1.4 Hz), 8.67 (d, 1H, H6, J=1.4 Hz), 8.16 (m, 1H, phenyl-H), 7.78
(AA'BB', 2H, benzyl-H), 7.54 (m, 1H, phenyl-H), 7.34 (m, 1H,
phenyl-H), 7.07-7.00 (m, 3H, arom. H), 6.00 (s, 2H, CH.sub.2), 4.07
(q, 2H, OCH.sub.2, J=7.0 Hz), 1.33 (t, 3H, CH.sub.3, J=7.0 Hz).
691
[0428] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.47 (d, 1H, H4,
J=1.4 Hz), 8.94 (d, 1H, H6, J=1.4 Hz), 8.16 (m, 1H, phenyl-H), 7.89
(AA'BB', 2H, benzyl-H), 7.63-7.50 (m, 3H, arom. H), 7.35 (m, 1H,
phenyl-H), 7.16 (s, 1H, isoxazole-H), 6.10 (s, 2H, CH.sub.2).
692
[0429] .sup.1H NMR (200 MHz, DMSO-d.sub.6) 69.30 (br s, 1H, H4),
8.66 (dd, 1H, H6, J=7.4, 1.4 Hz), 8.15 (m, 1H, phenyl-H), 7.89
(AA'BB', 2H, benzyl-H), 7.61-7.47 (m, 3H, arom. H), 7.33 (m, 1H,
phenyl-H), 7.16 (s, 1H, isoxazole-H), 6.04 (s, 2H, CH.sub.2).
Example 379
1,2,4-oxadiazoles
[0430] 693
[0431] A mixture of 4-methoxybenzonitrile (1.00 g), hydroxylamine
hydrochloride (0.785 g), KOH (0.640 g) and methanol (20 mL) was
heated to reflux for 3 hours. After cooling to room temperature the
precipitate was filtered off and the filtrate was evaporated. The
resulting residue was dissolved in 1N HCl (100 mL) and the
resulting solution was extracted with diethyl ether (100 mL). The
aqueous phase was neutralized by addition of solid NaHCO.sub.3 and
extracted with diethyl ether (2.times.100 mL). The combined organic
phases were dried over anhydrous sodium sulphate and evaporated to
give 450 mg of the desired amidoxime, which was used without
further purification.
[0432] A solution of 700 mg of (4-methoxyphenyl)amidoxime and 1.08
g (1.5 equivalents) chloroacetic anhydride in toluene (30 mL) was
heated to reflux for 3 hours. After cooling to ambient temperature
the reaction mixture was extracted subsequently with water (twice
50 mL), saturated sodium bicarbonate solution (twice 50 mL) and
water (50 mL). Finally, the toluene phase was dried over anhydrous
sodium sulphate and evaporated to give 660 mg of the desired
oxadiazole, which was used without further purification.
[0433] The final step was performed as described above (see, for
example, isoxazole analogues). Recrystallized from a mixture of
ethyl acetate and ethanol. Yield: 35%.
[0434] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.4 Hz), 8.28 (dd, 1H, H6, J=6.8, 1.4 Hz), 8.15 (m, 1H,
phenyl-H), 7.92-7.77 (m, 3H, arom. H), 7.49 (m, 1H, phenyl-H), 7.33
(m, 1H, phenyl-H), 7.08-7.00 (m, 3H, arom. H), 6.01 (s, 2H,
CH.sub.2), 3.80 (s, 3H, OCH.sub.3). 694
[0435] Prepared as described above, starting from
4-methylbenzonitrile.
[0436] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.23 (d, 1H, H4,
J=1.4 Hz), 8.31 (dd, 1H, H6, J=6.8, 1.4 Hz), 8.14 (m, 1H,
phenyl-H), 7.93-7.78 (m, 3H, arom. H), 7.50 (m, 1H, phenyl-H),
7.35-7.27 (m, 3H, arom. H), 6.25 (s, 2H, CH.sub.2), 2.35 (s, 3H,
CH.sub.3). 695
[0437] Prepared as described above, starting from
pyridine-2-carbonitrile.
[0438] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (d, 1H, H4,
J=1.4 Hz), 8.72 (ddd, 1H, pyridine-H), 8.32 (dd, 1H, H6, J=6.8, 1.4
Hz), 8.15 (m, 1H, phenyl-H), 8.00-7.90 (m, 3H, arom. H), 7.64-7.27
(m, 3H, arom. H), 6.30 (s, 2H, CH.sub.2). 696
[0439] Prepared as described above, starting from
4-chlorobenzonitrile.
[0440] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (d, 1H, H4,
J=1.4 Hz), 8.31 (dd, 1H, H6, J=6.8, 1.4 Hz), 8.16 (m, 1H,
phenyl-H), 7.96-7.90 (m, 3H, arom. H), 7.60 (AA'BB', 2H, benzyl-H),
7.49 (m, 1H, phenyl-H), 7.34 (m, 1H, phenyl-H), 6.28 (s, 2H,
CH.sub.2). 697
[0441] Prepared as described above, starting from
pyridine-4-carbonitrile.
[0442] .sup.1H NMR (200 MHz, DMSO-d.sub.6) .delta. 9.24 (d, 1H, H4,
J=1.4 Hz), 8.77 (AA'BB', 2H, pyridine-H2/6), 8.32 (dd, 1H, H6,
J=7.0, 1.4 Hz), 8.15 (m, 1H, phenyl-H), 7.93 (d, 1H, H7, J=7.0 Hz),
7.86 (AA'BB', 2H, pyridine-H3/5), 7.51 (m, 1H, phenyl-H), 7.32 (m,
1H, phenyl-H), 6.32 (s, 2H, CH.sub.2).
Part B
Methodology for Determination of Antiviral and Cytostatic
Activity
[0443] Cells and viruses
[0444] Madin-Darbey Bovine Kidney (MDBK) cells were maintained in
Dulbecco's modified Eagle medium (DMEM) supplemented with BVDV-free
5% fetal calf serum (DMEME-FCS) at 37.degree. C. in a humidified,
5% CO.sub.2 atmosphere. BVDV-1 (strain PE515) was used to assess
the antiviral activity in MDBK cells.
[0445] Anti-BVDV Assay
[0446] Ninety-six-well cell culture plates were seeded with MDBK
cells in DMEM-FCS so that cells reached 24 hr later confluency.
Then medium was removed and serial 5-fold dilutions of the test
compounds were added in a total volume of 100 .mu.L, after which
the virus inoculum (100 .mu.L) was added to each well. The virus
inoculum used resulted in a greater than 90% destruction of the
cell monolayer after 5 days incubation at 37.degree. C. Uninfected
cells and cells receiving virus without compound were included in
each assay plate. After 5 days, medium was removed and 90 .mu.L of
DMEM-FCS and 10 .mu.L of MTS/PMS solution (Promega) was added to
each well. Following a 2 hr incubation period at 37.degree. C. the
optical density of the wells was read at 498 nm in a microplate
reader. The 50% effective concentration (EC.sub.50) value was
defined as the concentration of compound that protects 50% of the
cell monolayer from virus-induced cytopathic effect.
[0447] Anti-HCV Assay/Replicon Assay--1
[0448] Huh-5-2 cells [a cell line with a persistent HCV replicon
1389luc-ubi-neo/NS3-3'/5.1; replicon with firefly
luciferase-ubiquitin-ne- omycin phosphotransferase fusion protein
and EMCV-IRES driven NS3-5B HCV polyprotein] was cultured in RPMI
medium (Gibco) supplemented with 10% fetal calf serum, 2 mM
L-glutamine (Life Technologies), 1.times.non-essential amino acids
(Life Technologies); 100 IU/mL penicillin and 100 ug/ml
streptomycin and 250 ug/mL G418 (Geneticin, Life Technologies).
Cells were seeded at a density of 7000 cells per well in 96 well
View Plate.TM. (Packard) in medium containing the same components
as described above, except for G418. Cells were allowed to adhere
and proliferate for 24 hr. At that time, culture medium was removed
and serial dilutions of the test compounds were added in culture
medium lacking G418. Interferon alfa 2a (500 IU) was included as a
positive control. Plates were further incubated at 37.degree. C.
and 5% CO.sub.2 for 72 hours. Replication of the HCV replicon in
Huh-5 cells results in luciferase activity in the cells. Luciferase
activity is measured by adding 50 .mu.L of 1.times.Glo-lysis buffer
(Promega) for 15 minutes followed by 50 .mu.L of the Steady-Glo
Luciferase assay reagent (Promega). Luciferase activity is measured
with a luminometer and the signal in each individual well is
expressed as a percentage of the untreated cultures. Parallel
cultures of Huh-5-2 cells, seeded at a density of 7000 cells/well
of classical 96-well cell culture plates (Becton-Dickinson) are
treated in a similar fashion except that no Glo-lysis buffer or
Steady-Glo Luciferase reagent is added. Instead the density of the
culture is measured by means of the MTS method (Promega).
[0449] Quantitative Analysis of HCV RNA by Taqman Real-Time
RT-PCR
[0450] Replicon cells were plated at 7.5.times.10.sup.3 cells per
well in a 96-well plate plates at 37.degree. C. and 5% CO.sub.2 in
Dulbecco's modified essential medium containing 10% fetal calf
serum, 1% nonessential amino acids and 1 mg/ml Geneticin. After
allowing 24 h for cell attachment, different dilutions of compound
were added to the cultures. Plates were incubated for 5 days, at
which time RNA was extracted using the Qiamp Rneazyi Kit (Qiagen,
Hilden, Germany). A 50 .mu.L PCR reaction contained TaqMan EZ
buffer (50 mmol/L Bicine, 115 mmol/L potassium acetate, 0.01 mmol/L
EDTA, 60 nmol/L 6-carboxy-X-rhodamine, and 8% glycerol, pH 8.2;
Perkin Elmer Corp./Applied Biosystems), 300 mmol/L deoxyadenosine
triphosphate, 300 .mu.mol/L deoxyguanosine triphosphate, 300 mmol/L
deoxycytidine triphosphate, 600 .mu.mol/L deoxyuridine
triphosphate, 200 .mu.mol/L forward primer [5'-ccg gcT Acc Tgc ccA
TTc], 200 .mu.mol/L reverse primer [ccA GaT cAT ccT gAT cgA cAA G],
100 .mu.mol/L TaqMan probe [6-FAM-AcA Tcg cAT cgA gcg Agc Acg
TAc-TAMRA], 3 mmol/L manganese acetate, 0.5 U AmpErase
uracil-N-glycosylase, 7.5 U rTth DNA polymerase, and 10 .mu.l of
RNA elution. After initial activation of uracil-N-glycosylase at
50.degree. C. for 2 minutes, RT was performed at 60.degree. C. for
30 minutes, followed by inactivation of uracil-N-glycosylase at
95.degree. C. for 5 minutes. Subsequent PCR amplification consisted
of 40 cycles of denaturation at 94.degree. C. for 20 seconds and
annealing and extension at 62.degree. C. for 1 minute in an ABI
7700 sequence detector. For each PCR run, negative template and
positive template samples were used. The cycle threshold value
(Ct-value) is defined as the number of PCR cycles for which the
signal exceeds the baseline, which defines a positive value. The
sample was considered to be positive if the Ct-value was <50.
Results are expressed as genomic equivalents (GE).
[0451] Anti-HCV Assay/Replicon Assay--2
[0452] HCV Replicon Media
[0453] DMEM w/High Glucose (or MEM)
[0454] 1.times. Glutamine
[0455] 1.times. Sodium Pyruvate
[0456] 10% Heat Inactivated FBS
[0457] 1.times. Antibiotics
[0458] Cell Culture Preparation
[0459] 1. Unthaw frozen stock in 10-12 mls of Media
[0460] 2. Allow cells to attach before adding G418 (4-6 hrs)
[0461] 3. Add G418 for a final concentration of 200 ug/mL (higher
amounts are possible but cells grow slowly)
[0462] 4. Split cells 1:4 to 1:6 for optimal growth
[0463] 5. In-house replicon seems to maintain Luciferase signal for
.about.20 passages
[0464] HCV Replicon Assay
[0465] 1. Dilute compounds in 100 uL of HCV Replicon Media (without
G418). If compounds are diluted in DMSO add DMSO to media (Final
DMSO concentration should be <1%)
[0466] 2. Once cells have reached 80-90% confluency, trypsinize
with 1.times. Trypsin
[0467] 3. Do not over trypsinize. These cells tend to clump if over
trypsinized
[0468] 4. For 96 well format add 6,000-8,000 cells per well (G418
is withheld during compound testing)
[0469] 5. Incubate for 3 days at 37.degree. C. Cells should be very
close to confluent.
[0470] 6. Remove media and wash cells with 1.times.PBS
[0471] 7. Remove PBS and add 100 .mu.L of 1.times.Promega Lysis
Buffer
[0472] 8. Incubate cells at Room Temperature for 5-20 minutes
[0473] 9. Add 100 .mu.L of room temperature Luciferase Substrate
Solution (Promega) to Microfluor Black Plate (VWR)
[0474] 10. Thoroughly Mix Cell lysate (pipet up and down) before
adding to Luciferase substrate
[0475] 11. Add 75 .mu.L of lysate to the Luciferase substrate
solution
[0476] 12. Read Plate On Top Count (FusionLucB program.about.5
second read)
[0477] 13. Left over lysate can be frozen and used for later
analysis
[0478] Determination of Cytostatic Effect on MDBK Cells
[0479] The effect of the drugs on exponentially growing MDBK cells
was assessed as follows. Cells were seeded at a density of 5000
cell/well in 96 well plates in MEM medium (Gibco) supplemented with
10% fetal calf serum, 2 mM L-glutamine (Life Technologies) and
bicarbonate (Life Technologies). Cells were cultured for 24 hr
after which serial dilutions of the test compounds were added.
Cultures were then again further incubated for 3 days after which
the effect on cell growth was quantified by means of the MTS method
(Promega). The concentration that results in 50% inhibition of cell
growth is defined as the 50% cytostatic concentration
(CC.sub.50).
[0480] HCV CC50 Assay Protocol
[0481] HCV Replicon Media
[0482] DMEM w/High Glucose (or MEM)
[0483] 1.times.Glutamine
[0484] 1.times. Sodium Pyruvate
[0485] 10% Heat Inactivated FBS
[0486] 1.times. Antibiotics
[0487] Cell Culture Preparation
[0488] 1. Unthaw frozen stock in 10-12 mls of Media
[0489] 2. Allow cells to attach before adding G418 (4-6 hrs)
[0490] 3. Add G418 for a final concentration of 200 ug/ml (higher
amounts are possible but cells grow slowly)
[0491] 4. Split cells 1:4 to 1:6 for optimal growth
[0492] 5. In-house replicon seems to maintain Luciferase signal for
.about.20 passages
[0493] HCV Replicon Assay
[0494] 1 Dilute compounds in 100 uL of HCV Replicon Media (without
G418). If compounds are diluted in DMSO add DMSO to media (Final
DMSO concentration should be <1%)
[0495] 2. Once cells have reached 80-90% confluency, trypsinize
with 1.times.Trypsin
[0496] 3. Do not over trypsinize. These cells tend to clump if over
trypsinized
[0497] 4. For 96 well format add 6,000-8,000 cells per well (G418
is withheld during compound testing)
[0498] 5. Incubate for 3 days at 37.degree. C. Cells should be very
close to confluent.
[0499] 6. Remove media and add 200 .mu.L of a 0.2 mg/mL MTT
solution prepared in media.
[0500] 7. Incubate for 1.5 hours to 2 hours.
[0501] 8. Remove media and add 150 .mu.L of DMSO
[0502] 9. Mix and incubate for 5 mins at room temperature
[0503] 10. Read plate at 530 nm in the plate reader.
[0504] Results
[0505] The compounds of Examples 2, 3A, 4 and 5 were found to have
an EC50 in Replicon assay 2 of, respectively in micromoles, 0.01,
0.02, 0.01 and 0.0039, and to have a CC50 in the CC50 assay
protocol of, respectively in micromoles, 26, 34, 19 and 10.8
(replicate 13.4).
[0506] Substantially all of the compounds in Table 1 demonstrated
activity of at least 1 micromolar in an anti-HCV/Replicon assay
system. In addition, a number of the compounds also exhibited
anti-BVDV activity.
* * * * *